Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

ABSTRACT

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 16/024,164, filed Jun.29, 2018, which is a continuation of Ser. No. 16/065,681, filed Jun. 22,2018, which is a 371 Application of PCT/EP2016/079059, filed Nov. 29,2016, which claims the benefit of U.S. Provisional Application Ser. No.62/270,968, filed Dec. 22, 2015, and claims priority from GB 1522667.3,filed Dec. 22, 2015, the content of each these applications is hereinincorporated by reference in their entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED AS A COMPLIANT ASCII TEXT FILE(.txt)

Pursuant to the EFS-Web legal framework and 37 CFR §§ 1.821-825 (seeMPEP § 2442.03(a)), a Sequence Listing in the form of an ASCII-complianttext file (entitled “2912919-060006_SEQ_LIST.txt,” created on Oct. 312018, 11,463 bytes in size) is submitted concurrently with the instantapplication, and the entire contents of the Sequence Listing areincorporated herein by reference.

The present invention relates to peptides, proteins, nucleic acids andcells for use in immunotherapeutic methods. In particular, the presentinvention relates to the immunotherapy of cancer. The present inventionfurthermore relates to tumor-associated T-cell peptide epitopes, aloneor in combination with other tumor-associated peptides that can forexample serve as active pharmaceutical ingredients of vaccinecompositions that stimulate anti-tumor immune responses, or to stimulateT cells ex vivo and transfer into patients. Peptides bound to moleculesof the major histocompatibility complex (MHC), or peptides as such, canalso be targets of antibodies, soluble T-cell receptors, and otherbinding molecules.

The present invention relates to several novel peptide sequences andtheir variants derived from HLA class I molecules of human tumor cellsthat can be used in vaccine compositions for eliciting anti-tumor immuneresponses, or as targets for the development ofpharmaceutically/immunologically active compounds and cells.

BACKGROUND OF THE INVENTION

Breast cancer is by far the most frequently diagnosed cancer and causeof cancer death among women. There were an estimated 1.7 million newcases (25% of all cancers in women) and 0.5 million cancer deaths (15%of all cancer deaths in women) in 2012. The annual incidence inindustrialized countries is 70-90 new cases per 100000 women which is2-fold higher compared to countries categorized as having low levels ofdevelopment.

Age-standardized incidence rates are highest in western Europe andlowest in East Asia. Mortality rates vary approximately 2-5-foldworldwide; the case fatality rate is lower in countries with higherlevels of human development. About 43% of the estimated new cases and34% of the cancer deaths occurred in Europe and North Amer-ica.

Whereas incidence has been generally increasing in most areas of theworld, it has peaked and declined over the past decade in a number ofhighly developed countries. Mortality rates have been declining in anumber of highly developed countries since the late 1980s and early1990s, a result of a combination of improved detection and earlierdiagnosis (through population-based screening) and more effectivetreatment regimens (World Cancer Report, 2014).

Well-characterized breast cancer risk factors include age, familyhistory, reproductive factors including nulliparity, first birth afterage 30, mammographic density, and atypia in a prior benign breastbiopsy. Agents that cause breast cancer include alcohol con-sumption,use of combined estrogen-progestogen contraceptives and menopausaltherapy, exposure to X- and γ-radiation and lifestyle factors such ashigh-calorie diets and lack of exercise. Physical activity has beenassociated with a 25-30% decrease in breast cancer risk due to adecrease of endogenous estrogens, adiposity, insulin resistance, leptin,and inflammation, which are all associated independently with increasedbreast cancer risk (Winzer et al., 2011).

A small proportion of breast cancers are due to inherited mutations inhigh-penetrance breast cancer susceptibility genes (BRCA1 and BRCA2).

Several lower-penetrance genes have been discovered by next-generationsequencing technology applied to examine the genomes of 100 breastcancers for somatic copy number changes and mutations in the codingexons of protein-coding genes (Stephens et al., 2012). The number ofsomatic mutations varied markedly between individual tumors. Strongcorrelations were evident between number of mutations, age at whichcancer was diagnosed, and cancer histological grade, and multiplemutational signatures were observed, including one, present in about 10%of tumors, characterized by numerous mutations of cytosine at TpCdinucleotides. Driver mutations were identified in several new cancergenes, including AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1,SMARCD1, and TBX3. Among the 100 tumors, there were driver mutations inat least 40 cancer genes and 73 different combinations of mutated cancergenes. Overall, one of the most highly contributing genes to developmentof breast cancer, TP53, is nonetheless probably only involved in 25% ofcancers, although its role in subsets of breast cancers, such astriple-negative/basal-like, is much higher. A large number of genesappear to be implicated in a small percentage of tumors, and this willprovide additional challenges to achieving the dream of apatient-specific targeted and personalized medical intervention.

Breast cancer is not a single disease and is heterogeneous bothclinically and morphologically. The current WHO Classification of Tumorsof the Breast (4th edition) recognizes more than 20 different subtypes.Most breast cancers arise from epithelial cells (carcinomas); thesetumors are subdivided into in situ and invasive lesions. In situcarcinomas are preinvasive lesions and further subdivided into ductalcarcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Thedistinction between DCIS and LCIS is the result not of themicro-anatomical site of origin (ducts vs lobules) but rather of adifference in the architectural and cytological features of the cells.DCIS and LCIS also differ in their distribution within the breast, aswell as their risk of recurrence and progression to invasive cancer.

Invasive carcinoma characterized as “no special type”, also known asductal carcinoma no special type or invasive ductal carcinoma, makes upthe largest subset of invasive breast cancer. This designationidentifies a heterogeneous group comprising tumors that are not easilycategorized by specific morphological features that characterize the“special subtypes”. Hence, it is a default diagnosis for all thosetumors (approximately 70%) that cannot be assigned a “special subtype”designation. The most common of the special subtypes include lobularcarcinoma, tubular carcinoma, mucinous carcinoma, carcinoma withmedullary and apocrine features, micropapillary and papillarycarcinomas, and metaplastic carcinomas.

Histological grade is a measure of how closely a tumor resembles itstissue of origin and is an integral part of a pathology report. Thecurrent grading system assesses the three parameters degree ofarchitectural differentiation, nuclear pleomorphism and proliferation ofthe tumor. Although this semiquantitative approach averages theintra-tumor heterogeneity that exists in many tumors, it remains apowerful indicator of patient prognosis. Histological grade is alsostrongly associated with histological type and with patterns ofmolecular alterations, such as estrogen receptor (ER) and progesteronereceptor (PR) expression and human epidermal growth factor receptor 2(HER2) protein over-expression and gene amplification.

Recent molecular and genetic studies have emphasized that breast canceris a highly heterogeneous group of diseases that differ in theirprognosis and response to treatment. Improved understanding of themolecular pathways and genetic alterations that underlie the differentbreast cancer subtypes is leading to a more targeted and personalizedapproach to breast cancer treatment.

The standard treatment for breast cancer patients depends on differentparameters: tumor stage, hormone receptor status and HER2 expressionpattern. The standard of care includes complete surgical resection ofthe tumor followed by radiation therapy. Chemotherapy with mainlyanthracyclines and taxanes may be started prior to or after resection.In advanced stages, additional chemotherapeutics like alkylating agents,fluorpyrimidines, platinum analogs, etc. can be applied as mono- orcombination therapy. Patients with HER2-positive tumors receive theanti-HER2 antibody trastuzumab in addition to the chemotherapeutics. Thevascular endothelial growth factor (VEGF) inhibitor bevacizumabsynergizes with paclitaxel or capecitabine monotherapy. Chemotherapy istypically less efficient in patients with estrogen or progesteronereceptor-positive tumors. For these patients, the standard regimencomprises an endocrine therapy with tamoxifen (first line) or aromataseinhibitors (second line) after initial chemotherapy (S3-LeitlinieMammakarzinom, 2012).

For more than a decade, gene expression profiling has been applied todefine molecular phenotypes of breast cancer and luminal A andbasal-like subtypes were found the two main subtypes of five that havebeen identified. This type of analysis has not only confirmed the twolarge subsets of breast cancer—ER-positive and ER-negative—but alsobrought to the fore differences within the ER categories.

Using these gene expression data, it is more and more possible toclassify breast cancer, develop signatures for “good” versus “poor”prognosis, and identify tumors that may or may not respond to particulartherapy (van de Vijver et al., 2002). Rapidly evolving knowledge of themolecular events and signaling pathways underlying the development andprogression of breast cancer has also led to the identification of agrowing number of new therapeutic targets and to the development ofdrugs against these targets. Many clinical trials are currently underway worldwide to evaluate the role of these new targeted therapies inthe treatment of patients with breast cancer. Newer targeted therapiesthat have been or are being evaluated, singly and in combination witheach other and with traditional cytotoxic agents, include angiogenesisinhibitors, tyrosine kinase inhibitors, inhibitors of mammalian targetof rapamycin (mTOR), poly(ADP-ribose) polymerase 1 (PARP1) inhibitors,insulin-like growth factor 1 receptor (IGF-1R) inhibitors, proteasomeinhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and others(Perez and Spano, 2012). The ultimate goal of this research is to beable to tailor breast cancer treatment for individual patients based onthe particular molecular features of the tumor. The molecular analysesare also relevant to survival. One study used modelling of messenger RNA(mRNA), copy number alterations, microRNAs, and methylation (Kristensenet al., 2012). For all breast cancers, the strongest predictor of goodoutcome was acquisition of a gene signature that favored a high T helpertype 1 (Th1)/cytotoxic T lymphocyte response at the expense ofTh2-driven immunity.

These data reflect that breast cancer is an immunogenic cancer entityand different types of infiltrating immune cells in primary tumorsexhibit distinct prognostic and predictive significance. A large numberof early phase immunotherapy trials have been conducted in breast cancerpatients. Most of the completed vaccination studies targeted HER2 andcarbohydrate antigens like MUC-1 and revealed rather disappointingresults. Clinical data on the effects of immune checkpoint modulationwith ipilimumab and other T cell-activating antibodies in breast cancerpatients are emerging (Emens, 2012).

Considering the severe side-effects and expense associated with treatingcancer, there is a need to identify factors that can be used in thetreatment of cancer in general and breast cancer in particular. There isalso a need to identify factors representing biomarkers for cancer ingeneral and breast cancer in particular, leading to better diagnosis ofcancer, assessment of prognosis, and prediction of treatment success.

Immunotherapy of cancer represents an option of specific targeting ofcancer cells while minimizing side effects. Cancer immunotherapy makesuse of the existence of tumor associated antigens.

The current classification of tumor associated antigens (TAAs) comprisesthe following major groups:

a) Cancer-testis antigens: The first TAAs ever identified that can berecognized by T cells belong to this class, which was originally calledcancer-testis (CT) antigens because of the expression of its members inhistologically different human tumors and, among normal tissues, only inspermatocytes/spermatogonia of testis and, occasion-ally, in placenta.Since the cells of testis do not express class I and II HLA molecules,these antigens cannot be recognized by T cells in normal tissues and cantherefore be considered as immunologically tumor-specific. Well-knownexamples for CT antigens are the MAGE family members and NY-ESO-1.b) Differentiation antigens: These TAAs are shared between tumors andthe normal tissue from which the tumor arose. Most of the knowndifferentiation antigens are found in melanomas and normal melanocytes.Many of these melanocyte lineage-related proteins are involved inbiosynthesis of melanin and are therefore not tumor specific butnevertheless are widely used for cancer immunotherapy. Examples include,but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma orPSA for prostate cancer.c) Over-expressed TAAs: Genes encoding widely expressed TAAs have beendetected in histologically different types of tumors as well as in manynormal tissues, generally with lower expression levels. It is possiblethat many of the epitopes processed and potentially presented by normaltissues are below the threshold level for T-cell recognition, whiletheir over-expression in tumor cells can trigger an anticancer responseby breaking previously established tolerance. Prominent examples forthis class of TAAs are Her-2/neu, survivin, telomerase, or WT1.d) Tumor-specific antigens: These unique TAAs arise from mutations ofnormal genes (such as β-catenin, CDK4, etc.). Some of these molecularchanges are associated with neoplastic transformation and/orprogression. Tumor-specific antigens are generally able to induce strongimmune responses without bearing the risk for autoimmune reactionsagainst normal tissues. On the other hand, these TAAs are in most casesonly relevant to the exact tumor on which they were identified and areusually not shared between many individual tumors. Tumor-specificity (or-association) of a peptide may also arise if the peptide originates froma tumor- (-associated) exon in case of proteins with tumor-specific(-associated) isoforms.e) TAAs arising from abnormal post-translational modifications: SuchTAAs may arise from proteins which are neither specific noroverexpressed in tumors but nevertheless become tumor associated byposttranslational processes primarily active in tumors. Examples forthis class arise from altered glycosylation patterns leading to novelepitopes in tumors as for MUC1 or events like protein splicing duringdegradation which may or may not be tumor specific.f) Oncoviral proteins: These TAAs are viral proteins that may play acritical role in the oncogenic process and, because they are foreign(not of human origin), they can evoke a T-cell response. Examples ofsuch proteins are the human papilloma type 16 virus proteins, E6 and E7,which are expressed in cervical carcinoma.

T-cell based immunotherapy targets peptide epitopes derived fromtumor-associated or tumor-specific proteins, which are presented bymolecules of the major histocompatibility complex (MHC). The antigensthat are recognized by the tumor specific T lymphocytes, that is, theepitopes thereof, can be molecules derived from all protein classes,such as enzymes, receptors, transcription factors, etc. which areexpressed and, as compared to unaltered cells of the same origin,usually up-regulated in cells of the respective tumor.

There are two classes of MHC-molecules, MHC class I and MHC class II.MHC class I molecules are composed of an alpha heavy chain andbeta-2-microglobulin, MHC class II molecules of an alpha and a betachain. Their three-dimensional conformation results in a binding groove,which is used for non-covalent interaction with peptides.

MHC class I molecules can be found on most nucleated cells. They presentpeptides that result from proteolytic cleavage of predominantlyendogenous proteins, defective ribosomal products (DRIPs) and largerpeptides. However, peptides derived from en-dosomal compartments orexogenous sources are also frequently found on MHC class I molecules.This non-classical way of class I presentation is referred to ascross-presentation in the literature (Brossart and Bevan, 1997; Rock etal., 1990). MHC class II molecules can be found predominantly onprofessional antigen presenting cells (APCs), and primarily presentpeptides of exogenous or transmembrane proteins that are taken up byAPCs e.g. during endocytosis, and are subsequently processed.

Complexes of peptide and MHC class I are recognized by CD8-positive Tcells bearing the appropriate T-cell receptor (TCR), whereas complexesof peptide and MHC class II molecules are recognized byCD4-positive-helper-T cells bearing the appropriate TCR. It is wellknown that the TCR, the peptide and the MHC are thereby present in astoichiometric amount of 1:1:1.

CD4-positive helper T cells play an important role in inducing andsustaining effective responses by CD8-positive cytotoxic T cells. Theidentification of CD4-positive T-cell epitopes derived from tumorassociated antigens (TAA) is of great importance for the development ofpharmaceutical products for triggering anti-tumor immune responses(Gnjatic et al., 2003). At the tumor site, T helper cells, support acytotoxic T cell- (CTL-) friendly cytokine milieu (Mortara et al., 2006)and attract effector cells, e.g. CTLs, natural killer (NK) cells,macrophages, and granulocytes (Hwang et al., 2007).

In the absence of inflammation, expression of MHC class II molecules ismainly restricted to cells of the immune system, especially professionalantigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells,macrophages, dendritic cells. In cancer patients, cells of the tumorhave been found to express MHC class II molecules (Dengjel et al.,2006).

Elongated (longer) peptides of the invention can act as MHC class IIactive epitopes. T-helper cells, activated by MHC class II epitopes,play an important role in orchestrating the effector function of CTLs inanti-tumor immunity. T-helper cell epitopes that trigger a T-helper cellresponse of the TH1 type support effector functions of CD8-positivekiller T cells, which include cytotoxic functions directed against tumorcells displaying tumor-associated peptide/MHC complexes on their cellsurfaces. In this way tumor-associated T-helper cell peptide epitopes,alone or in combination with other tumor-associated peptides, can serveas active pharmaceutical ingredients of vaccine compositions thatstimulate anti-tumor immune responses.

It was shown in mammalian animal models, e.g., mice, that even in theabsence of CD8-positive T lymphocytes, CD4-positive T cells aresufficient for inhibiting manifes-tation of tumors via inhibition ofangiogenesis by secretion of interferon-gamma (IFNγ) (Beatty andPaterson, 2001; Mumberg et al., 1999). There is evidence for CD4 T cellsas direct anti-tumor effectors (Braumuller et al., 2013; Tran et al.,2014).

Since the constitutive expression of HLA class II molecules is usuallylimited to immune cells, the possibility of isolating class II peptidesdirectly from primary tumors was previously not considered possible.However, Dengjel et al. were successful in identifying a number of MHCClass II epitopes directly from tumors (WO 2007/028574, EP 1 760 088B1).

Since both types of response, CD8 and CD4 dependent, contribute jointlyand syner-gistically to the anti-tumor effect, the identification andcharacterization of tumor-associated antigens recognized by either CD8+T cells (ligand: MHC class I molecule+peptide epitope) or byCD4-positive T-helper cells (ligand: MHC class II molecule+peptideepitope) is important in the development of tumor vaccines.

For an MHC class I peptide to trigger (elicit) a cellular immuneresponse, it also must bind to an MHC-molecule. This process isdependent on the allele of the MHC-molecule and specific polymorphismsof the amino acid sequence of the peptide. MHC-class-I-binding peptidesare usually 8-12 amino acid residues in length and usually contain twoconserved residues (“anchors”) in their sequence that interact with thecorresponding binding groove of the MHC-molecule. In this way, each MHCallele has a “binding motif” determining which peptides can bindspecifically to the binding groove.

In the MHC class I dependent immune reaction, peptides not only have tobe able to bind to certain MHC class I molecules expressed by tumorcells, they subsequently also have to be recognized by T cells bearingspecific T cell receptors (TCR).

For proteins to be recognized by T-lymphocytes as tumor-specific or-associated antigens, and to be used in a therapy, particularprerequisites must be fulfilled. The antigen should be expressed mainlyby tumor cells and not, or in comparably small amounts, by normalhealthy tissues. In a preferred embodiment, the peptide should beover-presented by tumor cells as compared to normal healthy tissues. Itis furthermore desirable that the respective antigen is not only presentin a type of tumor, but also in high concentrations (i.e. copy numbersof the respective peptide per cell). Tumor-specific and tumor-associatedantigens are often derived from proteins directly involved intransformation of a normal cell to a tumor cell due to their function,e.g. in cell cycle control or suppression of apoptosis. Additionally,downstream targets of the proteins directly causative for atransformation may be up-regulated and thus may be indirectlytumor-associated. Such indirect tumor-associated antigens may also betargets of a vaccination approach (Singh-Jasuja et al., 2004). It isessential that epitopes are present in the amino acid sequence of theantigen, in order to ensure that such a peptide (“immunogenic peptide”),being derived from a tumor associated antigen, leads to an in vitro orin vivo T-cell-response.

Basically, any peptide able to bind an MHC molecule may function as aT-cell epitope. A prerequisite for the induction of an in vitro or invivo T-cell-response is the presence of a T cell having a correspondingTCR and the absence of immunological tolerance for this particularepitope.

Therefore, TAAs are a starting point for the development of a T cellbased therapy including but not limited to tumor vaccines. The methodsfor identifying and character-izing the TAAs are usually based on theuse of T-cells that can be isolated from patients or healthy subjects,or they are based on the generation of differential transcriptionprofiles or differential peptide expression patterns between tumors andnormal tissues.

However, the identification of genes over-expressed in tumor tissues orhuman tumor cell lines, or selectively expressed in such tissues or celllines, does not provide precise information as to the use of theantigens being transcribed from these genes in an immune therapy. Thisis because only an individual subpopulation of epitopes of theseantigens are suitable for such an application since a T cell with acorresponding TCR has to be present and the immunological tolerance forthis particular epitope needs to be absent or minimal. In a verypreferred embodiment of the invention it is therefore important toselect only those over- or selectively presented peptides against whicha functional and/or a proliferating T cell can be found. Such afunctional T cell is defined as a T cell, which upon stimulation with aspecific antigen can be clonally expanded and is able to executeeffector functions (“effector T cell”).

In case of targeting peptide-MHC by specific TCRs (e.g. soluble TCRs)and antibodies or other binding molecules (scaffolds) according to theinvention, the immunogenicity of the underlying peptides is secondary.In these cases, the presentation is the determining factor.

SUMMARY OF THE INVENTION

In a first aspect of the present invention, the present inventionrelates to a peptide comprising an amino acid sequence selected from thegroup consisting of SEQ ID NO: 1 to SEQ ID NO: 43 or a variant sequencethereof which is at least 77%, preferably at least 88%, homologous(preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 toSEQ ID NO: 43, wherein said variant binds to MHC and/or induces T cellscross-reacting with said peptide, or a pharmaceutical acceptable saltthereof, wherein said peptide is not the underlying full-lengthpolypeptide.

The present invention further relates to a peptide of the presentinvention comprising a sequence that is selected from the groupconsisting of SEQ ID NO: 1 to SEQ ID NO: 43 or a variant thereof, whichis at least 77%, preferably at least 88%, homologous (preferably atleast 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 43,wherein said peptide or variant thereof has an overall length of between8 and 100, preferably between 8 and 30, and most preferred of between 8and 14 amino acids.

The following tables show the peptides according to the presentinvention, their respective SEQ ID NOs, and the prospective source(underlying) genes for these peptides. All peptides in Table 1 and Table2 bind to HLA-A*02. The peptides in Table 2 have been disclosed beforein large listings as results of high-throughput screenings with higherror rates or calculated using algorithms, but have not been associatedwith cancer at all before. The peptides in Table 3 are additionalpeptides that may be useful in combination with the other peptides ofthe invention. The peptides in Table 4 are furthermore useful in thediagnosis and/or treatment of various other malignancies that involve anover-expression or over-presentation of the respective underlyingpolypeptide.

TABLE 1 Peptides according to the present invention. J =phospho-serine, U = phospho-threonine SEQ Official ID No. SequenceGeneID(s) Gene Symbol(s)  1 KMPEHISTV   8483 CILP  2 ALAGSSPQV  79935CNTD2  3 ILLPPAHNJQ  54497 HEATR5B  4 SLVEGEAVHLA339488, 7020, 7021, 7022 TFAP2E, TFAP2A, TFAP2B, TFAP2C   5 ALNPVIYTV  1815 DRD4  6 ALTALQNYL   7021 TFAP2B  7 FIIPTVATA  85320 ABCC11  8GLVQSLTSI  85320 ABCC11  9  FMSKLVPAI 285386 TPRG1 10 GLHSLPPEV  80131LRRC8E 11 GLLPTSVSPRV  57758 SCUBE2 12 KAFPFYNTV101060527, 4671, 653406, 728519 NAIP 13 KLYEGIPVL 152110 NEK10 14KQLELELEV   4588 MUC6 15 SLFPSLVVV   5339 PLEC 16 SMMGLLTNL   2099 ESR117 TIASSIEKA 285555 STPG2 18 YILLQSPQL   4588 MUC6 19 ALEEQLHQV147183, 162605, 342574 KRT25, KRT28, KRT27 20 FSFPVSVGV   1846 DUSP4 21SLLTEPALV  23158 TBC1D9 22 YIDGLESRV 148327 CREB3L4 23 SLADAVEKV 160857CCDC122 24 GLLGFQAEA   9500 MAGED1 25 ILFDVVVFL 401152 C4orf3 26SLAWDVPAA   2194 FASN 27 SLAEPRVSV   2194 FASN 28 SLFSVPFFL  10548TM9SF1 29 ALEAUQLYL 120863 DEPDC4 30 FLSSEAANV   7127 TNFAIP2 31GLSYIYNTV  57511 COG6 32 GLVATLQSL   2537 IFI6 33 ILTELPPGV  55628ZNF407 34 SAFPEVRSL  63892 THADA 35 SLLSEIQAL 10142, 5116 AKAP9, PCNT 36TLLGLAVNV  56994 CHPT1 37 VLAHITADI  10765 KDM5B 38 LLMUVAGLKL 399909PCNXL3

TABLE 2 Additional peptides according to the presentinvention with no prior known cancer association. J =phospho-serine, U = phospho-threonine SEQ Official ID No. SequenceGeneID(s) Gene Symbol(s) 39 KLLDMELEM  2184 FAH 40 SAAFPGASL  9802DAZAP2 41 SLNDQGYLL 84515 MCM8 42 FLVEHVLTL 25800 SLC39A6 43 FLDEEVKLI 2512 FTL

TABLE 3 Peptides useful for e.g. personalized cancer therapies. SEQOfficial ID No. Sequence GeneID(s) Gene Symbol(s) 44 FLLDGSANV  1293COL6A3 45 FLYDWKSL  1293 COL6A3 46 FLFDGSANL  1293 COL6A3 47 FLIDSSEGV 1293 COL6A3 48 NLLDLDYEL  1293 COL6A3 49 GLTDNIHLV 25878 MXRA5 50TLSSIKVEV 25878 MXRA5 51 SLYKGLLSV 25788 RAD54B 52 FLVDGSWSV  1303COL12A1 53 SLAEEKLQASV  2194 FASN 54 SLFGQDVKAV 26036 ZNF451 55FLVDGSWSI 57642 COL20A1 56 ILVDWLVQV  9133 CCNB2 57 TVAEVIQSV 55083KIF26B 58 YVYQNNIYL  2191 FAP 59 KIVDFSYSV   701 BUB1B 60 ALPTVLVGV 5351 PLOD1 61 YLEPYLKEV 727947, 7381 UQCRB 62 ALLEMDARL 54512 EXOSC4 63ALVQDLAKA   891 CCNB1 64 FVFSFPVSV  1846 DUSP4 65 GLNEEIARV 10403 NDC8066 ILFPDIIARA 64110 MAGEF1 67 LTDITKGV  1938 EEF2 68 NLAEVVERV 26263FBXO22 69 RLDDLKMTV  3918 LAMC2 70 SISDVIAQV 56172 ANKH 71 SMMQTLLTV10916 MAGED2

The present invention furthermore generally relates to the peptidesaccording to the present invention for use in the treatment ofproliferative diseases, such as, for example, acute myelogenousleukemia, bile duct cancer, brain cancer, chronic lymphocytic leukemia,colorectal carcinoma, esophageal cancer, gallbladder cancer, gastriccancer, hepatocellular cancer, Merkel cell carcinoma, melanoma,non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer,pancreatic cancer, prostate cancer, renal cell cancer, small cell lungcancer, urinary bladder cancer and uterine cancer.

Particularly preferred are the peptides—alone or incombination—according to the present invention selected from the groupconsisting of SEQ ID NO: 1 to SEQ ID NO: 43. More preferred are thepeptides—alone or in combination—selected from the group consisting ofSEQ ID NO: 1 to SEQ ID NO: 28 (see Table 1), and their uses in theimmunotherapy of breast cancer, acute myelogenous leukemia, bile ductcancer, brain cancer, chronic lymphocytic leukemia, colorectalcarcinoma, esophageal cancer, gallbladder cancer, gastric cancer,hepatocellular cancer, Merkel cell carcinoma, melanoma, non-Hodgkinlymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer,prostate cancer, renal cell cancer, small cell lung cancer, urinarybladder cancer and uterine cancer, and preferably breast cancer.

As shown in the following Tables 4A and B, many of the peptidesaccording to the present invention are also found on other tumor typesand can, thus, also be used in the immunotherapy of other indications.Also, refer to FIGS. 1A-1N, and Example 1.

TABLE 4APeptides according to the present invention and their specific uses inother proliferative diseases, especially in other cancerous diseases. The tableshows for selected peptides on which additional tumor types they were found andeither over-presented on more than 5% of the measured tumor samples, or presentedon more than 5% of the measured tumor samples with a ratio of geometric meanstumor vs normal tissues being larger than 3. Over-presentation is defined as higherpresentation on the tumor sample as compared to the normal sample with highestpresentation. Normal tissues against which over-presentation was tested were:adipose tissue, adrenal gland, blood cells, blood vessel, bone marrow, brain,cartilage, esophagus, eye, gallbladder, heart, kidney, large intestine, liver,lung, lymph node, nerve, pancreas, parathyroid gland, peritoneum, pituitary gland,pleura, salivary gland, skeletal muscle, skin, small intestine, spleen, stomach,thymus, thyroid gland, trachea, ureter, and urinary bladder. SE ID No.Sequence Other relevant organs/diseases  1 KMPEHISTV PC  2 ALAGSSPQV HCC 4 SLVEGEAVHLA Gallbladder Cancer, Bile Duct Cancer 14 KQLELELEV PC 15SLFPSLVW NHL, Melanoma, Gallbladder Cancer, Bile Duct Cancer 18YILLQSPQL HCC, PC, Esophageal Cancer 20 FSFPVSVGVNSCLC, SCLC, GC, NHL, Melanoma, Esophageal Cancer, Urinary bladdercancer, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 21SLLTEPALV HCC, CLL, NHL 22 YIDGLESRVPrC, AML, Melanoma, Esophageal Cancer, OC, Uterine Cancer 23 SLADAVEKVSCLC, NHL, Melanoma 24 GLLGFQAEARCC, Brain Cancer, HCC, NHL, AML, Melanoma, Esophageal Cancer,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 25 ILFDWVFLSCLC, NHL 26 SLAWDVPAAHCC, NHL, Melanoma, Esophageal Cancer, Urinary bladder cancer 27SLAEPRVSV HCC, PrC, Melanoma, Urinary bladder cancer 28 SLFSVPFFLNSCLC, Brain Cancer, HCC, NHL, Melanoma, Urinary bladder cancer 30FLSSEAANV SCLC, HCC, NHL, Urinary bladder cancer, Uterine Cancer 31GLSYIYNTV CLL, NHL, Esophageal Cancer, Urinary bladder cancer, UterineCancer 32 GLVATLQSLPC, AML, Melanoma, Esophageal Cancer, Gallbladder Cancer, BileDuct Cancer 33 ILTELPPGV CLL, NHL 34 SAFPEVRSL HCC, CLL 35 SLLSEIQALCRC, CLL 36 TLLGLAVNV SCLC 37 VLAHITADISCLC, CLL, NHL, AML, Esophageal Cancer, Urinary bladder cancer,Uterine Cancer 38 LLMUVAGLKLNSCLC, RCC, CRC, HCC, NHL, BRCA, Urinary bladder cancer,Gallbladder Cancer, Bile Duct Cancer 39 KLLDMELEMRCC, HCC, NHL, Melanoma, OC, Urinary bladder cancer, GallbladderCancer, Bile Duct Cancer 40 SAAFPGASLSCLC, CLL, AML, Gallbladder Cancer, Bile Duct Cancer 41 SLNDQGYLLNHL, Melanoma 42 FLVEHVLTL CLL, NHL, Melanoma, Urinary bladder cancer 43FLDEEVKLI RCC, Melanoma, Urinary bladder cancer 44 FLLDGSANVNSCLC, SCLC, GC, CRC, HCC, PC, NHL, Melanoma, Esophageal Cancer, OC, Urinary bladder cancer, UterineCancer, Gallbladder Cancer, Bile Duct Cancer 45 FLYDVVKSLNSCLC, SCLC, PC, NHL, Gallbladder Cancer, Bile Duct Cancer 46 FLFDGSANLNSCLC, SCLC, GC, CRC, PC, Melanoma, Esophageal Cancer, Urinarybladder cancer, Gallbladder Cancer, Bile Duct Cancer 47 FLIDSSEGVNSCLC, SCLC, GC, CRC, PC, NHL, Melanoma, Esophageal Cancer, OC,Urinary bladder cancer, Gallbladder Cancer, Bile Duct Cancer 48NLLDLDYELNSCLC, SCLC, GC, CRC, PC, NHL, Melanoma, Esophageal Cancer, OC,Urinary bladder cancer, Uterine Cancer, Gallbladder Cancer, BileDuct Cancer 49 GLTDNIHLVNSCLC, SCLC, RCC, GC, CRC, PC, NHL, Melanoma, Esophageal Cancer,Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 50 TLSSIKVEVNSCLC, RCC, GC, CRC, PC, PrC, NHL, Melanoma, Esophageal Cancer,OC, Gallbladder Cancer, Bile Duct Cancer 51 SLYKGLLSVNSCLC, SCLC, RCC, Brain Cancer, CRC, HCC, NHL, AML, Melanoma,Esophageal Cancer, OC, Urinary bladder, cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 52 FLVDGSWSVNSCLC, SCLC, GC, CRC, PC, NHL, Melanoma, Esophageal Cancer, OC,Urinary bladder cancer, Gallbladder Cancer, Bile Duct Cancer 53SLAEEKLQASV HCC, PrC, Urinary bladder cancer 54 SLFGQDVKAVNSCLC, SCLC, RCC, Brain Cancer, CRC, HCC, CLL, NHL, MCC,Melanoma, Esophageal Cancer, OC, Urinary bladder cancer, UterineCancer, Gallbladder Cancer, Bile Duct Cancer 56 ILVDWLVQVNSCLC, SCLC, RCC, Brain Cancer, CRC, HCC, NHL, AML, Melanoma,Esophageal Cancer, OC, Urinary bladder cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 57 TVAEVIQSVNSCLC, PC, PrC, NHL, Melanoma, Esophageal Cancer, OC, Urinarybladder cancer, Uterine Cancer, Gallbladder Cancer, Bile Duct Cancer 58YVYQNNIYLNSCLC, SCLC, GC, CRC, HCC, PC, NHL, Melanoma, Esophageal Cancer, OC, Urinary bladder cancer, Uterine Cancer, Gallbladder Cancer,Bile Duct Cancer 59 KIVDFSYSVNSCLC, SCLC, Brain Cancer, CRC, NHL, MCC, Melanoma, OC, Urinarybladder cancer, Uterine Cancer 60 ALPTVLVGVNSCLC, RCC, Brain Cancer, GC, CRC, HCC, PC, Melanoma, EsophagealCancer, OC, Urinary bladder cancer, Uterine Cancer, GallbladderCancer, Bile Duct Cancer 61 YLEPYLKEVNSCLC, SCLC, Brain Cancer, CRC, HCC, NHL, AML, Melanoma, EsophagealCancer, OC, Urinary bladder cancer, Uterine Cancer, GallbladderCancer, Bile Duct Cancer 62 ALLEMDARLNSCLC, SCLC, RCC, Brain Cancer, CRC, HCC, NHL, AML, MCC, Melanoma,Esophageal Cancer, OC, Urinary bladder cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 63 ALVQDLAKANSCLC, SCLC, RCC, GC, CRC, HCC, PC, NHL, AML, Melanoma, EsophagealCancer, OC, Urinary bladder cancer, Uterine Cancer, GallbladderCancer, Bile Duct Cancer 64 FVFSFPVSVNSCLC, SCLC, GC, PC, NHL, Melanoma, Esophageal Cancer, Urinarybladder cancer, Gallbladder Cancer, Bile Duct Cancer 65 GLNEEIARVNSCLC, SCLC, Brain Cancer, CRC, HCC, NHL, AML, MCC, Melanoma,Esophageal Cancer, OC, Urinary bladder cancer, Uterine Cancer 66ILFPDIIARA NSCLC, SCLC, RCC, Brain Cancer, CLL, NHL, AML, Melanoma, OC,Urinarybladder cancer, Uterine Cancer, Gallbladder Cancer, BileDuct Cancer 67 LTDITKGV NHL 68 NLAEWERVNSCLC, SCLC, Brain Cancer, HCC, PrC, CLL, NHL, MCC, Melanoma, OC,Gallbladder Cancer, Bile Duct Cancer 69 RLDDLKMTVNSCLC, SCLC, RCC, GC, CRC, HCC, PC, NHL, Melanoma, EsophagealCancer, OC, Urinary bladder cancer, Uterine Cancer, GallbladderCancer, Bile Duct Cancer 70 SISDVIAQVBrain Cancer, CRC, HCC, PC, PrC, Melanoma, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer 71 SMMQTLLTVGallbladder Cancer, Bile Duct Cancer NSCLC = non-small cell lung cancer,SCLC = small cell lung cancer, RCC = kidney cancer, CRC = colon orrectum cancer, GC = stomach cancer, HCC = liver cancer, PC = pancreaticcancer, PrC = prostate cancer, leukemia, BRCA = breast cancer, MCC =Merkel cell carcinoma

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 1, 14, 18, 32, 44, 45, 46, 47, 48, 49, 50, 52, 57, 58,60, 63, 64, 69, and 70 for the—in one preferred embodimentcombined—treatment of PC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 2, 18, 21, 24, 26, 27, 28, 30, 34, 38, 39, 44, 51, 53,54, 56, 58, 60, 61, 62, 63, 65, 68, 69, and 70 for the—in one preferredembodiment combined—treatment of HCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 4, 15, 20, 24, 32, 38, 39, 40, 44, 45, 46, 47, 48, 49,50, 51, 52, 54, 56, 57, 58, 60, 61, 62, 63, 64, 66, 68, 69, 70, and 71for the—in one preferred embodiment combined—treatment of gallbladdercancer and/or bile duct cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 15, 20, 21, 23, 24, 25, 26, 28, 30, 31, 33, 37, 38,39, 41, 42, 44, 45, 47, 48, 49, 50, 51, 52, 54, 56, 57, 58, 59, 61, 62,63, 64, 65, 66, 67, 68, and 69 for the—in one preferred embodimentcombined—treatment of NHL.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 15, 20, 22, 23, 24, 26, 27, 28, 32, 39, 41, 42, 43,44, 46, 47, 48, 49, 50, 51, 52, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64,65, 66, 68, 69, and 70 for the—in one preferred embodimentcombined—treatment of melanoma.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 18, 20, 22, 24, 26, 31, 32, 37, 44, 46, 47, 48, 49,50, 51, 52, 54, 56, 57, 58, 60, 61, 62, 63, 64, 65, 66, and 69 forthe—in one preferred embodiment combined—treatment of esophageal cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 28, 38, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54,56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 68, and 69 for the—in onepreferred embodiment combined—treatment of NSCLC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 23, 25, 30, 36, 37, 40, 44, 45, 46, 47, 48, 49,51, 52, 54, 56, 58, 59, 61, 62, 63, 64, 65, 66, 68, and 69 for the—inone preferred embodiment combined—treatment of SCLC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 46, 47, 48, 49, 50, 52, 58, 60, 63, 64, and 69 forthe—in one preferred embodiment combined—treatment of GC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 26, 27, 28, 30, 31, 37, 38, 39, 42, 43, 44, 46,47, 48, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, and69 for the—in one preferred embodiment combined—treatment of urinarybladder cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 22, 24, 30, 31, 37, 44, 48, 49, 51, 54, 56, 57,58, 59, 60, 61, 62, 63, 65, 66, 69, and 70 for the—in one preferredembodiment combined—treatment of uterine cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 22, 27, 50, 53, 57, 68, and 70 for the—in onepreferred embodiment combined—treatment of PrC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 22, 24, 32, 37, 40, 51, 56, 61, 62, 63, 65, and 66 forthe—in one preferred embodiment combined—treatment of AML.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 22, 39, 44, 47, 48, 49, 50, 51, 52, 54, 56, 57, 58,59, 60, 61, 62, 63, 65, 66, 68, and 69 for the—in one preferredembodiment combined—treatment of OC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 24, 38, 39, 43, 49, 50, 51, 54, 56, 60, 62, 63, 66,and 69 for the—in one preferred embodiment combined—treatment of RCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 24, 28, 51, 54, 56, 59, 60, 61, 62, 65, 66, 68, and 70for the—in one preferred embodiment combined—treatment of brain cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 21, 31, 33, 34, 35, 37, 40, 42, 54, 66, and 68 forthe—in one preferred embodiment combined—treatment of CLL.

Thus, another aspect of the present invention relates to the use of thepeptides according to the present invention for the—preferablycombined—treatment of a prolifer-ative disease selected from the groupof breast cancer, acute myelogenous leukemia, bile duct cancer, braincancer, chronic lymphocytic leukemia, colorectal carcinoma, esophagealcancer, gallbladder cancer, gastric cancer, hepatocellular cancer,Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small celllung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renalcell cancer, small cell lung cancer, urinary bladder cancer and uterinecancer.

TABLE 1BPeptides according to the present invention and their specific uses in otherproliferative diseases, especially in other cancerous diseases. The table shows,like Table 4A, for selected peptides on which additional tumor types they werefound showing over-presentation (including specific presentation) on more than 5%of the measured tumor samples, or presentation on more than 5% of the measuredtumor samples with a ratio of geometric means tumor vs normal tissues being largerthan 3. Over-presentation is defined as higher presentation on the tumor sample ascompared to the normal sample with highest presentation. Normal tissues againstwhich over-presentation was tested were: adipose tissue, adrenal gland, bloodcells, blood vessel, bone marrow, brain, esophagus, eye, gallbladder, heart, kidney,large intestine, liver, lung, lymph node, nerve, pancreas, parathyroid gland,peritoneum, pituitary, pleura, salivary gland, skeletal muscle, skin, smallintestine, spleen, stomach, thyroid gland, trachea, ureter, urinary bladder.SEQ ID NO. Sequence Additional Entities  1 KMPEHISTV Melanoma  4SLVEGEAVHLA Melanoma, Esophageal Cancer, HNSCC 10 GLHSLPPEV HNSCC 15SLFPSLVVV Bile Duct Cancer, AML, HNSCC 20 FSFPVSVGVOC, Esophageal Cancer, Urinary bladder cancer, Uterine Cancer,Gallbladder Cancer, Bile Duct Cancer, HNSCC 21 SLLTEPALV AML 22YIDGLESRV SCLC, Uterine Cancer 23 SLADAVEKV Uterine Cancer, HNSCC 24GLLGFQAEAMelanoma, Esophageal Cancer, Uterine Cancer, Gallbladder Caner, BileDuct Cancer, HNSCC 26 SLAWDVPAA HNSCC 28 SLFSVPFFLPC, PrC, Urinary bladder cancer, Uterine Cancer, HNSCC 30 FLSSEAANV OC31 GLSYIYNTV CRC, HNSCC 32 GLVATLQSLUterine Cancer, Bile Duct Cancer, HNSCC 33 ILTELPPGV AML, HNSCC 34SAFPEVRSL AML 35 SLLSEIQAL AML, NHL 36 TLLGLAVNV Brain Cancer 37VLAHITADI CRC, Urinary bladder cancer, Uterine Cancer, HNSCC 39KLLDMELEM Esophageal Cancer 40 SAAFPGASL Melanoma, Bile Duct Cancer 41SLNDQGYLL AML 42 FLVEHVLTL HNSCC NSCLC = non-small cell lung cancer,SCLC = small cell lung cancer, RCC = kidney cancer, CRC = colon orrectum cancer, GC = stomach cancer, HCC = liver cancer, PC = pancreaticcancer, PrC = prostate cancer, leukemia, BRCA = breast cancer, MCC =Merkel cell carcinoma, OC = ovarian cancer, NHL = non-Hodgkin lymphoma,AML = acute myeloid leukemia, CLL = chronic lymphocytic leukemia.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 1, 4, 24, and 40 for the—in one preferred embodimentcombined—treatment of melanoma.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 4, 20, 24, and 39 for the—in one preferred embodimentcombined—treatment of esophageal cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 4, 10, 15, 20, 23, 24, 26, 28, 31, 33, 37, and 42 forthe—in one preferred embodiment combined—treatment of HNSCC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 15, 20, 24, 32, and 40 for the—in one preferredembodiment combined—treatment of bile duct cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 15, 21, 33, 34, 35, and 41 for the—in one preferredembodiment combined—treatment of AML.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, and 30 for the—in one preferred embodimentcombined—treatment of OC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 28, and 37 for the—in one preferred embodimentcombined—treatment of urinary bladder cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, 22, 23, 24, 28, 32, and 37 for the—in onepreferred embodiment combined—treatment of uterine cancer.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 20, and 24 for the—in one preferred embodimentcombined—treatment of gallbladder cancer.

Thus, another aspect of the present invention relates to the use of thepeptide according to the present invention according to SEQ ID NO: 28for the—in one preferred embodiment combined—treatment of PC or PrC.

Thus, another aspect of the present invention relates to the use of thepeptide according to the present invention according to SEQ ID NO: 22for the—in one preferred embodiment combined—treatment of SCLC.

Thus, another aspect of the present invention relates to the use of atleast one peptide according to the present invention according to anyone of SEQ ID NO: 31, and 37 for the—in one preferred embodimentcombined—treatment of CRC.

Thus, another aspect of the present invention relates to the use of thepeptide according to the present invention according to SEQ ID NO: 35for the—in one preferred embodiment combined—treatment of NHL.

The present invention furthermore relates to peptides according to thepresent invention that have the ability to bind to a molecule of thehuman major histocompatibility complex (MHC) class-I or—in an elongatedform, such as a length-variant—MHC class

The present invention further relates to the peptides according to thepresent invention wherein said peptides (each) consist or consistessentially of an amino acid sequence according to SEQ ID NO: 1 to SEQID NO: 43.

The present invention further relates to the peptides according to thepresent invention, wherein said peptide is modified and/or includesnon-peptide bonds.

The present invention further relates to the peptides according to thepresent invention, wherein said peptide is part of a fusion protein, inparticular fused to the N-terminal amino acids of the HLA-DRantigen-associated invariant chain (Ii), or fused to (or into thesequence of) an antibody, such as, for example, an antibody that isspecific for dendritic cells.

The present invention further relates to a nucleic acid, encoding thepeptides according to the present invention. The present inventionfurther relates to the nucleic acid according to the present inventionthat is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable ofexpressing and/or expressing a nucleic acid according to the presentinvention.

The present invention further relates to a peptide according to thepresent invention, a nucleic acid according to the present invention oran expression vector according to the present invention for use in thetreatment of diseases and in medicine, in particular in the treatment ofcancer.

The present invention further relates to antibodies that are specificagainst the peptides according to the present invention or complexes ofsaid peptides according to the present invention with MHC, and methodsof making these.

The present invention further relates to T-cell receptors (TCRs), inparticular soluble TCR (sTCRs) and cloned TCRs engineered intoautologous or allogeneic T cells, and methods of making these, as wellas NK cells or other cells bearing said TCR or cross-reacting with saidTCRs.

The antibodies and TCRs are additional embodiments of theimmunotherapeutic use of the peptides according to the invention athand.

The present invention further relates to a host cell comprising anucleic acid according to the present invention or an expression vectoras described before. The present invention further relates to the hostcell according to the present invention that is an antigen presentingcell, and preferably is a dendritic cell.

The present invention further relates to a method for producing apeptide according to the present invention, said method comprisingculturing the host cell according to the present invention, andisolating the peptide from said host cell or its culture medium.

The present invention further relates to said method according to thepresent invention, wherein the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellor artificial antigen-presenting cell by contacting a sufficient amountof the antigen with an antigen-presenting cell.

The present invention further relates to the method according to thepresent invention, wherein the antigen-presenting cell comprises anexpression vector capable of expressing or expressing said peptidecontaining SEQ ID No. 1 to SEQ ID No.: 43, preferably containing SEQ IDNo. 1 to SEQ ID No. 28, or a variant amino acid sequence.

The present invention further relates to activated T cells, produced bythe method according to the present invention, wherein said T cellselectively recognizes a cell which expresses a polypeptide comprisingan amino acid sequence according to the present invention.

The present invention further relates to a method of killing targetcells in a patient which target cells aberrantly express a polypeptidecomprising any amino acid sequence according to the present invention,the method comprising administering to the patient an effective numberof T cells as produced according to the present invention.

The present invention further relates to the use of any peptide asdescribed, the nucleic acid according to the present invention, theexpression vector according to the present invention, the cell accordingto the present invention, the activated T lymphocyte, the T cellreceptor or the antibody or other peptide- and/or peptide-MHC-bindingmolecules according to the present invention as a medicament or in themanufacture of a medicament. Preferably, said medicament is activeagainst cancer.

Preferably, said medicament is a cellular therapy, a vaccine or aprotein based on a soluble TCR or antibody.

The present invention further relates to a use according to the presentinvention, wherein said cancer cells are breast cancer, acutemyelogenous leukemia, bile duct cancer, brain cancer, chroniclymphocytic leukemia, colorectal carcinoma, esophageal cancer,gallbladder cancer, gastric cancer, hepatocellular cancer, Merkel cellcarcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer,ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer,small cell lung cancer, urinary bladder cancer and uterine cancer, andpreferably breast cancer cells.

The present invention further relates to biomarkers based on thepeptides according to the present invention, herein called “targets”,that can be used in the diagnosis of cancer, preferably breast cancer.The marker can be over-presentation of the peptide(s) themselves, orover-expression of the corresponding gene(s). The markers may also beused to predict the probability of success of a treatment, preferably animmunotherapy, and most preferred an immunotherapy targeting the sametarget that is identified by the biomarker. For example, an antibody orsoluble TCR can be used to stain sections of the tumor to detect thepresence of a peptide of interest in complex with MHC.

Optionally the antibody carries a further effector function such as animmune stimulating domain or toxin.

The present invention also relates to the use of these novel targets inthe context of cancer treatment.

Both therapeutic and diagnostic uses against additional cancerousdiseases are disclosed in the following more detailed description of theunderlying expression products (polypeptides) of the peptides accordingto the invention.

A single nucleotide polymorphism of ABCC11 was shown to be associatedwith a shorter relapse-free survival in patients with non-small celllung cancer who were treated with S-1 adjuvant chemotherapy (Tsuchiya etal., 2016). ABCC11 was described as a promoter of a multi-drugresistance phenotype in breast cancer. Furthermore, high expression ofABCC11 in breast tumors was shown to be associated with aggressivesubtypes and low disease-free survival (Honorat et al., 2013; Yamada etal., 2013). ABCC11 transcript levels in colorectal cancer patients wereshown to be significantly lower in non-responders to palliativechemotherapy in comparison with responders which associated withsignificantly shorter disease-free intervals (Hlavata et al., 2012).ABCC11 was described as a potential biomarker for pemetrexed (MTA)treatment in lung adenocarcinomas (Uemura et al., 2010). ABCC11up-regulation in acute myeloid leukemia was shown to be associated witha low probability of overall survival assessed over 4 years and mayserve as a predictive marker (Guo et al., 2009). ABCC11 was shown to beup-regulated in hepatocellular carcinoma (Borel et al., 2012).

AKAP9 was shown to be up-regulated in colorectal cancer. The level ofAKAP9 expression correlated with colorectal cancer infiltrating depthand metastasis and lower survival rate in patients. Knock-down of AKAP9inhibited cell proliferation, invasion and metastasis in culturedcolorectal cancer cells, and AKAP9 deficiency in vivo was shown toaffect the colorectal cancer tumor growth and metastasis (Hu et al.,2016). A non-synonymous single-nucleotide polymorphism of AKAP9 wasdescribed as being associated with breast cancer susceptibility (Milneet al., 2014). AKAP9 was described as a novel putative cancer geneassociated with oral squamous cell carcinoma, and as a gene which formsan oncogenic fusion with the BRAF gene in thyroid cancer (Onken et al.,2014; Ganly et al., 2013).

BUB1B is a tumor inhibitory protein. BUB1B regulates the spindleassembly checkpoint. BUB1B is inactivated or down-regulated in tumors.Mutations in BUB1B are also linked to tumor development (Ayton and Oren,2011; Fagin, 2002; Malumbres and Barbacid, 2007; Rao et al., 2009).BUB1B is associated with gastric carcinogenesis through oncogenicactivation (Resende et al., 2010). BUB1B mutation is one of the causesfor colorectal cancer (Karess et al., 2013; Grady, 2004).

CCNB1 is a well-described tumor antigen and CCNB1 over-expression hasbeen described for breast, head and neck, prostate, colorectal, lung andliver cancers (Egloff et al., 2006). CCNB1 was shown to be up-regulatedin a variety of cancer entities, including colorectal cancer, breastcancer, lung cancer and renal cancer. The down-regulation of CCNB1 leadsto G2/M phase cell cycle arrest and the inhibition of proliferation andmigration (Chang et al., 2013; Sakurai et al., 2014; Fang et al., 2014;Ding et al., 2014). Genetic polymorphisms in the CCNB1 gene are relatedwith breast cancer susceptibility, progression and survival of ChineseHan woman (Li et al., 2013b).

CCNB2 is up-regulated in colorectal adenocarcinoma (Park et al., 2007).CCNB2 is over-expressed in various human tumors. Strong CCNB2 expressionin tumor cells is associated with a poor prognosis in patients withadenocarcinoma of lung and invasive breast carcinoma (Takashima et al.,2014; Albulescu, 2013).

Due to its regulating function in choline metabolism as well as being adirect target of estrogen receptor alpha, CHPT1 was identified as acandidate therapeutic target in breast cancer (Jia et al., 2016). CHPT1was found to be over-expressed in chronic lymphocytic leukemia (CLL)(Trojani et al., 2011).

COL12A1 is over-expressed in drug-resistant variants of ovarian cancercell lines (Januchowski et al., 2014). In colorectal cancer, COL12A1 isover-expressed in desmoplastic stroma by and around cancer-associatedfibroblasts, as well as in cancer cells lining the invasion front(Karagiannis et al., 2012).

COL20A1 was described as one of 16 genes which combined could be used asa breast cancer risk predictive model for Han Chinese breast cancers(Huang et al., 2013).

COL6A3 encodes the alpha-3 chain of type VI collagen, a beaded filamentcollagen found in most connective tissues, playing an important role inthe organization of matrix components (RefSeq, 2002). COL6A3 mutation(s)significantly predicted a better overall survival in patients withcolorectal carcinoma independent of tumor differentiation and TNMstaging (Yu et al., 2015). COL6A3 expression was reported to beincreased in pancreatic cancer, colon cancer, gastric cancer,mucoepidermoid carcinomas and ovarian cancer. Cancer associatedtranscript variants including exons 3, 4 and 6 were detected in coloncancer, bladder cancer, prostate cancer and pancreatic cancer (Arafat etal., 2011; Smith et al., 2009; Yang et al., 2007; Xie et al., 2014;Leivo et al., 2005; Sherman-Baust et al., 2003; Gardina et al., 2006;Thorsen et al., 2008). In ovarian cancer COL6A3 levels correlated withhigher tumor grade and in pancreatic cancer COL6A3 was shown torepresent a suitable diagnostic serum biomarker (Sherman-Baust et al.,2003; Kang et al., 2014).

It was shown that CREB3L4 is part of the hypoxia inducedhypoxia-IL6-p-STAT3-MI R155-3p-CREBRF-CREB3-ATG5 pathway, which isresponsible for an up-regulated autophagic process in glioblastomacells, head and neck cancer progression and prostate cancer (Qi et al.,2002; Bornstein et al., 2016; Xue et al., 2016a; Xue et al., 2016b). Asstress-regulated transcription factor, over-expression of CREB3 bothsubstantially increases the migration of metastatic breast cancer cellsand enhances NF-kappa B activation (Kim et al., 2010; Choi et al.,2014).

DAZAP2 gene expression is down-regulated in multiple myeloma (MM) cellsand may associate with carcinogenesis by participating in signalingpathways to regulate proliferation and differentiation of plasma cells(Shi et al., 2004). DAZAP2 is involved in the pathogenesis of MM andcould thus be used as a genetic cancer marker (Shi et al., 2007).

It was shown that DEP domain containing interacts with mTOR via theinteracting protein DEPTOR, which represents a novel prognostic markerfor differentiated thyroid carcinoma (Pei et al., 2011).

Being associated with an alerted stress level, it was shown thatDRD2-DRD4 is increased in PMBCs of breast cancer patients (Pornour etal., 2014; Akbari et al., 2015). DRD4 is able to stimulate the ERK½kinase signaling pathway and is epigenetically inhibited in pediatrictumors of the central nervous system (Unland et al., 2014). In addition,DRD4 possesses the ability to mediate ERK and Akt/NF-kappa B activationhaving an effect on cell proliferation (Zhen et al., 2001).

DUSP4 is known as a tumor suppressor gene, a lack of DUSP4 is thereforea negative prognostic indicator in diffuse large B cell lymphoma (DLBCL)(Schmid et al., 2015). Low concentrations of DUSP4 correlate with a hightumor proliferation in basal-like breast cancer (BLBC) by activating theRas-ERK pathway (Balko et al., 2012). Autophagic cell death in head andneck squamous cell carcinoma depends on DUSP4 concentrations (Li et al.,2014).

EEF2 protein was shown to be over-expressed in lung, esophageal,pancreatic, breast and prostate cancer, in glioblastoma multiforme andin non-Hodgkin's lymphoma and to play an oncogenic role in cancer cellgrowth (Oji et al., 2014; Zhu et al., 2014).

Mutations and single nucleotide polymorphisms of ESR1 are associatedwith risk for different cancer types including liver, prostate,gallbladder and breast cancer. The up-regulation of ESR1 expression isconnected with cell proliferation and tumor growth but the overallsurvival of patients with ESR1 positive tumors is better due to thesuccessfully therapy with selective estrogen receptor modulators (Sun etal., 2015; Hayashi et al., 2003; Bogush et al., 2009; Miyoshi et al.,2010; Xu et al., 2011; Yakimchuk et al., 2013; Fuqua et al., 2014). ESR1signaling interferes with different pathways responsible for celltransformation, growth and survival like the EGFR/IGFR, PI3K/Akt/mTOR,p53, HER2, NFkappaB and TGF-beta pathways (Frasor et al., 2015; Band andLaiho, 2011; Berger et al., 2013; Skandalis et al., 2014; Mehta andTripathy, 2014; Ciruelos Gil, 2014).

EXOSC4 is part of the RNA exosome, an essential ribonuclease complexinvolved in RNA processing and decay. EXOSC4 promotor activity isincreased in hepatocellular carcinoma, due to DNA hypomethylation.EXOSC4 effectively and specifically inhibits cancer cell growth and cellinvasive capacities (Stefanska et al., 2014; Drazkowska et al., 2013).

It was shown that FAH is significantly up-regulated in colorectalcarcinomas (Roth et al., 2010). There is a high risk of liver cancer intyrosinemia I patients lacking FAH but the precise reason for that isstill unknown (Tanguay et al., 1996; Kim et al., 2000).

FAP encodes a transmembrane serine protease which is selectivelyexpressed in reactive stromal fibroblasts of epithelial cancers(cancer-associated fibroblasts or CAFs), granulation tissue of healingwounds, and malignant cells of bone and soft tissue sar-comas (RefSeq,2002). FAP plays an important role in cancer growth and metastasisthrough its involvement in cell adhesion, migration processes andremodeling of the extracellular matrix (ECM) (Jacob et al., 2012). Theover-expression of FAP correlates with poor prognosis, advanced tumorstaging, metastasis formation and invasive potential in various cancers,thereunder in colon cancer, esophagus squamous cell carcinoma,pancreatic adenocarcinoma, glioblastoma, osteosarcoma, ovarian cancerand breast cancer (Wikberg et al., 2013; Kashyap et al., 2009; Cohen etal., 2008; Mentlein et al., 2011; Yuan et al., 2013; Zhang et al., 2011;Ariga et al., 2001).

FASN is a fatty acid synthase and involved in the enriched lipidsynthesis in different types of cancer, including breast, pancreatic,prostate, liver, ovarian, colon and endometrial cancer (Wu et al., 2014;Zhao et al., 2013). FBXO22 is a ubiquitin ligase and regulates histoneH3 lysine 9 and 36 methylation levels by targeting histone demethyl-aseKDM4A for ubiquitin-mediated proteasomal degradation (Tan et al., 2011).

FTL encodes the light chain of the ferritin protein representing themajor intracellular iron storage protein in prokaryotes and eukaryotes(RefSeq, 2002). It was shown that FTL effects iron delivery,immunosuppression, angiogenesis and cell proliferation and isup-regulated in various cancer types such as breast cancer, glioblastomaand renal cell carcinoma (RCC) (Na et al., 2015; Buranrat and Connor,2015; Wu et al., 2016). silencing of FTL leads to an inhibition ofglioblastoma cell proliferation via the GADD45/JNK pathway (Buranrat andConnor, 2015). Increased FTL levels represent a diagnostic andprognostic marker for breast cancer (Jezequel et al., 2012; Chekhun etal., 2013; Buranrat and Connor, 2015).

Also, known as G1P3, IF16 is able to affect the balance of pro- andanti-apoptotic members of Bcl-2 family proteins leading to breast cancerdevelopment (Cheriyath et al., 2012). By inhibiting caspase 3, IFI6functions as a survival protein that inhibits mito-chondrial-mediatedapoptosis and is up-regulated in gastric cancer, oral tongue squamouscell carcinoma and colorectal cancer (Ye et al., 2008; Leiszter et al.,2013; Tahara E Jr et al., 2005).

As epigenetic factor, KDMSB supports proliferation, migration andinvasion of human OSCC, head and neck squamous cell carcinoma (HNSCC),breast cancer and lung cancer by suppressing p53 expression (Shen etal., 2015; Tang et al., 2015; Zhao and Liu, 2015; Lin et al., 2015).Also, known as JARID1B, KDMSB promotes metastasis anepithelial-mesenchymal transition in various tumor types via PTEN/AKTsignaling (Tang et al., 2015).

High expression of KIF26B in breast cancer associates with poorprognosis (Wang et al., 2013b). KIF26B up-regulation was significantlycorrelated with tumor size analyzing CRC tumor tissues and pairedadjacent normal mucosa. KIF26B plays an important role in colorectalcarcinogenesis and functions as a novel prognostic indicator and apotential therapeutic target for CRC (Wang et al., 2015).

LAMC2 belongs to the family of laminins, a family of extracellularmatrix glycoproteins. Laminins are the major non-collagenous constituentof basement membranes. They have been implicated in a wide variety ofbiological processes including cell adhesion, differentiation,migration, signaling, neurite outgrowth and metastasis. LAMC2 encodes aprotein which is expressed in several fetal tissues and is specificallylocalized to epithelial cells in skin, lung and kidney (RefSeq, 2002).LAMC2 is highly expressed in anaplastic thyroid carcinoma and isassociated with tumor progression, migration, and invasion by modulatingsignaling of EGFR (Garg et al., 2014). LAMC2 expression predicted poorerprognosis in stage II colorectal cancer patients (Kevans et al., 2011).

LAMC2 expression together with three other biomarkers was found to besignificantly associated with the presence of LN metastasis in oralsquamous cell carcinoma patients (Zanaruddin et al., 2013).

LRRC8E encodes a member of a small, conserved family of proteinscontaining a string of extracellular leucine-rich repeats. A relatedprotein is involved in B-cell development (RefSeq, 2002). LRRC8E isover-expressed in osteosarcoma and neuroblastoma tissues in comparisonto normal samples (Orentas et al., 2012).

MAGED1 encodes the D1 member of the melanoma antigen gene (MAGE) familyand is involved in the p75 neurotrophin receptor mediated programmedcell death pathway (RefSeq, 2002). Although MAGED1 is known as a tumorsuppressor that induces cell apoptosis and suppresses cell metastasis,it is over-expressed in lung cancer, melanoma and colon cancer (Yang etal., 2014). MAGED1 is up-regulated in hepatocellular carcinoma where itaffects cell progression via interactions with apoptosis-antagonizingtranscription factor (AATF) and could thus represent a novel cancerbiomarker (Shimizu et al., 2016). MAGED1 plays an essential role in lifeactivities, including differentiation, apoptosis, and cell cycle and wasshown to affect the Wnt/beta-catenin signal pathway in esophagealsquamous cell carcinoma (Zhou et al., 2016; Zhang et al., 2016).

MAGED2 encodes melanoma antigen family D, 2, a member of a new definedMAGED cluster in Xp11.2, a hot spot for X-linked mental retardation.MAGED2 is expressed ubiquitously with high expression levels in specificbrain regions and in the interstitium of testes. MAGED2 is a potentialnegative regulator of wildtype p53 activity (Langnaese et al., 2001;Papageorgio et al., 2007). MAGED2 over-expression is associated withmelanoma, breast cancer and colon cancer (Li et al., 2004; Strekalova etal., 2015).

MAGEF1 encodes a member of the melanoma antigen (MAGE) superfamily thatcontains a microsatellite repeat and is ubiquitously expressed,suggesting a role in normal cell physiology (Stone et al., 2001).Flavopiridol induces an inhibition of human tumor cell proliferation andthe down-regulation of MAGEF1 in different human tumor cell lines (Lu etal., 2004). MAGEF1 is significantly over-expressed in colorectal cancertissues (Chung et al., 2010).

MCM8 encodes the minichromosome maintenance 8 homologous recombinationrepair factor which is part of a hexameric protein complex that is a keycomponent of the pre-replication complex and may be associated withlength of reproductive lifespan and menopause (RefSeq, 2002). MCM8 wasfound to be over-expressed in squamous cell carcinoma of the uterinecervix and was identified as direct target of MYCN, a strong inducer ofcell proliferation, in neuroblastoma (Ono et al., 2009; Koppen et al.,2007).

Genetic variants of MUC6 have been reported to modify the risk ofdeveloping gastric cancer (Resende et al., 2011). In salivary glandtumors the expression patterns of MUC6 appear to be very closelycorrelated with the histopathological tumor type indi-cating theirpotential use to improve diagnostic accuracy (Mahomed, 2011). Studieshave identified a differential expression of MUC6 in breast cancertissues when compared with the non-neoplastic breast tissues(Mukhopadhyay et al., 2011).

A Chinese study identified MXRA5 as the second most frequently mutatedgene in non-small cell lung cancer (Xiong et al., 2012). In coloncancer, MXRA5 was shown to be over-expressed and might serve as abiomarker for early diagnosis and omental metastasis (Zou et al., 2002;Wang et al., 2013a).

Influencing the activity of caspases, a dysregulation of NAIP was foundin various cancer types (Saleem et al., 2013). NAIP is significantlyover-expressed in bladder cancer, hepatocellular carcinoma, colon cancerand neuroblastoma cells where it is leading to anti-cancer drugresistances (Li et al., 2013a; Harvey et al., 2015; Xu et al., 2015).

It was shown that NDC80 regulates cell proliferation and apoptosis andis over-expressed in pancreatic cancer (PC), ovarian cancer, gastriccancer and human hepatocellular carcinoma (Liu et al., 2014; Hu et al.,2015b; Mo et al., 2013). A knockdown of NDC80 in PC induced cell cyclearrest at G0/G1 phase via suppression of Cyclin B1, Cdc2 and Cdc25A (Huet al., 2015a). NDC80 over-expression in gastric cancer cells inducedasymmetrical chromosome alignments, abnormal cell division, and thusren-dered chromosomal instability (Qu et al., 2014).

NEK10 encodes the NIMA-related kinase 10 protein and is located onchromosome 3p24.1 (RefSeq, 2002). The non-synonymous single-nucleotidepolymorphism NEK10-L513S at 3p24 was shown to be associated with breastcancer risk (Milne et al., 2014). Single-nucleotide polymorphisms inSLC4A7/NEK10 in BRCA2 carriers were shown to be associated withER-positive breast cancer (Mulligan et al., 2011). NEK10 was describedas being implicated in DNA damage response (Fry et al., 2012). NEK10 wasdescribed as a mediator of G2/M cell cycle arrest which is associatedwith the MAPK/ERK signaling pathway members ERK½, Raf-1 and MEK1 (Monizand Stambolic, 2011).

PCNT is an integral component of the centrosome that serves as amultifunctional scaffold for anchoring numerous proteins and proteincomplexes. Increased PCNT levels and centrosomal abnormalities have beendescribed in a variety of hematologic malignancies and solid tumors,including AML, CML, mantle cell lymphoma, breast cancer and prostatecancer (Delaval and Doxsey, 2010).

PLEC encodes the plakin family member plectin, a protein involved in thecross-linking and organization of the cytoskeleton and adhesioncomplexes (Bouameur et al., 2014). PLEC is over-expressed in colorectaladenocarcinoma, head and neck squamous cell carcinoma and pancreaticcancer (Lee et al., 2004; Katada et al., 2012; Bausch et al., 2011).

PLOD1 is responsible for lysine hydroxylation during theposttranslational modification of type I collagen (Tasker et al., 2006).and PLOD1 expression is associated with human breast cancer progression(Gilkes et al., 2013).

RAD54 encodes a protein belonging to the DEAD-like helicase superfamily.It shares similarity with Saccharomyces cerevisiae RAD54 and RDH54, bothof which are involved in homologous recombination and repair of DNA.This protein binds to double-stranded DNA, and displays ATPase activityin the presence of DNA. This gene is highly expressed in testis andspleen, which suggests active roles in meiotic and mi-toticrecombination (RefSeq, 2002). Homozygous mutations of RAD54B wereobserved in primary lymphoma and colon cancer (Hiramoto et al., 1999).RAD54B coun-teracts genome-destabilizing effects of direct binding ofRAD51 to dsDNA in human tumor cells (Mason et al., 2015).

Being involved in the hedgehog signaling pathway, SCUBE2 plays a centralrole in metastasis and angiogenesis in breast cancer and represents apotential biomarker for squamous cell carcinoma, colorectal cancer andendometrial cancer (Skrzypczak et al., 2013; Parris et al., 2014).SCUBE2 was identified as a novel tumor suppressor and showed correlatingtranscript levels with the expression of estrogen receptor alpha, PR andtumor suppressor PTEN (Song et al., 2015). In addition, SCUBE2 plays akey role in suppressing breast-carcinoma-cell mobility and invasivenessby increasing the formation of the epithelial E-cadherin-containingadherent junctions to promote epithelial differentiation and drive thereversal of epithelial-mesenchymal transition (Lin et al., 2014).

It was shown that SLC39A6 plays a crucial role in breast cancermetastasis by inacti-vating GSK-3beta (glycogen synthase kinase 3beta)via Akt, resulting in an activation of Snail (Hogstrand et al., 2013).Besides breast cancer, SLC39A6 was also found to be over-expressed inmelanoma, esophageal squamous cell carcinoma (ESCC), prostate, ovarian,pancreatic and uterine cancer (Unno et al., 2014; Sussman et al., 2014;Cui et al., 2015). An induced down-regulation of SLC39A6 inhepatocellular carcinoma resulted in decreased SLC39A6 expression,subsequently down-regulated SNAIL and up-regulated E-cadherin expression(Shen et al., 2013; Lian et al., 2016).

The expression of TBC1D9 was elevated in breast carcinomas of malescompared to those of females, in which ER status appeared to be relatedto expression (Andres et al., 2014). Over-expression of TBC1 D9 wascorrelated with reduced time to disease-related mortality in breastcarcinoma. Polymorphism in the TBC1D9 gene was linked with clinicaloutcomes in gastric cancer patients treated with post-operative adjuvantchemotherapy (Li et al., 2011; Andres et al., 2013).

It was shown that TFAP2A regulates different cancer- andinvasion-related genes such as MMP-2 in non-small-cell lung cancer andcyclooxygenase-2 (COX-2) in nasopharyngeal carcinomas and may play arole in the development of ovarian cancer (Du et al., 2015; Lai et al.,2013; Shi et al., 2015). TFAP2A is highly over-expressed innasopharyngeal carcinoma, where it promotes cell growth and tissuedifferentiation via HIF-1alpha-mediated VEGF/PEDF signaling (Shi et al.,2014). By interacting with Id1, TFAP2A is able to suppress theexpression of S100A9 and tumor suppressor KiSS-1 and thus promotesbreast cancer metastasis (Gumireddy et al., 2014; Mitchell et al.,2006).

TFAP2B plays a critical role in regulating lung adenocarcinomas growthand could serve as a promising therapeutic target for lung cancertreatment (Fu et al., 2014). It was shown that TFAP2B is over-expressedin melanoma cells showing an increased expression of MMP-2 as well as anincreased invasiveness (Gershenwald et al., 2001). Inactivation ofTFAP2B (and TFAP2A) lead to the formation of retinoblastoma due to theinability to differentiate along the amacrine/horizontal cell lineage(Li et al., 2010).

Over-expression of TFAP2C has been found in breast carcinomas as well asin germ cell tumors (Turner et al., 1998; Hoei-Hansen et al., 2004). Itis reported that TFAP2C induces p21 expression, arrests cell cycle andsuppresses the tumor growth of breast carcinoma cells (Li et al., 2006).

TFAP2E encodes the transcription factor AP-2 epsilon (activatingenhancer binding protein 2 epsilon) and is located on chromosome 1p34.3(RefSeq, 2002). Aberrant methylation of TFAP2E has been attributed tothe sensitivity of gastric cancer cells towards the anti-cancer drug5-fluorouridine (Wu et al., 2015; Sun et al., 2016). TFAP2Ehyper-methylation is associated with good clinical outcomes and may beconsidered as an independent prognostic factor in patients withcuratively resected colorectal cancer (Quyun et al., 2010; Zhang et al.,2014b; Park et al., 2015).

Single nucleotide polymorphisms in the THADA gene have been correlatedwith the risk of prostate cancer and colorectal cancer. Chromosomalrearrangements of the THADA gene has been found in thyroid adenomas(Rippe et al., 2003; Cheng et al., 2011; Zhao et al., 2014; Li et al.,2015).

TM9SF1 was identified as one of 17 common differentially expressed genesin urinary bladder cancer (Zaravinos et al., 2011).

TNFAIP2 encodes TNF alpha induced protein 2 and it has been suggested tobe a retinoic acid target gene in acute promyelocytic leukemia (RefSeq,2002). TNFAIP2 rs8126 polymorphism has been significantly associatedwith susceptibility of head and neck squamous cell carcinoma, gastriccancer and esophageal squamous cell carcinoma. Moreover, the TNFAIP2mRNA and protein were found to be elevated in nasopharyngeal carcinomatumor cells compared with adjacent normal tissues. Others have observedover-expression of TNFAIP2 in glioma samples (Chen et al., 2011; Liu etal., 2011; Xu et al., 2013; Zhang et al., 2014a; Cheng et al., 2015).Furthermore, over-expression of TNFAIP2 was correlated with shorterdistant metastasis-free survival in nasopharyngeal carcinoma patients(Chen et al., 2011).

TPRG1 encodes the tumor protein p63 regulated 1 and is located onchromosome 3q28 (RefSeq, 2002). It was shown that there is an existingfusion of HMGA1 to the LPP/TPRG1 intergenic region in lipoma, which mayplay a role in tumorigenesis (Wang et al., 2010).

UQCRB is a subunit of mitochondrial complex III. Inhibition of UQCRB intumor cells suppresses hypoxia-induced tumor angiogenesis (Jung et al.,2013). Two single nucleotide polymorphisms in the 3′ untranslated regionof UQCRB are candidates as prognostic markers for colorectal cancer(Lascorz et al., 2012).

ZNF407 encodes the zinc finger protein 407 which may be involved intranscriptional regulation processes (RefSeq, 2002). A mutation ofZNF407 was found in gastro-in-testinal stromal tumors and identified aspart of a minimal set of genetic abnormalities sufficient for thedevelopment of a very low risk clinically symptomatic gastric stromaltumor (Klinke et al., 2015).

ZNF451 is a transcriptional co-factor localized to promyelocyticleukemia bodies that interferes with androgen receptor and TGFI3signaling (Feng et al., 2014; Karvonen et al., 2008).

Stimulation of an immune response is dependent upon the presence ofantigens recognized as foreign by the host immune system. The discoveryof the existence of tumor associated antigens has raised the possibilityof using a host's immune system to in-tervene in tumor growth. Variousmechanisms of harnessing both the humoral and cellular arms of theimmune system are currently being explored for cancer immunotherapy.

Specific elements of the cellular immune response are capable ofspecifically recognizing and destroying tumor cells. The isolation ofT-cells from tumor-infiltrating cell populations or from peripheralblood suggests that such cells play an important role in natural immunedefense against cancer. CD8-positive T-cells in particular, whichrecognize class I molecules of the major histocompatibility complex(MHC)-bearing peptides of usually 8 to 10 amino acid residues derivedfrom proteins or defect ribosomal products (DRIPS) located in thecytosol, play an important role in this response. The MHC-molecules ofthe human are also designated as human leukocyte-antigens (HLA).

The term “T-cell response” means the specific proliferation andactivation of effector functions induced by a peptide in vitro or invivo. For MHC class I restricted cytotoxic T cells, effector functionsmay be lysis of peptide-pulsed, peptide-precursor pulsed or naturallypeptide-presenting target cells, secretion of cytokines, preferablyInterferon-gamma, TNF-alpha, or IL-2 induced by peptide, secretion ofeffector molecules, preferably granzymes or perforins induced bypeptide, or degranulation.

The term “peptide” is used herein to designate a series of amino acidresidues, connected one to the other typically by peptide bonds betweenthe alpha-amino and carbonyl groups of the adjacent amino acids. Thepeptides are preferably 9 amino acids in length, but can be as short as8 amino acids in length, and as long as 10 or 11 amino acids or longer,and in case of MHC class II peptides (elongated variants of the peptidesof the invention) they can be as long as 12, 13, 14, 15, 16, 17, 18, 19or 20 or more amino acids in length.

Furthermore, the term “peptide” shall include salts of a series of aminoacid residues, connected one to the other typically by peptide bondsbetween the alpha-amino and carbonyl groups of the adjacent amino acids.Preferably, the salts are pharmaceutical acceptable salts of thepeptides, such as, for example, the chloride or acetate(trifluoro-acetate) salts. It has to be noted that the salts of thepeptides according to the present invention differ substantially fromthe peptides in their state(s) in vivo, as the peptides are not salts invivo.

The term “peptide” shall also include “oligopeptide”. The term“oligopeptide” is used herein to designate a series of amino acidresidues, connected one to the other typically by peptide bonds betweenthe alpha-amino and carbonyl groups of the adjacent amino acids. Thelength of the oligopeptide is not critical to the invention, as long asthe correct epitope or epitopes are maintained therein. Theoligopeptides are typically less than about 30 amino acid residues inlength, and greater than about 15 amino acids in length.

The term “polypeptide” designates a series of amino acid residues,connected one to the other typically by peptide bonds between thealpha-amino and carbonyl groups of the adjacent amino acids. The lengthof the polypeptide is not critical to the invention as long as thecorrect epitopes are maintained. In contrast to the terms peptide oroligopeptide, the term polypeptide is meant to refer to moleculescontaining more than about 30 amino acid residues.

The term “full length polypeptide” means a complete protein (amino acidchain) or complete subunit (amino acid chain) of a multimeric protein.

A peptide, oligopeptide, protein or polynucleotide coding for such amolecule is “immunogenic” (and thus is an “immunogen” within the presentinvention), if it is capable of inducing an immune response. In the caseof the present invention, immunogenicity is more specifically defined asthe ability to induce a T-cell response. Thus, an “immunogen” would be amolecule that is capable of inducing an immune response, and in the caseof the present invention, a molecule capable of inducing a T-cellresponse. In another aspect, the immunogen can be the peptide, thecomplex of the peptide with MHC, oligopeptide, and/or protein that isused to raise specific antibodies or TCRs against it.

A class I T cell “epitope” requires a short peptide that is bound to aclass I MHC receptor, forming a ternary complex (MHC class I alphachain, beta-2-microglobulin, and peptide) that can be recognized by a Tcell bearing a matching T-cell receptor binding to the MHC/peptidecomplex with appropriate affinity. Peptides binding to MHC class Imolecules are typically 8-14 amino acids in length, and most typically 9amino acids in length.

In humans, there are three different genetic loci that encode MHC classI molecules (the MHC-molecules of the human are also designated humanleukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02,and HLA-B*07 are examples of different MHC class I alleles that can beexpressed from these loci.

TABLE 5 Expression frequencies F of HLA-A*02 and HLA-A*24 and the mostfrequent HLA-DR serotypes. Frequencies are deduced from haplotypefrequencies Gf within the American population adapted from Mori et al.(Mori et al., 1997) employing the Hardy-Weinberg formula F = 1 − (1 −Gf)². Combinations of A*02 or A*24 with certain HLA-DR alleles might beenriched or less frequent than expected from their single frequenciesdue to linkage disequilibrium. For details refer to Chanock et al.(Chanock et al., 2004). Calculated phenotype Allele Population fromallele frequency A*02 Caucasian (North America)  49.1% A*02 AfricanAmerican (North America)  34.1% A*02 Asian American (North America) 43.2% A*02 Latin American (North American)  48.3% DR1 Caucasian (NorthAmerica)  19.4% DR2 Caucasian (North America)  28.2% DR3 Caucasian(North America)  20.6% DR4 Caucasian (North America)  30.7% DR5Caucasian (North America)  23.3% DR6 Caucasian (North America)  26.7%DR7 Caucasian (North America)  24.8% DR8 Caucasian (North America)  5.7%DR9 Caucasian (North America)  2.1% DR1 African (North) American 13.20%DR2 African (North) American 29.80% DR3 African (North) American 24.80%DR4 African (North) American 11.10% DR5 African (North) American 31.10%DR6 African (North) American 33.70% DR7 African (North) American 19.20%DR8 African (North) American 12.10% DR9 African (North) American  5.80%DR1 Asian (North) American  6.80% DR2 Asian (North) American 33.80% DR3Asian (North) American  9.20% DR4 Asian (North) American 28.60% DR5Asian (North) American 30.00% DR6 Asian (North) American 25.10% DR7Asian (North) American 13.40% DR8 Asian (North) American 12.70% DR9Asian (North) American 18.60% DR1 Latin (North) American 15.30% DR2Latin (North) American 21.20% DR3 Latin (North) American 15.20% DR4Latin (North) American 36.80% DR5 Latin (North) American 20.00% DR6Latin (North) American 31.10% DR7 Latin (North) American 20.20% DR8Latin (North) American 18.60% DR9 Latin (North) American  2.10% A*24Philippines   65% A*24 Russia Nenets   61% A*24:02 Japan   59% A*24Malaysia   58% A*24:02 Philippines   54% A*24 India   47% A*24 SouthKorea   40% A*24 Sri Lanka   37% A*24 China   32% A*24:02 India   29%A*24 Australia West   22% A*24 USA   22% A*24 Russia Samara   20% A*24South America   20% A*24 Europe   18%

The peptides of the invention, preferably when included into a vaccineof the invention as described herein bind to A*02. A vaccine may alsoinclude pan-binding MHC class II peptides. Therefore, the vaccine of theinvention can be used to treat cancer in patients that are A*02positive, whereas no selection for MHC class II allotypes is necessarydue to the pan-binding nature of these peptides.

If A*02 peptides of the invention are combined with peptides binding toanother allele, for example A*24, a higher percentage of any patientpopulation can be treated compared with addressing either MHC class Iallele alone. While in most populations less than 50% of patients couldbe addressed by either allele alone, a vaccine comprising HLA-A*24 andHLA-A*02 epitopes can treat at least 60% of patients in any relevantpopulation. Specifically, the following percentages of patients will bepositive for at least one of these alleles in various regions: USA 61%,Western Europe 62%, China 75%, South Korea 77%, Japan 86% (calculatedfrom www.allelefrequencies.net).

In a preferred embodiment, the term “nucleotide sequence” refers to aheteropolymer of deoxyribonucleotides.

The nucleotide sequence coding for a particular peptide, oligopeptide,or polypeptide may be naturally occurring or they may be syntheticallyconstructed. Generally, DNA segments encoding the peptides,polypeptides, and proteins of this invention are assembled from cDNAfragments and short oligonucleotide linkers, or from a series ofoligonucleotides, to provide a synthetic gene that is capable of beingexpressed in a recombinant transcriptional unit comprising regulatoryelements derived from a micro-bial or viral operon.

As used herein the term “a nucleotide coding for (or encoding) apeptide” refers to a nucleotide sequence coding for the peptideincluding artificial (man-made) start and stop codons compatible for thebiological system the sequence is to be expressed by, for example, adendritic cell or another cell system useful for the production of TCRs.

As used herein, reference to a nucleic acid sequence includes bothsingle stranded and double stranded nucleic acid. Thus, for example forDNA, the specific sequence, unless the context indicates otherwise,refers to the single strand DNA of such sequence, the duplex of suchsequence with its complement (double stranded DNA) and the complement ofsuch sequence.

The term “coding region” refers to that portion of a gene which eithernaturally or normally codes for the expression product of that gene inits natural genomic environment, i.e., the region coding in vivo for thenative expression product of the gene.

The coding region can be derived from a non-mutated (“normal”), mutatedor altered gene, or can even be derived from a DNA sequence, or gene,wholly synthesized in the laboratory using methods well known to thoseof skill in the art of DNA synthesis.

The term “expression product” means the polypeptide or protein that isthe natural translation product of the gene and any nucleic acidsequence coding equivalents resulting from genetic code degeneracy andthus coding for the same amino acid(s).

The term “fragment”, when referring to a coding sequence, means aportion of DNA comprising less than the complete coding region, whoseexpression product retains essentially the same biological function oractivity as the expression product of the complete coding region.

The term “DNA segment” refers to a DNA polymer, in the form of aseparate fragment or as a component of a larger DNA construct, which hasbeen derived from DNA isolated at least once in substantially pure form,i.e., free of contaminating endogenous materials and in a quantity orconcentration enabling identification, manipulation, and recovery of thesegment and its component nucleotide sequences by standard bio-chemicalmethods, for example, by using a cloning vector. Such segments areprovided in the form of an open reading frame uninterrupted by internalnon-translated sequences, or introns, which are typically present ineukaryotic genes. Sequences of non-translated DNA may be presentdownstream from the open reading frame, where the same do not interferewith manipulation or expression of the coding regions.

The term “primer” means a short nucleic acid sequence that can be pairedwith one strand of DNA and provides a free 3′-OH end at which a DNApolymerase starts synthesis of a deoxyribonucleotide chain.

The term “promoter” means a region of DNA involved in binding of RNApolymerase to initiate transcription.

The term “isolated” means that the material is removed from its originalenvironment (e.g., the natural environment, if it is naturallyoccurring). For example, a naturally-occurring polynucleotide orpolypeptide present in a living animal is not isolated, but the samepolynucleotide or polypeptide, separated from some or all of thecoexisting materials in the natural system, is isolated. Suchpolynucleotides could be part of a vector and/or such polynucleotides orpolypeptides could be part of a composition, and still be isolated inthat such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides,disclosed in accordance with the present invention may also be in“purified” form. The term “purified” does not require absolute purity;rather, it is intended as a relative definition, and can includepreparations that are highly purified or preparations that are onlypartially purified, as those terms are understood by those of skill inthe relevant art. For example, individual clones isolated from a cDNAlibrary have been conventionally purified to electrophoretichomogeneity. Purification of starting material or natural material to atleast one order of magnitude, preferably two or three orders, and morepreferably four or five orders of magnitude is expressly contemplated.Furthermore, a claimed polypeptide which has a purity of preferably99.999%, or at least 99.99% or 99.9%; and even desirably 99% by weightor greater is expressly encompassed.

The nucleic acids and polypeptide expression products disclosedaccording to the present invention, as well as expression vectorscontaining such nucleic acids and/or such polypeptides, may be in“enriched form”. As used herein, the term “enriched” means that theconcentration of the material is at least about 2, 5, 10, 100, or 1000times its natural concentration (for example), advantageously 0.01%, byweight, preferably at least about 0.1% by weight. Enriched preparationsof about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. Thesequences, constructs, vectors, clones, and other materials comprisingthe present invention can advantageously be in enriched or isolatedform. The term “active fragment” means a fragment, usually of a peptide,polypeptide or nucleic acid sequence, that generates an immune response(i.e., has immunogenic activity) when administered, alone or optionallywith a suitable adjuvant or in a vector, to an animal, such as a mammal,for example, a rabbit or a mouse, and also including a human, suchimmune response taking the form of stimulating a T-cell response withinthe recipient animal, such as a human. Alternatively, the “activefragment” may also be used to induce a T-cell response in vitro.

As used herein, the terms “portion”, “segment” and “fragment”, when usedin relation to polypeptides, refer to a continuous sequence of residues,such as amino acid residues, which sequence forms a subset of a largersequence. For example, if a polypeptide were subjected to treatment withany of the common endopeptidases, such as trypsin or chymotrypsin, theoligopeptides resulting from such treatment would represent portions,segments or fragments of the starting polypeptide. When used in relationto polynucleotides, these terms refer to the products produced bytreatment of said polynucleotides with any of the endonucleases.

In accordance with the present invention, the term “percent identity” or“percent identical”, when referring to a sequence, means that a sequenceis compared to a claimed or described sequence after alignment of thesequence to be compared (the “Compared Sequence”) with the described orclaimed sequence (the “Reference Sequence”). The percent identity isthen determined according to the following formula:

percent identity=100[1−(C/R)]

wherein C is the number of differences between the Reference Sequenceand the Compared Sequence over the length of alignment between theReference Sequence and the Compared Sequence, wherein(i) each base or amino acid in the Reference Sequence that does not havea corresponding aligned base or amino acid in the Compared Sequence and(ii) each gap in the Reference Sequence and(iii) each aligned base or amino acid in the Reference Sequence that isdifferent from an aligned base or amino acid in the Compared Sequence,constitutes a difference and(iiii) the alignment has to start at position 1 of the alignedsequences;and R is the number of bases or amino acids in the Reference Sequenceover the length of the alignment with the Compared Sequence with any gapcreated in the Reference Sequence also being counted as a base or aminoacid.

If an alignment exists between the Compared Sequence and the ReferenceSequence for which the percent identity as calculated above is aboutequal to or greater than a specified minimum Percent Identity, then theCompared Sequence has the specified minimum percent identity to theReference Sequence even though alignments may exist in which the hereinabove calculated percent identity is less than the specified percentidentity.

As mentioned above, the present invention thus provides a peptidecomprising a sequence that is selected from the group of consisting ofSEQ ID NO: 1 to SEQ ID NO: 43 or a variant thereof which is 88%homologous to SEQ ID NO: 1 to SEQ ID NO: 43, or a variant thereof thatwill induce T cells cross-reacting with said peptide. The peptides ofthe invention have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class-I or elongated versions of saidpeptides to class II.

In the present invention, the term “homologous” refers to the degree ofidentity (see percent identity above) between sequences of two aminoacid sequences, i.e. peptide or polypeptide sequences. Theaforementioned “homology” is determined by comparing two sequencesaligned under optimal conditions over the sequences to be compared. Sucha sequence homology can be calculated by creating an alignment using,for example, the ClustalW algorithm. Commonly available sequenceanalysis software, more specifically, Vector NTI, GENETYX or other toolsare provided by public databases.

A person skilled in the art will be able to assess, whether T cellsinduced by a variant of a specific peptide will be able to cross-reactwith the peptide itself (Appay et al., 2006; Colombetti et al., 2006;Fong et al., 2001; Zaremba et al., 1997).

By a “variant” of the given amino acid sequence the inventors mean thatthe side chains of, for example, one or two of the amino acid residuesare altered (for example by replacing them with the side chain ofanother naturally occurring amino acid residue or some other side chain)such that the peptide is still able to bind to an HLA molecule insubstantially the same way as a peptide consisting of the given aminoacid sequence in consisting of SEQ ID NO: 1 to SEQ ID NO: 43. Forexample, a peptide may be modified so that it at least maintains, if notimproves, the ability to interact with and bind to the binding groove ofa suitable MHC molecule, such as HLA-A*02 or -DR, and in that way it atleast maintains, if not improves, the ability to bind to the TCR ofactivated T cells.

These T cells can subsequently cross-react with cells and kill cellsthat express a polypeptide that contains the natural amino acid sequenceof the cognate peptide as defined in the aspects of the invention. Ascan be derived from the scientific literature and databases (Rammenseeet al., 1999; Godkin et al., 1997), certain positions of HLA bindingpeptides are typically anchor residues forming a core sequence fittingto the binding motif of the HLA receptor, which is defined by polar,electrophysical, hydrophobic and spatial properties of the polypeptidechains constituting the binding groove. Thus, one skilled in the artwould be able to modify the amino acid sequences set forth in SEQ ID NO:1 to SEQ ID NO 43, by maintaining the known anchor residues, and wouldbe able to determine whether such variants maintain the ability to bindMHC class I or II molecules. The variants of the present inventionretain the ability to bind to the TCR of activated T cells, which cansubsequently cross-react with and kill cells that express a polypeptidecontaining the natural amino acid sequence of the cognate peptide asdefined in the aspects of the invention.

The original (unmodified) peptides as disclosed herein can be modifiedby the substitution of one or more residues at different, possiblyselective, sites within the peptide chain, if not otherwise stated.Preferably those substitutions are located at the end of the amino acidchain. Such substitutions may be of a conservative nature, for example,where one amino acid is replaced by an amino acid of similar structureand characteristics, such as where a hydrophobic amino acid is replacedby another hydrophobic amino acid. Even more conservative would bereplacement of amino acids of the same or similar size and chemicalnature, such as where leucine is replaced by isoleucine. In studies ofsequence variations in families of naturally occurring homologousproteins, certain amino acid substitutions are more often tolerated thanothers, and these are often show correlation with similarities in size,charge, polarity, and hydrophobicity between the original amino acid andits replacement, and such is the basis for defining “conservativesubstitutions.”

Conservative substitutions are herein defined as exchanges within one ofthe following five groups: Group 1-small aliphatic, nonpolar or slightlypolar residues (Ala, Ser, Thr, Pro, Gly); Group 2-polar, negativelycharged residues and their amides (Asp, Asn, Glu, Gin); Group 3-polar,positively charged residues (His, Arg, Lys); Group 4-large, aliphatic,nonpolar residues (Met, Leu, Ile, Val, Cys); and Group 5-large, aromaticresidues (Phe, Tyr, Trp).

Less conservative substitutions might involve the replacement of oneamino acid by another that has similar characteristics but is somewhatdifferent in size, such as replacement of an alanine by an isoleucineresidue. Highly non-conservative replace-ments might involvesubstituting an acidic amino acid for one that is polar, or even for onethat is basic in character. Such “radical” substitutions cannot,however, be dis-missed as potentially ineffective since chemical effectsare not totally predictable and radical substitutions might well giverise to serendipitous effects not otherwise predictable from simplechemical principles.

Of course, such substitutions may involve structures other than thecommon L-amino acids. Thus, D-amino acids might be substituted for theL-amino acids commonly found in the antigenic peptides of the inventionand yet still be encompassed by the disclo-sure herein. In addition,non-standard amino acids (i.e., other than the common naturallyoccurring proteinogenic amino acids) may also be used for substitutionpurposes to produce immunogens and immunogenic polypeptides according tothe present invention.

If substitutions at more than one position are found to result in apeptide with substantially equivalent or greater antigenic activity asdefined below, then combinations of those substitutions will be testedto determine if the combined substitutions result in additive orsynergistic effects on the antigenicity of the peptide. At most, no morethan 4 positions within the peptide would be simultaneously substituted.

A peptide consisting essentially of the amino acid sequence as indicatedherein can have one or two non-anchor amino acids (see below regardingthe anchor motif) exchanged without that the ability to bind to amolecule of the human major histocompatibility complex (MHC) class-I or-II is substantially changed or is negatively affected, when compared tothe non-modified peptide. In another embodiment, in a peptide consistingessentially of the amino acid sequence as indicated herein, one or twoamino acids can be exchanged with their conservative exchange partners(see herein below) without that the ability to bind to a molecule of thehuman major histocompatibility complex (MHC) class-I or -II issubstantially changed, or is negatively affected, when compared to thenon-modified peptide.

The amino acid residues that do not substantially contribute tointeractions with the T-cell receptor can be modified by replacementwith other amino acids whose incorpora-tion does not substantiallyaffect T-cell reactivity and does not eliminate binding to the relevantMHC. Thus, apart from the proviso given, the peptide of the inventionmay be any peptide (by which term the inventors include oligopeptide orpolypeptide), which includes the amino acid sequences or a portion orvariant thereof as given.

TABLE 7 Variants and motif of the peptidesaccording to SEQ ID NO: 1, 5, and 12. Position 1 2 3 4 5 6 7 8 9SEQ ID NO. 1 K M P E H I S T V Variants I L A L I L L L L A A I A L A AA V I V L V V A T I T L T T A Q I Q L Q Q A SEQ ID NO. 5 A L N P V I Y TV I L I I I I A M L M I M M A A L A I A A A V L V I V V A T L T I T T AQ L Q I Q Q A SEQ ID NO. 12 K A F P F Y N T V L I A M L M I M M A L L LI L L A V L V I V V A T L T I T T A Q L Q I Q Q A

Longer (elongated) peptides may also be suitable. It is possible thatMHC class I epitopes, although usually between 8 and 11 amino acidslong, are generated by peptide processing from longer peptides orproteins that include the actual epitope. It is preferred that theresidues that flank the actual epitope are residues that do notsubstantially affect proteolytic cleavage necessary to expose the actualepitope during processing.

The peptides of the invention can be elongated by up to four aminoacids, that is 1, 2, 3 or 4 amino acids can be added to either end inany combination between 4:0 and 0:4. Combinations of the elongationsaccording to the invention can be found in Table

TABLE 7 Combinations of the elongations of peptides of the inventionC-terminus N-terminus 4 0 3 0 or 1 2 0 or 1 or 2 1 0 or 1 or 2 or 3 0 0or 1 or 2 or 3 or 4 N-terminus C-terminus 4 0 3 0 or 1 2 0 or 1 or 2 1 0or 1 or 2 or 3 0 0 or 1 or 2 or 3 or 4

The amino acids for the elongation/extension can be the peptides of theoriginal sequence of the protein or any other amino acid(s). Theelongation can be used to enhance the stability or solubility of thepeptides.

Thus, the epitopes of the present invention may be identical tonaturally occurring tumor-associated or tumor-specific epitopes or mayinclude epitopes that differ by no more than four residues from thereference peptide, as long as they have substantially identicalantigenic activity.

In an alternative embodiment, the peptide is elongated on either or bothsides by more than 4 amino acids, preferably to a total length of up to30 amino acids. This may lead to MHC class II binding peptides. Bindingto MHC class II can be tested by methods known in the art.

Accordingly, the present invention provides peptides and variants of MHCclass I epitopes, wherein the peptide or variant has an overall lengthof between 8 and 100, preferably between 8 and 30, and most preferredbetween 8 and 14, namely 8, 9, 10, 11, 12, 13, 14 amino acids, in caseof the elongated class II binding peptides the length can also be 15,16, 17, 18, 19, 20, 21 or 22 amino acids.

Of course, the peptide or variant according to the present inventionwill have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class I or II. Binding of a peptide ora variant to a MHC complex may be tested by methods known in the art.

Preferably, when the T cells specific for a peptide according to thepresent invention are tested against the substituted peptides, thepeptide concentration at which the substituted peptides achieve half themaximal increase in lysis relative to background is no more than about 1mM, preferably no more than about 1 μM, more preferably no more thanabout 1 nM, and still more preferably no more than about 100 pM, andmost preferably no more than about 10 pM. It is also preferred that thesubstituted peptide be recognized by T cells from more than oneindividual, at least two, and more preferably three individuals.

In a particularly preferred embodiment of the invention the peptideconsists or consists essentially of an amino acid sequence according toSEQ ID NO: 1 to SEQ ID NO: 43.

“Consisting essentially of” shall mean that a peptide according to thepresent invention, in addition to the sequence according to any of SEQID NO: 1 to SEQ ID NO 43 or a variant thereof contains additional N-and/or C-terminally located stretches of amino acids that are notnecessarily forming part of the peptide that functions as an epitope forMHC molecules epitope.

Nevertheless, these stretches can be important to provide an efficientintroduction of the peptide according to the present invention into thecells. In one embodiment of the present invention, the peptide is partof a fusion protein which comprises, for example, the 80 N-terminalamino acids of the HLA-DR antigen-associated invariant chain (p33, inthe following “Ii”) as derived from the NCBI, Gen Bank Accession numberX00497. In other fusions, the peptides of the present invention can befused to an antibody as described herein, or a functional part thereof,in particular into a sequence of an antibody, so as to be specificallytargeted by said antibody, or, for example, to or into an antibody thatis specific for dendritic cells as described herein.

In addition, the peptide or variant may be modified further to improvestability and/or binding to MHC molecules in order to elicit a strongerimmune response. Methods for such an optimization of a peptide sequenceare well known in the art and include, for example, the introduction ofreverse peptide bonds or non-peptide bonds.

In a reverse peptide bond amino acid residues are not joined by peptide(—CO—NH—) linkages but the peptide bond is reversed. Such retro-inversopeptidomimetics may be made using methods known in the art, for examplesuch as those described in Meziere et al (1997) (Meziere et al., 1997),incorporated herein by reference. This approach involves makingpseudopeptides containing changes involving the backbone, and not theorientation of side chains. Meziere et al. (Meziere et al., 1997) showthat for MHC binding and T helper cell responses, these pseudopeptidesare useful. Retro-inverse peptides, which contain NH—CO bonds instead ofCO—NH peptide bonds, are much more resistant to proteolysis.

A non-peptide bond is, for example, —CH₂—NH, —CH₂S—, —CH₂CH₂—, —CH═CH—,—COCH₂—, —CH(OH)CH₂—, and —CH₂SO—. U.S. Pat. No. 4,897,445 provides amethod for the solid phase synthesis of non-peptide bonds (—CH₂—NH) inpolypeptide chains which involves polypeptides synthesized by standardprocedures and the non-peptide bond synthesized by reacting an aminoaldehyde and an amino acid in the presence of NaCNBH₃.

Peptides comprising the sequences described above may be synthesizedwith additional chemical groups present at their amino and/or carboxytermini, to enhance the stability, bioavailability, and/or affinity ofthe peptides. For example, hydrophobic groups such as carbobenzoxyl,dansyl, or t-butyloxycarbonyl groups may be added to the peptides' aminotermini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonylgroup may be placed at the peptides' amino termini. Additionally, thehydrophobic group, t-butyloxycarbonyl, or an amido group may be added tothe peptides' carboxy termini.

Further, the peptides of the invention may be synthesized to alter theirsteric configu-ration. For example, the D-isomer of one or more of theamino acid residues of the peptide may be used, rather than the usualL-isomer. Still further, at least one of the amino acid residues of thepeptides of the invention may be substituted by one of the well-knownnon-naturally occurring amino acid residues. Alterations such as thesemay serve to increase the stability, bioavailability and/or bindingaction of the peptides of the invention.

Similarly, a peptide or variant of the invention may be modifiedchemically by reacting specific amino acids either before or aftersynthesis of the peptide. Examples for such modifications are well knownin the art and are summarized e.g. in R. Lundblad, Chemical Reagents forProtein Modification, 3rd ed. CRC Press, 2004 (Lundblad, 2004), which isincorporated herein by reference. Chemical modification of amino acidsincludes but is not limited to, modification by acylation, amidination,pyridoxylation of lysine, reductive alkylation, trinitrobenzylation ofamino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amidemodification of carboxyl groups and sulphydryl modification by performicacid oxidation of cysteine to cysteic acid, formation of mer-curialderivatives, formation of mixed disulphides with other thiol compounds,reaction with maleimide, carboxymethylation with iodoacetic acid oriodoacetamide and car-bamoylation with cyanate at alkaline pH, althoughwithout limitation thereto. In this regard, the skilled person isreferred to Chapter 15 of Current Protocols In Protein Science, Eds.Coligan et al. (John Wiley and Sons NY 1995-2000) (Coligan et al., 1995)for more extensive methodology relating to chemical modification ofproteins.

Briefly, modification of e.g. arginyl residues in proteins is oftenbased on the reaction of vicinal dicarbonyl compounds such asphenylglyoxal, 2,3-butanedione, and 1,2-cy-clohexanedione to form anadduct. Another example is the reaction of methylglyoxal with arginineresidues. Cysteine can be modified without concomitant modification ofother nucleophilic sites such as lysine and histidine. As a result, alarge number of reagents are available for the modification of cysteine.The websites of companies such as Sigma-Aldrich (www.sigma-aldrich.com)provide information on specific reagents.

Selective reduction of disulfide bonds in proteins is also common.Disulfide bonds can be formed and oxidized during the heat treatment ofbiopharmaceuticals. Woodward's Reagent K may be used to modify specificglutamic acid residues.N-(3-(dimethyla-mino)propyl)-N′-ethylcarbodiimide can be used to formintra-molecular crosslinks between a lysine residue and a glutamic acidresidue. For example, diethylpyrocarbonate is a reagent for themodification of histidyl residues in proteins. Histidine can also bemodified using 4-hydroxy-2-nonenal. The reaction of lysine residues andother α-amino groups is, for example, useful in binding of peptides tosurfaces or the cross-linking of proteins/peptides. Lysine is the siteof attachment of poly(ethylene)glycol and the major site of modificationin the glycosylation of proteins. Methionine residues in proteins can bemodified with e.g. iodoacetamide, bromoethylamine, and chloramine T.

Tetranitromethane and N-acetylimidazole can be used for the modificationof tyrosyl residues. Cross-linking via the formation of dityrosine canbe accomplished with hydrogen peroxide/copper ions.

Recent studies on the modification of tryptophan have usedN-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide or3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-in-dole (BPNS-skatole).

Successful modification of therapeutic proteins and peptides with PEG isoften associated with an extension of circulatory half-life whilecross-linking of proteins with glutar-aldehyde, polyethylene glycoldiacrylate and formaldehyde is used for the preparation of hydrogels.Chemical modification of allergens for immunotherapy is often achievedby carbamylation with potassium cyanate.

A peptide or variant, wherein the peptide is modified or includesnon-peptide bonds is a preferred embodiment of the invention.

Another embodiment of the present invention relates to a non-naturallyoccurring peptide wherein said peptide consists or consists essentiallyof an amino acid sequence according to SEQ ID No: 1 to SEQ ID No: 43 andhas been synthetically produced (e.g. synthesized) as a pharmaceuticallyacceptable salt. Methods to synthetically produce peptides are wellknown in the art. The salts of the peptides according to the presentinvention differ substantially from the peptides in their state(s) invivo, as the peptides as generated in vivo are no salts. The non-naturalsalt form of the peptide mediates the solubility of the peptide, inparticular in the context of pharmaceutical compositions comprising thepeptides, e.g. the peptide vaccines as disclosed herein. A sufficientand at least substantial solubility of the peptide(s) is required inorder to efficiently provide the peptides to the subject to be treated.Preferably, the salts are pharmaceutically acceptable salts of thepeptides. These salts according to the invention include alkaline andearth alkaline salts such as salts of the Hofmeister series comprisingas anions PO₄ ³⁻, SO₄ ²⁻, CH₃COO⁻, Cl⁻, Br, NO₃ ⁻, ClO₄ ⁻, SCN⁻ and ascations NH₄ ⁺, Rb⁺, K⁺, Na⁺, Cs⁺, Li⁺, Zn²⁺, Mg²⁺, Ca²⁺, Mn²⁺, Cu²⁺ andBa²⁺. Particularly salts are selected from (NH₄)₃PO₄, (NH₄)₂HPO₄,(NH₄)H₂PO₄, (NH₄)₂SO₄, NH₄CH₃COO, NH₄Cl, NH₄Br, NH₄NO₃, NH₄ClO₄, NH₄I,NH₄SCN, Rb₃PO₄, Rb₂HPO₄, RbH₂PO₄, Rb₂SO₄, Rb₄CH₃COO, Rb₄Cl, Rb₄Br,Rb₄NO₃, Rb₄ClO₄, Rb₄I, Rb₄SCN, K₃PO₄, K₂HPO₄, KH₂PO₄, K₂SO₄, KCH₃COO,KCl, KBr, KNO₃, KClO₄, KI, KSCN, Na₃PO₄, Na₂HPO₄, NaH₂PO₄, Na₂SO₄,NaCH₃COO, NaCl, NaBr, NaNO₃, NaClO₄, Nal, NaSCN, ZnCl₂ Cs₃PO₄, Cs₂HPO₄,CsH₂PO₄, Cs₂SO₄, CsCH₃COO, CsCl, CsBr, CsNO₃, CsClO₄, CSI, CsSCN,Li₃PO₄, Li₂HPO₄, LiH₂PO₄, Li₂SO₄, LiCH₃COO, LiCl, LiBr, LiNO₃, LiClO₄,Lil, LiSCN, Cu₂SO₄, Mg₃(PO₄)₂, Mg₂HPO₄, Mg(H₂PO₄)₂, Mg₂SO₄, Mg(CH₃COO)₂,MgCl₂, MgBr₂, Mg(NO₃)₂, Mg(ClO₄)₂, MgI₂, Mg(SCN)₂, MnCl₂, Ca₃(PO₄),Ca₂HPO₄, Ca(H₂PO₄)₂, CaSO₄, Ca(CH₃COO)₂, CaCl₂, CaBr₂, Ca(NO₃)₂,Ca(ClO₄)₂, CaI₂, Ca(SCN)₂, Ba₃(PO₄)₂, Ba₂HPO₄, Ba(H₂PO₄)₂, BaSO₄,Ba(CH₃COO)₂, BaCl₂, BaBr₂, Ba(NO₃)₂, Ba(ClO₄)₂, Bal₂, and Ba(SCN)₂.Particularly preferred are NH acetate, MgCl₂, KH₂PO₄, Na₂SO₄, KCl, NaCl,and CaCl₂, such as, for example, the chloride or acetate(trifluoroacetate) salts.

Generally, peptides and variants (at least those containing peptidelinkages between amino acid residues) may be synthesized by theFmoc-polyamide mode of solid-phase peptide synthesis as disclosed byLukas et al. (Lukas et al., 1981) and by references as cited therein.Temporary N-amino group protection is afforded by the9-fluorenyl-methyloxycarbonyl (Fmoc) group. Repetitive cleavage of thishighly base-labile protecting group is done using 20% piperidine in N,N-dimethylformamide. Side-chain functionalities may be protected astheir butyl ethers (in the case of serine threonine and tyrosine), butylesters (in the case of glutamic acid and aspartic acid),butyloxycarbonyl derivative (in the case of lysine and histidine),trityl derivative (in the case of cysteine) and4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case ofarginine). Where glutamine or asparagine are C-terminal residues, use ismade of the 4,4′-dimethoxybenzhydryl group for protection of the sidechain amido functionalities. The solid-phase support is based on apolydimethyl-acrylamide polymer constituted from the three monomersdimethylacrylamide (backbone-monomer), bisacryloyleth-ylene diamine(cross linker) and acryloylsarcosine methyl ester (functionalizingagent). The peptide-to-resin cleavable linked agent used is theacid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All aminoacid derivatives are added as their preformed symmetrical anhydridederivatives with the exception of asparagine and glutamine, which areadded using a reversed N, N-dicyclohexyl-carbodiimide/1hydroxybenzotria-zole mediated coupling procedure. All coupling anddeprotection reactions are monitored using ninhydrin, trinitrobenzenesulphonic acid or isotin test procedures. Upon completion of synthesis,peptides are cleaved from the resin support with concomitant removal ofside-chain protecting groups by treatment with 95% trifluoroacetic acidcontaining a 50% scavenger mix. Scavengers commonly used includeethanedithiol, phe-nol, anisole and water, the exact choice depending onthe constituent amino acids of the peptide being synthesized. Also acombination of solid phase and solution phase methodologies for thesynthesis of peptides is possible (see, for example, (Bruckdorfer etal., 2004), and the references as cited therein).

Trifluoroacetic acid is removed by evaporation in vacuo, with subsequenttrituration with diethyl ether affording the crude peptide. Anyscavengers present are removed by a simple extraction procedure which onlyophilization of the aqueous phase affords the crude peptide free ofscavengers. Reagents for peptide synthesis are generally available frome.g. Calbiochem-Novabiochem (Nottingham, UK).

Purification may be performed by any one, or a combination of,techniques such as re-crystallization, size exclusion chromatography,ion-exchange chromatography, hydrophobic interaction chromatography and(usually) reverse-phase high performance liquid chromatography usinge.g. acetonitrile/water gradient separation.

Analysis of peptides may be carried out using thin layer chromatography,electrophoresis, in particular capillary electrophoresis, solid phaseextraction (CSPE), reverse-phase high performance liquid chromatography,amino-acid analysis after acid hydrol-ysis and by fast atom bombardment(FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF massspectrometric analysis.

In order to select over-presented peptides, a presentation profile iscalculated showing the median sample presentation as well as replicatevariation. The profile juxtaposes samples of the tumor entity ofinterest to a baseline of normal tissue samples. Each of these profilescan then be consolidated into an over-presentation score by calculatingthe p-value of a Linear Mixed-Effects Model (Pinheiro et al., 2015)adjusting for multiple testing by False Discovery Rate (Benjamini andHochberg, 1995) (cf. Example 1, FIGS. 1A-1N).

For the identification and relative quantitation of HLA ligands by massspectrometry, HLA molecules from shock-frozen tissue samples werepurified and HLA-associated peptides were isolated. The isolatedpeptides were separated and sequences were identified by onlinenano-electrospray-ionization (nanoESI) liquid chromatography-massspectrometry (LC-MS) experiments. The resulting peptide sequences werever-ified by comparison of the fragmentation pattern of naturaltumor-associated peptides (TUMAPs) recorded from breast cancer samples(N=17 A*02-positive samples) with the fragmentation patterns ofcorresponding synthetic reference peptides of identical sequences. Sincethe peptides were directly identified as ligands of HLA molecules ofprimary tumors, these results provide direct evidence for the naturalprocessing and presentation of the identified peptides on primary cancertissue obtained from 17 breast cancer patients.

The discovery pipeline XPRESIDENT® v2.1 (see, for example, US2013-0096016, which is hereby incorporated by reference in its entirety)allows the identification and selection of relevant over-presentedpeptide vaccine candidates based on direct relative quantitation ofHLA-restricted peptide levels on cancer tissues in comparison to severaldifferent non-cancerous tissues and organs. This was achieved by thedevelopment of label-free differential quantitation using the acquiredLC-MS data processed by a proprietary data analysis pipeline, combiningalgorithms for sequence identification, spectral clustering, ioncounting, retention time alignment, charge state deconvolution andnormalization.

Presentation levels including error estimates for each peptide andsample were established. Peptides exclusively presented on tumor tissueand peptides over-presented in tumor versus non-cancerous tissues andorgans have been identified.

HLA-peptide complexes from breast cancer tissue samples were purifiedand HLA-associated peptides were isolated and analyzed by LC-MS (seeexamples). All TUMAPs contained in the present application wereidentified with this approach on primary breast cancer samplesconfirming their presentation on primary breast cancer.

TUMAPs identified on multiple breast cancer and normal tissues werequantified using ion-counting of label-free LC-MS data. The methodassumes that LC-MS signal areas of a peptide correlate with itsabundance in the sample. All quantitative signals of a peptide invarious LC-MS experiments were normalized based on central tendency,averaged per sample and merged into a bar plot, called presentationprofile. The presentation profile consolidates different analysismethods like protein database search, spectral clustering, charge statedeconvolution (decharging) and retention time alignment andnormalization.

Besides over-presentation of the peptide, mRNA expression of theunderlying gene was tested. mRNA data were obtained via RNASeq analysesof normal tissues and cancer tissues (cf. Example 2, FIGS. 2A-2C). Anadditional source of normal tissue data was a database of publiclyavailable RNA expression data from around 3000 normal tissue samples(Lonsdale, 2013). Peptides which are derived from proteins whose codingmRNA is highly expressed in cancer tissue, but very low or absent invital normal tissues, were preferably included in the present invention.

The present invention provides peptides that are useful in treatingcancers/tumors, preferably breast cancer that over- or exclusivelypresent the peptides of the invention. These peptides were shown by massspectrometry to be naturally presented by HLA molecules on primary humanbreast cancer samples.

Many of the source gene/proteins (also designated “full-length proteins”or “underlying proteins”) from which the peptides are derived were shownto be highly over-expressed in cancer compared with normaltissues—“normal tissues” in relation to this invention shall mean eitherhealthy breast cells or other normal tissue cells, demonstrating a highdegree of tumor association of the source genes (see Example 2).Moreover, the peptides themselves are strongly over-presented on tumortissue—“tumor tissue” in relation to this invention shall mean a samplefrom a patient suffering from breast cancer, but not on normal tissues(see Example 1).

HLA-bound peptides can be recognized by the immune system, specificallyT lymphocytes. T cells can destroy the cells presenting the recognizedHLA/peptide complex, e.g. breast cancer cells presenting the derivedpeptides.

The peptides of the present invention have been shown to be capable ofstimulating T cell responses and/or are over-presented and thus can beused for the production of antibodies and/or TCRs, such as soluble TCRs,according to the present invention (see Example 3, Example 4).Furthermore, the peptides when complexed with the respective MHC can beused for the production of antibodies and/or TCRs, in particular sTCRs,according to the present invention, as well. Respective methods are wellknown to the person of skill, and can be found in the respectiveliterature as well. Thus, the peptides of the present invention areuseful for generating an immune response in a patient by which tumorcells can be destroyed. An immune response in a patient can be inducedby direct administration of the described peptides or suitable precursorsubstances (e.g. elongated peptides, proteins, or nucleic acids encodingthese peptides) to the patient, ideally in combination with an agentenhancing the immunogenicity (i.e. an adjuvant). The immune responseoriginating from such a therapeutic vaccination can be expected to behighly specific against tumor cells because the target peptides of thepresent invention are not presented on normal tissues in comparable copynumbers, preventing the risk of undesired autoimmune reactions againstnormal cells in the patient.

The present description further relates to T-cell receptors (TCRs)comprising an alpha chain and a beta chain (“alpha/beta TCRs”). Alsoprovided are peptides according to the invention capable of binding toTCRs and antibodies when presented by an MHC molecule. The presentdescription also relates to nucleic acids, vectors and host cells forexpressing TCRs and peptides of the present description; and methods ofusing the same.

The term “T-cell receptor” (abbreviated TCR) refers to a heterodimericmolecule comprising an alpha polypeptide chain (alpha chain) and a betapolypeptide chain (beta chain), wherein the heterodimeric receptor iscapable of binding to a peptide antigen presented by an HLA molecule.The term also includes so-called gamma/delta TCRs.

In one embodiment the description provides a method of producing a TCRas described herein, the method comprising culturing a host cell capableof expressing the TCR under conditions suitable to promote expression ofthe TCR.

The description in another aspect relates to methods according to thedescription, wherein the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellor artificial antigen-presenting cell by contacting a sufficient amountof the antigen with an antigen-presenting cell or the antigen is loadedonto class I or II MHC tetramers by tetramerizing the antigen/class I orII MHC complex monomers.

The alpha and beta chains of alpha/beta TCR's, and the gamma and deltachains of gamma/delta TCRs, are generally regarded as each having two“domains”, namely variable and constant domains. The variable domainconsists of a concatenation of variable region (V), and joining region(J). The variable domain may also include a leader region (L). Beta anddelta chains may also include a diversity region (D). The alpha and betaconstant domains may also include C-terminal transmembrane (TM) domainsthat anchor the alpha and beta chains to the cell membrane.

With respect to gamma/delta TCRs, the term “TCR gamma variable domain”as used herein refers to the concatenation of the TCR gamma V (TRGV)region without leader region (L), and the TCR gamma J (TRGJ) region, andthe term TCR gamma constant domain refers to the extracellular TRGCregion, or to a C-terminal truncated TRGC sequence. Likewise the term“TCR delta variable domain” refers to the concatenation of the TCR deltaV (TRDV) region without leader region (L) and the TCR delta D/J(TRDD/TRDJ) region, and the term “TCR delta constant domain” refers tothe extracellular TRDC region, or to a C-terminal truncated TRDCsequence.

TCRs of the present description preferably bind to an peptide-HLAmolecule complex with a binding affinity (KD) of about 100 μM or less,about 50 μM or less, about 25 μM or less, or about 10 μM or less. Morepreferred are high affinity TCRs having binding affinities of about 1 μMor less, about 100 nM or less, about 50 nM or less, about 25 nM or less.Non-limiting examples of preferred binding affinity ranges for TCRs ofthe present invention include about 1 nM to about 10 nM; about 10 nM toabout 20 nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM;about 40 nM to about 50 nM; about 50 nM to about 60 nM; about 60 nM toabout 70 nM; about 70 nM to about 80 nM; about 80 nM to about 90 nM; andabout 90 nM to about 100 nM.

As used herein in connect with TCRs of the present description,“specific binding” and grammatical variants thereof are used to mean aTCR having a binding affinity (KD) for a peptide-HLA molecule complex of100 μM or less.

Alpha/beta heterodimeric TCRs of the present description may have anintroduced disulfide bond between their constant domains. Preferred TCRsof this type include those which have a TRAC constant domain sequenceand a TRBC1 or TRBC2 constant domain sequence except that Thr 48 of TRACand Ser 57 of TRBC1 or TRBC2 are replaced by cysteine residues, the saidcysteines forming a disulfide bond between the TRAC constant domainsequence and the TRBC1 or TRBC2 constant domain sequence of the TCR.

With or without the introduced inter-chain bond mentioned above,alpha/beta heterodimeric TCRs of the present description may have a TRACconstant domain sequence and a TRBC1 or TRBC2 constant domain sequence,and the TRAC constant domain sequence and the TRBC1 or TRBC2 constantdomain sequence of the TCR may be linked by the native disulfide bondbetween Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.

TCRs of the present description may comprise a detectable label selectedfrom the group consisting of a radionuclide, a fluorophore and biotin.TCRs of the present description may be conjugated to a therapeuticallyactive agent, such as a radionuclide, a chemotherapeutic agent, or atoxin.

In an embodiment, a TCR of the present description having at least onemutation in the alpha chain and/or having at least one mutation in thebeta chain has modified glycosylation compared to the unmutated TCR.

In an embodiment, a TCR comprising at least one mutation in the TCRalpha chain and/or TCR beta chain has a binding affinity for, and/or abinding half-life for, a peptide-HLA molecule complex, which is at leastdouble that of a TCR comprising the unmutated TCR alpha chain and/orunmutated TCR beta chain. Affinity-enhancement of tumor-specific TCRs,and its exploitation, relies on the existence of a window for optimalTCR affinities. The existence of such a window is based on observationsthat TCRs specific for HLA-A2-restricted pathogens have KD values thatare generally about 10-fold lower when compared to TCRs specific forHLA-A2-restricted tumor-associated self-antigens. It is now known,although tumor antigens have the potential to be immunogenic, becausetumors arise from the individual's own cells only mutated proteins orproteins with altered translational processing will be seen as foreignby the immune system. Antigens that are upregulated or overexpressed (socalled self-antigens) will not necessarily induce a functional immuneresponse against the tumor: T-cells expressing TCRs that are highlyreactive to these antigens will have been negatively selected within thethymus in a process known as central tolerance, meaning that onlyT-cells with low-affinity TCRs for self-antigens remain. Therefore,affinity of TCRs or variants of the present description to pepides canbe enhanced by methods well known in the art.

The present description further relates to a method of identifying andisolating a TCR according to the present description, said methodcomprising incubating PBMCs from HLA-A*02-negative healthy donors withA2/peptide monomers, incubating the PBMCs with tetramer-phycoerythrin(PE) and isolating the high avidity T-cells by fluorescence activatedcell sorting (FACS)-Calibur analysis.

The present description further relates to a method of identifying andisolating a TCR according to the present description, said methodcomprising obtaining a transgenic mouse with the entire human TCRαβ geneloci (1.1 and 0.7 Mb), whose T-cells express a diverse human TCRrepertoire that compensates for mouse TCR deficiency, immunizing themouse with a peptide, incubating PBMCs obtained from the transgenic micewith tetramer-phycoerythrin (PE), and isolating the high avidity T-cellsby fluorescence activated cell sorting (FACS)-Calibur analysis.

In one aspect, to obtain T-cells expressing TCRs of the presentdescription, nucleic acids encoding TCR-alpha and/or TCR-beta chains ofthe present description are cloned into expression vectors, such asgamma retrovirus or lentivirus. The recombinant viruses are generatedand then tested for functionality, such as antigen specificity andfunctional avidity. An aliquot of the final product is then used totransduce the target T-cell population (generally purified from patientPBMCs), which is expanded before infusion into the patient.

In another aspect, to obtain T-cells expressing TCRs of the presentdescription, TCR RNAs are synthesized by techniques known in the art,e.g., in vitro transcription systems. The in vitro-synthesized TCR RNAsare then introduced into primary CD8+ T-cells obtained from healthydonors by electroporation to re-express tumor specific TCR-alpha and/orTCR-beta chains.

To increase the expression, nucleic acids encoding TCRs of the presentdescription may be operably linked to strong promoters, such asretroviral long terminal repeats (LTRs), cytomegalovirus (CMV), murinestem cell virus (MSCV) U3, phosphoglycerate kinase (PGK), β-actin,ubiquitin, and a simian virus 40 (SV40)/CD43 composite promoter,elongation factor (EF)-1a and the spleen focus-forming virus (SFFV)promoter. In a preferred embodiment, the promoter is heterologous to thenucleic acid being expressed.

In addition to strong promoters, TCR expression cassettes of the presentdescription may contain additional elements that can enhance transgeneexpression, including a central polypurine tract (cPPT), which promotesthe nuclear translocation of lentiviral constructs (Follenzi et al.,2000), and the woodchuck hepatitis virus posttranscriptional regulatoryelement (wPRE), which increases the level of transgene expression byincreasing RNA stability (Zufferey et al., 1999).

The alpha and beta chains of a TCR of the present invention may beencoded by nucleic acids located in separate vectors, or may be encodedby polynucleotides located in the same vector.

Achieving high-level TCR surface expression requires that both theTCR-alpha and TCR-beta chains of the introduced TCR be transcribed athigh levels. To do so, the TCR-alpha and TCR-beta chains of the presentdescription may be cloned into bi-cistronic constructs in a singlevector, which has been shown to be capable of over-coming this obstacle.The use of a viral intraribosomal entry site (IRES) between theTCR-alpha and TCR-beta chains results in the coordinated expression ofboth chains, because the TCR-alpha and TCR-beta chains are generatedfrom a single transcript that is broken into two proteins duringtranslation, ensuring that an equal molar ratio of TCR-alpha andTCR-beta chains are produced. (Schmitt et al. 2009).

Nucleic acids encoding TCRs of the present description may be codonoptimized to increase expression from a host cell. Redundancy in thegenetic code allows some amino acids to be encoded by more than onecodon, but certain codons are less “optimal” than others because of therelative availability of matching tRNAs as well as other factors(Gustafsson et al., 2004). Modifying the TCR-alpha and TCR-beta genesequences such that each amino acid is encoded by the optimal codon formammalian gene expression, as well as eliminating mRNA instabilitymotifs or cryptic splice sites, has been shown to significantly enhanceTCR-alpha and TCR-beta gene expression (Scholten et al., 2006).

Furthermore, mispairing between the introduced and endogenous TCR chainsmay result in the acquisition of specificities that pose a significantrisk for autoimmunity. For example, the formation of mixed TCR dimersmay reduce the number of CD3 molecules available to form properly pairedTCR complexes, and therefore can significantly decrease the functionalavidity of the cells expressing the introduced TCR (Kuball et al.,2007).

To reduce mispairing, the C-terminus domain of the introduced TCR chainsof the present description may be modified in order to promoteinterchain affinity, while de-creasing the ability of the introducedchains to pair with the endogenous TCR. These strategies may includereplacing the human TCR-alpha and TCR-beta C-terminus domains with theirmurine counterparts (murinized C-terminus domain); generating a secondinterchain disulfide bond in the C-terminus domain by introducing asecond cysteine residue into both the TCR-alpha and TCR-beta chains ofthe introduced TCR (cysteine modification); swapping interactingresidues in the TCR-alpha and TCR-beta chain C-terminus domains(“knob-in-hole”); and fusing the variable domains of the TCR-alpha andTCR-beta chains directly to CD3ζ (CD3ζ fusion). (Schmitt et al. 2009).

In an embodiment, a host cell is engineered to express a TCR of thepresent description. In preferred embodiments, the host cell is a humanT-cell or T-cell progenitor. In some embodiments the T-cell or T-cellprogenitor is obtained from a cancer patient. In other embodiments theT-cell or T-cell progenitor is obtained from a healthy donor. Host cellsof the present description can be allogeneic or autologous with respectto a patient to be treated. In one embodiment, the host is a gamma/deltaT-cell transformed to express an alpha/beta TCR.

A “pharmaceutical composition” is a composition suitable foradministration to a human being in a medical setting. Preferably, apharmaceutical composition is sterile and produced according to GMPguidelines.

The pharmaceutical compositions comprise the peptides either in the freeform or in the form of a pharmaceutically acceptable salt (see alsoabove). As used herein, “a pharmaceutically acceptable salt” refers to aderivative of the disclosed peptides wherein the peptide is modified bymaking acid or base salts of the agent. For example, acid salts areprepared from the free base (typically wherein the neutral form of thedrug has a neutral —NH₂ group) involving reaction with a suitable acid.Suitable acids for preparing acid salts include both organic acids,e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalicacid, malic acid, malonic acid, succinic acid, maleic acid, fumaricacid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelicacid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonicacid, salicylic acid, and the like, as well as inorganic acids, e.g.,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acidphosphoric acid and the like. Conversely, preparation of basic salts ofacid moieties which may be present on a peptide are prepared using apharmaceutically acceptable base such as sodium hydroxide, potassiumhydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or thelike.

In an especially preferred embodiment, the pharmaceutical compositionscomprise the peptides as salts of acetic acid (acetates), trifluoroacetates or hydrochloric acid (chlo-rides).

Preferably, the medicament of the present invention is animmunotherapeutic such as a vaccine. It may be administered directlyinto the patient, into the affected organ or systemically i.d., i.m.,s.c., i.p. and i.v., or applied ex vivo to cells derived from thepatient or a human cell line which are subsequently administered to thepatient, or used in vitro to select a subpopulation of immune cellsderived from the patient, which are then re-administered to the patient.If the nucleic acid is administered to cells in vitro, it may be usefulfor the cells to be transfected so as to co-express immune-stimulatingcytokines, such as interleukin-2. The peptide may be substantially pure,or combined with an immune-stimulating adjuvant (see below) or used incombination with immune-stimulatory cytokines, or be administered with asuitable delivery system, for example liposomes. The peptide may also beconjugated to a suitable carrier such as keyhole limpet haemocyanin(KLH) or mannan (see WO 95/18145 and (Longenecker et al., 1993)). Thepeptide may also be tagged, may be a fusion protein, or may be a hybridmolecule. The peptides whose sequence is given in the present inventionare expected to stimulate CD4 or CD8 T cells. However, stimulation ofCD8 T cells is more efficient in the presence of help provided by CD4T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 Tcells the fusion partner or sections of a hybrid molecule suitablyprovide epitopes which stimulate CD4-positive T cells. CD4- andCD8-stimulating epitopes are well known in the art and include thoseidentified in the present invention.

In one aspect, the vaccine comprises at least one peptide having theamino acid sequence set forth SEQ ID No. 1 to SEQ ID No. 43, and atleast one additional peptide, preferably two to 50, more preferably twoto 25, even more preferably two to 20 and most preferably two, three,four, five, six, seven, eight, nine, ten, eleven, twelve, thir-teen,fourteen, fifteen, sixteen, seventeen or eighteen peptides. Thepeptide(s) may be derived from one or more specific TAAs and may bind toMHC class I molecules.

A further aspect of the invention provides a nucleic acid (for example apolynucleotide) encoding a peptide or peptide variant of the invention.The polynucleotide may be, for example, DNA, cDNA, PNA, RNA orcombinations thereof, either single- and/or dou-ble-stranded, or nativeor stabilized forms of polynucleotides, such as, for example,polynucleotides with a phosphorothioate backbone and it may or may notcontain introns so long as it codes for the peptide. Of course, onlypeptides that contain naturally occurring amino acid residues joined bynaturally occurring peptide bonds are en-codable by a polynucleotide. Astill further aspect of the invention provides an expression vectorcapable of expressing a polypeptide according to the invention.

A variety of methods have been developed to link polynucleotides,especially DNA, to vectors for example via complementary cohesivetermini. For instance, complementary homopolymer tracts can be added tothe DNA segment to be inserted to the vector DNA. The vector and DNAsegment are then joined by hydrogen bonding between the complementaryhomopolymeric tails to form recombinant DNA molecules.

Synthetic linkers containing one or more restriction sites provide analternative method of joining the DNA segment to vectors. Syntheticlinkers containing a variety of restriction endonuclease sites arecommercially available from a number of sources including InternationalBiotechnologies Inc. New Haven, Conn., USA.

A desirable method of modifying the DNA encoding the polypeptide of theinvention employs the polymerase chain reaction as disclosed by Saiki RK, et al. (Saiki et al., 1988). This method may be used for introducingthe DNA into a suitable vector, for example by engineering in suitablerestriction sites, or it may be used to modify the DNA in other usefulways as is known in the art. If viral vectors are used, pox- orade-novirus vectors are preferred.

The DNA (or in the case of retroviral vectors, RNA) may then beexpressed in a suitable host to produce a polypeptide comprising thepeptide or variant of the invention. Thus, the DNA encoding the peptideor variant of the invention may be used in accordance with knowntechniques, appropriately modified in view of the teachings containedherein, to construct an expression vector, which is then used totransform an appropriate host cell for the expression and production ofthe polypeptide of the invention. Such techniques include thosedisclosed, for example, in U.S. Pat. Nos. 4,440,859, 4,530,901,4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006,4,766,075, and 4,810,648.

The DNA (or in the case of retroviral vectors, RNA) encoding thepolypeptide constituting the compound of the invention may be joined toa wide variety of other DNA sequences for introduction into anappropriate host. The companion DNA will depend upon the nature of thehost, the manner of the introduction of the DNA into the host, andwhether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as aplasmid, in proper orientation and correct reading frame for expression.If necessary, the DNA may be linked to the appropriate transcriptionaland translational regulatory control nucleotide sequences recognized bythe desired host, although such controls are generally available in theexpression vector. The vector is then introduced into the host throughstandard techniques. Generally, not all of the hosts will be transformedby the vector. Therefore, it will be necessary to select for transformedhost cells. One selection technique involves incorporating into theexpression vector a DNA sequence, with any necessary control elements,that codes for a selectable trait in the transformed cell, such asanti-biotic resistance.

Alternatively, the gene for such selectable trait can be on anothervector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of theinvention are then cultured for a sufficient time and under appropriateconditions known to those skilled in the art in view of the teachingsdisclosed herein to permit the expression of the polypeptide, which canthen be recovered.

Many expression systems are known, including bacteria (for example E.coli and Bacillus subtilis), yeasts (for example Saccharomycescerevisiae), filamentous fungi (for example Aspergillus spec.), plantcells, animal cells and insect cells. Preferably, the system can bemammalian cells such as CHO cells available from the ATCC Cell BiologyCollection.

A typical mammalian cell vector plasmid for constitutive expressioncomprises the CMV or SV40 promoter with a suitable poly A tail and aresistance marker, such as neomycin. One example is pSVL available fromPharmacia, Piscataway, N.J., USA. An example of an inducible mammalianexpression vector is pMSG, also available from Pharmacia. Useful yeastplasmid vectors are pRS403-406 and pRS413-416 and are generallyavailable from Stratagene Cloning Systems, La Jolla, Calif. 92037, USA.Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integratingplasmids (Ylps) and incorporate the yeast selectable markers HIS3, TRP1,LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps).CMV promoter-based vectors (for example from Sigma-Aldrich) providetransient or stable expression, cytoplasmic expression or secretion, andN-terminal or C-terminal tagging in various combinations of FLAG,3×FLAG, c-myc or MAT. These fusion proteins allow for detection,purification and analysis of recombinant protein. Dual-tagged fusionsprovide flexibility in detection.

The strong human cytomegalovirus (CMV) promoter regulatory region drivesconstitutive protein expression levels as high as 1 mg/L in COS cells.For less potent cell lines, protein levels are typically ˜0.1 mg/L. Thepresence of the SV40 replication origin will result in high levels ofDNA replication in SV40 replication permissive COS cells. CMV vectors,for example, can contain the pMB1 (derivative of pBR322) origin forreplication in bacterial cells, the b-lactamase gene for ampicillinresistance selection in bacteria, hGH polyA, and the f1 origin. Vectorscontaining the pre-pro-trypsin leader (PPT) sequence can direct thesecretion of FLAG fusion proteins into the culture medium forpurification using ANTI-FLAG antibodies, resins, and plates. Othervectors and expression systems are well known in the art for use with avariety of host cells.

In another embodiment two or more peptides or peptide variants of theinvention are encoded and thus expressed in a successive order (similarto “beads on a string” constructs). In doing so, the peptides or peptidevariants may be linked or fused together by stretches of linker aminoacids, such as for example LLLLLL, or may be linked without anyadditional peptide(s) between them. These constructs can also be usedfor cancer therapy, and may induce immune responses both involving MHC Iand MHC II.

The present invention also relates to a host cell transformed with apolynucleotide vector construct of the present invention. The host cellcan be either prokaryotic or eukaryotic. Bacterial cells may bepreferred prokaryotic host cells in some circumstances and typically area strain of E. coli such as, for example, the E. coli strains DH5available from Bethesda Research Laboratories Inc., Bethesda, Md., USA,and RR1 available from the American Type Culture Collection (ATCC) ofRockville, Md., USA (No ATCC 31343). Preferred eukaryotic host cellsinclude yeast, insect and mammalian cells, preferably vertebrate cellssuch as those from a mouse, rat, monkey or human fibroblastic and coloncell lines. Yeast host cells include YPH499, YPH500 and YPH501, whichare generally available from Stratagene Cloning Systems, La Jolla,Calif. 92037, USA. Preferred mammalian host cells include Chinesehamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swissmouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkeykidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293cells which are human embryonic kidney cells. Preferred insect cells areSf9 cells which can be transfected with baculovirus expression vectors.An overview regarding the choice of suitable host cells for expressioncan be found in, for example, the textbook of Paulina Balbás and ArgeliaLorence “Methods in Molecular Biology Recombinant Gene Expression,Reviews and Protocols,” Part One, Second Edition, ISBN978-1-58829-262-9, and other literature known to the person of skill.

Transformation of appropriate cell hosts with a DNA construct of thepresent invention is accomplished by well-known methods that typicallydepend on the type of vector used. With regard to transformation ofprokaryotic host cells, see, for example, Cohen et al. (Cohen et al.,1972) and (Green and Sambrook, 2012). Transformation of yeast cells isdescribed in Sherman et al. (Sherman et al., 1986). The method of Beggs(Beggs, 1978) is also useful. With regard to vertebrate cells, reagentsuseful in transfecting such cells, for example calcium phosphate andDEAE-dextran or liposome formulations, are available from StratageneCloning Systems, or Life Technologies Inc., Gaithersburg, Md. 20877,USA. Electroporation is also useful for transforming and/or transfectingcells and is well known in the art for transforming yeast cell,bacterial cells, insect cells and vertebrate cells.

Successfully transformed cells, i.e. cells that contain a DNA constructof the present invention, can be identified by well-known techniquessuch as PCR. Alternatively, the presence of the protein in thesupernatant can be detected using antibodies.

It will be appreciated that certain host cells of the invention areuseful in the preparation of the peptides of the invention, for examplebacterial, yeast and insect cells. However, other host cells may beuseful in certain therapeutic methods. For example, antigen-presentingcells, such as dendritic cells, may usefully be used to express thepeptides of the invention such that they may be loaded into appropriateMHC molecules. Thus, the current invention provides a host cellcomprising a nucleic acid or an expression vector according to theinvention.

In a preferred embodiment, the host cell is an antigen presenting cell,in particular a dendritic cell or antigen presenting cell. APCs loadedwith a recombinant fusion protein containing prostatic acid phosphatase(PAP) were approved by the U.S. Food and Drug Administration (FDA) onApr. 29, 2010, to treat asymptomatic or minimally symptomatic metastaticHRPC (Sipuleucel-T) (Rini et al., 2006; Small et al., 2006).

A further aspect of the invention provides a method of producing apeptide or its variant, the method comprising culturing a host cell andisolating the peptide from the host cell or its culture medium.

In another embodiment, the peptide, the nucleic acid or the expressionvector of the invention are used in medicine. For example, the peptideor its variant may be prepared for intravenous (i.v.) injection,sub-cutaneous (s.c.) injection, intradermal (i.d.) injection,intraperitoneal (i.p.) injection, intramuscular (i.m.) injection.Preferred methods of peptide injection include s.c., i.d., i.p., i.m.,and i.v. Preferred methods of DNA injection include i.d., i.m., s.c.,i.p. and i.v. Doses of e.g. between 50 μg and 1.5 mg, preferably 125 μgto 500 μg, of peptide or DNA may be given and will depend on therespective peptide or DNA. Dosages of this range were successfully usedin previous trials (Walter et al., 2012).

The polynucleotide used for active vaccination may be substantiallypure, or contained in a suitable vector or delivery system. The nucleicacid may be DNA, cDNA, PNA, RNA or a combination thereof. Methods fordesigning and introducing such a nucleic acid are well known in the art.An overview is provided by e.g. Teufel et al. (Teufel et al., 2005).Polynucleotide vaccines are easy to prepare, but the mode of action ofthese vectors in inducing an immune response is not fully understood.Suitable vectors and delivery systems include viral DNA and/or RNA, suchas systems based on adenovi-rus, vaccinia virus, retroviruses, herpesvirus, adeno-associated virus or hybrids containing elements of morethan one virus. Non-viral delivery systems include cationic lipids andcationic polymers and are well known in the art of DNA delivery.Physical delivery, such as via a “gene-gun” may also be used. Thepeptide or peptides encoded by the nucleic acid may be a fusion protein,for example with an epitope that stimulates T cells for the respectiveopposite CDR as noted above.

The medicament of the invention may also include one or more adjuvants.Adjuvants are substances that non-specifically enhance or potentiate theimmune response (e.g., immune responses mediated by CD8-positive T cellsand helper-T (TH) cells to an antigen, and would thus be considereduseful in the medicament of the present invention. Suitable adjuvantsinclude, but are not limited to, 1018 ISS, aluminum salts, AMPLIVAX®,AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligandsderived from flagellin, FLT3 ligand, GM-CSF, 1030, 1031, Imiquimod(ALDARA®), resiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13,IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, ISPatch, ISS, ISCOMATRIX, ISCOMs, JuvImmune®, LipoVac, MALP2, MF59,monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, MontanideISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions,OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system,poly(lactid co-glycolid) [PLG]-based and dextran microparticles,talactoferrin SRL172, Virosomes and other Virus-like particles, YF-17D,VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which isderived from saponin, mycobacterial extracts and synthetic bacterialcell wall mimics, and other proprietary adjuvants such as Ribi's Detox,Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred.Several immunological adjuvants (e.g., MF59) specific for dendriticcells and their preparation have been described previously (Allison andKrummel, 1995). Also, cytokines may be used. Several cytokines have beendirectly linked to influencing dendritic cell migration to lymphoidtissues (e.g., TNF-), accelerating the maturation of dendritic cellsinto efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF,IL-1 and IL-4) (U.S. Pat. No. 5,849,589, specifically incorporatedherein by reference in its entirety) and acting as immunoadjuvants(e.g., IL-12, IL-15, IL-23, IL-7, IFN-alpha. IFN-beta) (Gabrilovich etal., 1996).

CpG immunostimulatory oligonucleotides have also been reported toenhance the effects of adjuvants in a vaccine setting. Without beingbound by theory, CpG oligonucleotides act by activating the innate(non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9.CpG triggered TLR9 activation enhances antigen-specific humoral andcellular responses to a wide variety of antigens, including peptide orprotein antigens, live or killed viruses, dendritic cell vaccines,autologous cellular vaccines and polysaccharide conjugates in bothprophylactic and therapeutic vaccines. More importantly it enhancesdendritic cell maturation and differentiation, resulting in enhancedactivation of TH1 cells and strong cytotoxic T-lymphocyte (CTL)generation, even in the absence of CD4 T cell help. The TH1 bias inducedby TLR9 stimulation is maintained even in the presence of vaccineadjuvants such as alum or incomplete Freund's adjuvant (IFA) thatnormally promote a TH2 bias. CpG oligonucleotides show even greateradjuvant activity when formulated or co-administered with otheradjuvants or in formulations such as microparticles, nanoparticles,lipid emulsions or similar formulations, which are especially necessaryfor inducing a strong response when the antigen is relatively weak. Theyalso accelerate the immune response and enable the antigen doses to bereduced by approximately two orders of magnitude, with comparableantibody responses to the full-dose vaccine without CpG in someexperiments (Krieg, 2006). U.S. Pat. No. 6,406,705 B1 describes thecombined use of CpG oligonucleotides, non-nucleic acid adjuvants and anantigen to induce an antigen-specific immune response. A CpG TLR9antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen(Berlin, Germany) which is a preferred component of the pharmaceuticalcomposition of the present invention. Other TLR binding molecules suchas RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

Other examples for useful adjuvants include, but are not limited tochemically modified CpGs (e.g. CpR, Idera), dsRNA analogues such asPoly(I:C) and derivates thereof (e.g. AmpliGen®, Hiltonol®, poly-(ICLC),poly(IC-R), poly(I:C12U), non-CpG bacterial DNA or RNA as well asimmunoactive small molecules and antibodies such as cyclophosphamide,sunitinib, Bevacizumab®, celebrex, NCX-4016, sildenafil, tadalafil,var-denafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632,pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodiestargeting key structures of the immune system (e.g. anti-CD40,anti-TGFbeta, anti-TNFalpha receptor) and SC58175, which may acttherapeutically and/or as an adjuvant. The amounts and concentrations ofadjuvants and additives useful in the context of the present inventioncan readily be determined by the skilled artisan without undueexperimentation.

Preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF,cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, CpGoligonucleotides and derivates, poly-(I:C) and derivates, RNA,sildenafil, and particulate formulations with PLG or virosomes.

In a preferred embodiment, the pharmaceutical composition according tothe invention the adjuvant is selected from the group consisting ofcolony-stimulating factors, such as Granulocyte Macrophage ColonyStimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod,resiquimod, and interferon-alpha.

In a preferred embodiment, the pharmaceutical composition according tothe invention the adjuvant is selected from the group consisting ofcolony-stimulating factors, such as Granulocyte Macrophage ColonyStimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimodand resiquimod. In a preferred embodiment of the pharmaceuticalcomposition according to the invention, the adjuvant iscyclophosphamide, imiquimod or resiquimod. Even more preferred adjuvantsare Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, MontanideISA-51, poly-ICLC (Hiltonol®) and anti-CD40 mAB, or combinationsthereof.

This composition is used for parenteral administration, such assubcutaneous, intradermal, intramuscular or oral administration. Forthis, the peptides and optionally other molecules are dissolved orsuspended in a pharmaceutically acceptable, preferably aqueous carrier.In addition, the composition can contain excipients, such as buffers,binding agents, blasting agents, diluents, flavors, lubricants, etc. Thepeptides can also be administered together with immune stimulatingsubstances, such as cytokines. An extensive listing of excipients thatcan be used in such a composition, can be, for example, taken from A.Kibbe, Handbook of Pharmaceutical Excipients (Kibbe, 2000). Thecomposition can be used for a prevention, prophylaxis and/or therapy ofadeno-matous or cancerous diseases. Exemplary formulations can be foundin, for example, EP2112253.

It is important to realize that the immune response triggered by thevaccine according to the invention attacks the cancer in differentcell-stages and different stages of development. Furthermore, differentcancer associated signaling pathways are attacked. This is an advantageover vaccines that address only one or few targets, which may cause thetumor to easily adapt to the attack (tumor escape). Furthermore, not allindividual tumors express the same pattern of antigens. Therefore, acombination of several tumor-associated peptides ensures that everysingle tumor bears at least some of the targets. The composition isdesigned in such a way that each tumor is expected to express several ofthe antigens and cover several independent pathways necessary for tumorgrowth and maintenance. Thus, the vaccine can easily be used“off-the-shelf” for a larger patient population. This means that apre-selection of patients to be treated with the vaccine can berestricted to HLA typing, does not require any additional biomarkerassessments for antigen expression, but it is still ensured that severaltargets are simultaneously attacked by the induced immune response,which is important for efficacy (Banchereau et al., 2001; Walter et al.,2012).

As used herein, the term “scaffold” refers to a molecule thatspecifically binds to an (e.g. antigenic) determinant. In oneembodiment, a scaffold is able to direct the entity to which it isattached (e.g. a (second) antigen binding moiety) to a target site, forexample to a specific type of tumor cell or tumor stroma bearing theantigenic determinant (e.g. the complex of a peptide with MHC, accordingto the application at hand). In another embodiment, a scaffold is ableto activate signaling through its target antigen, for example a T cellreceptor complex antigen. Scaffolds include but are not limited toantibodies and fragments thereof, antigen binding domains of anantibody, comprising an antibody heavy chain variable region and anantibody light chain variable region, binding proteins comprising atleast one Ankyrin repeat motif and single domain antigen binding (SDAB)molecules, aptamers, (soluble) TCRs and (modified) cells such asallogenic or autologous T cells. To assess whether a molecule is ascaffold binding to a target, binding assays can be performed.

“Specific” binding means that the scaffold binds the peptide-MHC-complexof interest better than other naturally occurring peptide-MHC-complexes,to an extent that a scaffold armed with an active molecule that is ableto kill a cell bearing the specific target is not able to kill anothercell without the specific target but presenting other peptide-MHCcomplex(es). Binding to other peptide-MHC complexes is irrelevant if thepeptide of the cross-reactive peptide-MHC is not naturally occurring,i.e. not derived from the human HLA-peptidome. Tests to assess targetcell killing are well known in the art. They should be performed usingtarget cells (primary cells or cell lines) with unaltered peptide-MHCpresentation, or cells loaded with peptides such that naturallyoccurring peptide-MHC levels are reached.

Each scaffold can comprise a labelling which provides that the boundscaffold can be detected by determining the presence or absence of asignal provided by the label. For example, the scaffold can be labelledwith a fluorescent dye or any other applicable cellular marker molecule.Such marker molecules are well known in the art. For example, afluorescence-labelling, for example provided by a fluorescence dye, canprovide a visualization of the bound aptamer by fluorescence or laserscanning microscopy or flow cytometry.

Each scaffold can be conjugated with a second active molecule such asfor example IL-21, anti-CD3, anti-CD28.

For further information on polypeptide scaffolds see for example thebackground sec-tion of WO 2014/071978A1 and the references citedtherein.

The present invention further relates to aptamers. Aptamers (see forexample WO 2014/191359 and the literature as cited therein) are shortsingle-stranded nucleic acid molecules, which can fold into definedthree-dimensional structures and recognize specific target structures.They have appeared to be suitable alternatives for developing targetedtherapies. Aptamers have been shown to selectively bind to a variety ofcomplex targets with high affinity and specificity.

Aptamers recognizing cell surface located molecules have been identifiedwithin the past decade and provide means for developing diagnostic andtherapeutic ap-proaches. Since aptamers have been shown to possessalmost no toxicity and immunogenicity they are promising candidates forbiomedical applications. Indeed, aptamers, for example prostate-specificmembrane-antigen recognizing aptamers, have been successfully employedfor targeted therapies and shown to be functional in xen-ograft in vivomodels. Furthermore, aptamers recognizing specific tumor cell lines havebeen identified.

DNA aptamers can be selected to reveal broad-spectrum recognitionproperties for various cancer cells, and particularly those derived fromsolid tumors, while non-tumor-igenic and primary healthy cells are notrecognized. If the identified aptamers recognize not only a specifictumor sub-type but rather interact with a series of tumors, this rendersthe aptamers applicable as so-called broad-spectrum diagnostics andthera-peutics.

Further, investigation of cell-binding behavior with flow cytometryshowed that the aptamers revealed very good apparent affinities that arewithin the nanomolar range.

Aptamers are useful for diagnostic and therapeutic purposes. Further, itcould be shown that some of the aptamers are taken up by tumor cells andthus can function as molecular vehicles for the targeted delivery ofanti-cancer agents such as siRNA into tumor cells.

Aptamers can be selected against complex targets such as cells andtissues and complexes of the peptides comprising, preferably consistingof, a sequence according to any of SEQ ID NO 1 to SEQ ID NO 43,according to the invention at hand with the MHC molecule, using thecell-SELEX (Systematic Evolution of Ligands by Exponential enrichment)technique.

The peptides of the present invention can be used to generate anddevelop specific antibodies against MHC/peptide complexes. These can beused for therapy, targeting toxins or radioactive substances to thediseased tissue. Another use of these antibodies can be targetingradionuclides to the diseased tissue for imaging purposes such as PET.This use can help to detect small metastases or to determine the sizeand precise localization of diseased tissues.

Therefore, it is a further aspect of the invention to provide a methodfor producing a recombinant antibody specifically binding to a humanmajor histocompatibility complex (MHC) class I or II being complexedwith a HLA-restricted antigen, the method comprising: immunizing agenetically engineered non-human mammal comprising cells expressing saidhuman major histocompatibility complex (MHC) class I or II with asoluble form of a MHC class I or II molecule being complexed with saidHLA-restricted antigen; isolating mRNA molecules from antibody producingcells of said non-human mammal; producing a phage display librarydisplaying protein molecules encoded by said mRNA molecules; andisolating at least one phage from said phage display library, said atleast one phage displaying said antibody specifically binding to saidhuman major histocompatibility complex (MHC) class I or II beingcomplexed with said HLA-restricted antigen.

It is a further aspect of the invention to provide an antibody thatspecifically binds to a human major histocompatibility complex (MHC)class I or II being complexed with a HLA-restricted antigen, wherein theantibody preferably is a polyclonal antibody, monoclonal antibody,bi-specific antibody and/or a chimeric antibody.

Respective methods for producing such antibodies and single chain classI major histocompatibility complexes, as well as other tools for theproduction of these antibodies are disclosed in WO 03/068201, WO2004/084798, WO 01/72768, WO 03/070752, and in publications (Cohen etal., 2003a; Cohen et al., 2003b; Denkberg et al., 2003), which for thepurposes of the present invention are all explicitly incorporated byreference in their entireties.

Preferably, the antibody is binding with a binding affinity of below 20nanomolar, preferably of below 10 nanomolar, to the complex, which isalso regarded as “specific” in the context of the present invention.

The present invention relates to a peptide comprising a sequence that isselected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 43, ora variant thereof which is at least 88% homologous (preferablyidentical) to SEQ ID NO: 1 to SEQ ID NO: 43 or a variant thereof thatinduces T cells cross-reacting with said peptide, wherein said peptideis not the underlying full-length polypeptide.

The present invention further relates to a peptide comprising a sequencethat is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:43 or a variant thereof which is at least 88% homologous (preferablyidentical) to SEQ ID NO: 1 to SEQ ID NO: 43, wherein said peptide orvariant has an overall length of between 8 and 100, preferably between 8and 30, and most preferred between 8 and 14 amino acids.

The present invention further relates to the peptides according to theinvention that have the ability to bind to a molecule of the human majorhistocompatibility complex (MHC) class-I or -II.

The present invention further relates to the peptides according to theinvention wherein the peptide consists or consists essentially of anamino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 43.

The present invention further relates to the peptides according to theinvention, wherein the peptide is (chemically) modified and/or includesnon-peptide bonds.

The present invention further relates to the peptides according to theinvention, wherein the peptide is part of a fusion protein, inparticular comprising N-terminal amino acids of the HLA-DRantigen-associated invariant chain (Ii), or wherein the peptide is fusedto (or into) an antibody, such as, for example, an antibody that isspecific for dendritic cells.

The present invention further relates to a nucleic acid, encoding thepeptides according to the invention, provided that the peptide is notthe complete (full) human protein.

The present invention further relates to the nucleic acid according tothe invention that is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable ofexpressing or expressing a nucleic acid according to the presentinvention.

The present invention further relates to a peptide according to thepresent invention, a nucleic acid according to the present invention oran expression vector according to the present invention for use inmedicine, in particular in the treatment of breast cancer.

The present invention further relates to a host cell comprising anucleic acid according to the invention or an expression vectoraccording to the invention.

The present invention further relates to the host cell according to thepresent invention that is an antigen presenting cell, and preferably adendritic cell.

The present invention further relates to a method of producing a peptideaccording to the present invention, said method comprising culturing thehost cell according to the present invention, and isolating the peptidefrom said host cell or its culture medium.

The present invention further relates to the method according to thepresent invention, where-in the antigen is loaded onto class I or II MHCmolecules expressed on the surface of a suitable antigen-presenting cellby contacting a sufficient amount of the antigen with anantigen-presenting cell.

The present invention further relates to the method according to theinvention, wherein the antigen-presenting cell comprises an expressionvector capable of expressing said peptide containing SEQ ID NO: 1 to SEQID NO: 43 or said variant amino acid sequence.

The present invention further relates to activated T cells, produced bythe method according to the present invention, wherein said T cellsselectively recognizes a cell which aberrantly expresses a polypeptidecomprising an amino acid sequence according to the present invention.

The present invention further relates to a method of killing targetcells in a patient which target cells aberrantly express a polypeptidecomprising any amino acid sequence according to the present invention,the method comprising administering to the patient an effective numberof T cells as according to the present invention.

The present invention further relates to the use of any peptidedescribed, a nucleic acid according to the present invention, anexpression vector according to the present invention, a cell accordingto the present invention, or an activated cytotoxic T lymphocyteaccording to the present invention as a medicament or in the manufactureof a medicament. The present invention further relates to a useaccording to the present invention, wherein the medicament is activeagainst cancer.

The present invention further relates to a use according to theinvention, wherein the medicament is a vaccine. The present inventionfurther relates to a use according to the invention, wherein themedicament is active against cancer.

The present invention further relates to a use according to theinvention, wherein said cancer cells are breast cancer cells or othersolid or hematological tumor cells such as acute myelogenous leukemia,bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectalcarcinoma, esophageal cancer, gallbladder cancer, gastric cancer,hepatocellular cancer, Merkel cell carcinoma, melanoma, non-Hodgkinlymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer,prostate cancer, renal cell cancer, small cell lung cancer, urinarybladder cancer and uterine cancer.

The present invention further relates to particular marker proteins andbiomarkers based on the peptides according to the present invention,herein called “targets” that can be used in the diagnosis and/orprognosis of breast cancer. The present invention also relates to theuse of these novel targets for cancer treatment.

The term “antibody” or “antibodies” is used herein in a broad sense andincludes both polyclonal and monoclonal antibodies. In addition tointact or “full” immunoglobulin molecules, also included in the term“antibodies” are fragments (e.g. CDRs, Fv, Fab and Fc fragments) orpolymers of those immunoglobulin molecules and humanized versions ofimmunoglobulin molecules, as long as they exhibit any of the desiredproperties (e.g., specific binding of a breast cancer marker(poly)peptide, delivery of a toxin to a breast cancer cell expressing acancer marker gene at an increased level, and/or inhibiting the activityof a breast cancer marker polypeptide) according to the invention.

Whenever possible, the antibodies of the invention may be purchased fromcommercial sources. The antibodies of the invention may also begenerated using well-known methods. The skilled artisan will understandthat either full length breast cancer marker polypeptides or fragmentsthereof may be used to generate the antibodies of the invention. Apolypeptide to be used for generating an antibody of the invention maybe partially or fully purified from a natural source, or may be producedusing recombinant DNA techniques.

For example, a cDNA encoding a peptide according to the presentinvention, such as a peptide according to SEQ ID NO: 1 to SEQ ID NO: 43polypeptide, or a variant or fragment thereof, can be expressed inprokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast,insect, or mammalian cells), after which the recombinant protein can bepurified and used to generate a monoclonal or polyclonal antibodypreparation that specifically bind the breast cancer marker polypeptideused to generate the antibody according to the invention.

One of skill in the art will realize that the generation of two or moredifferent sets of monoclonal or polyclonal antibodies maximizes thelikelihood of obtaining an antibody with the specificity and affinityrequired for its intended use (e.g., ELISA, immunohistochemistry, invivo imaging, immunotoxin therapy). The antibodies are tested for theirdesired activity by known methods, in accordance with the purpose forwhich the antibodies are to be used (e.g., ELISA, immunohistochemistry,immunotherapy, etc.; for further guidance on the generation and testingof antibodies, see, e.g., Greenfield, 2014 (Greenfield, 2014)). Forexample, the antibodies may be tested in ELISA assays or, Western blots,immunohistochemical staining of formalin-fixed cancers or frozen tissuesections. After their initial in vitro characterization, antibodiesintended for therapeutic or in vivo diagnostic use are tested accordingto known clinical testing methods.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a substantially homogeneous population of antibodies,i.e.; the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. The monoclonal antibodies herein specifically include“chimeric” antibodies in which a portion of the heavy and/or light chainis identical with or homologous to corresponding sequences in antibodiesderived from a particular species or belonging to a particular antibodyclass or subclass, while the remainder of the chain(s) is identical withor homologous to corresponding sequences in antibodies derived fromanother species or belonging to another antibody class or subclass, aswell as fragments of such antibodies, so long as they exhibit thedesired antagonistic activity (U.S. Pat. No. 4,816,567, which is herebyincorporated in its entirety).

Monoclonal antibodies of the invention may be prepared using hybridomamethods. In a hybridoma method, a mouse or other appropriate host animalis typically immunized with an immunizing agent to elicit lymphocytesthat produce or are capable of producing antibodies that willspecifically bind to the immunizing agent. Alternatively, thelymphocytes may be immunized in vitro.

The monoclonal antibodies may also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567. DNA encoding themonoclonal antibodies of the invention can be readily isolated andsequenced using conventional procedures (e.g., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of murine antibodies).

In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof, particularly Fabfragments, can be accomplished using routine techniques known in theart. For instance, digestion can be performed using papain. Examples ofpapain digestion are described in WO 94/29348 and U.S. Pat. No.4,342,566. Papain digestion of antibodies typically produces twoidentical antigen binding fragments, called Fab fragments, each with asingle antigen binding site, and a residual Fc fragment. Pepsintreatment yields a F(ab′)2 fragment and a pFc′ fragment.

The antibody fragments, whether attached to other sequences or not, canalso include insertions, deletions, substitutions, or other selectedmodifications of particular regions or specific amino acids residues,provided the activity of the fragment is not significantly altered orimpaired compared to the non-modified antibody or antibody fragment.These modifications can provide for some additional property, such as toremove/add amino acids capable of disulfide bonding, to increase itsbio-longevity, to alter its secretory characteristics, etc. In any case,the antibody fragment must possess a bioactive property, such as bindingactivity, regulation of binding at the binding domain, etc. Functionalor active regions of the antibody may be identified by mutagenesis of aspecific region of the protein, followed by expression and testing ofthe expressed polypeptide. Such methods are readily apparent to askilled practitioner in the art and can include site-specificmutagenesis of the nucleic acid encoding the antibody fragment.

The antibodies of the invention may further comprise humanizedantibodies or human antibodies. Humanized forms of non-human (e.g.,murine) antibodies are chimeric immunoglobulins, immunoglobulin chainsor fragments thereof (such as Fv, Fab, Fab′ or other antigen-bindingsubsequences of antibodies) which contain minimal sequence derived fromnon-human immunoglobulin. Humanized antibodies include humanimmunoglobulins (recipient antibody) in which residues from acomplementary determining region (CDR) of the recipient are replaced byresidues from a CDR of a non-human species (donor antibody) such asmouse, rat or rabbit having the desired specificity, affinity andcapacity. In some instances, Fv framework (FR) residues of the humanimmunoglobulin are replaced by corresponding non-human residues.Humanized antibodies may also comprise residues which are found neitherin the recipient antibody nor in the imported CDR or frameworksequences. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the CDR regions correspond to thoseof a non-human immunoglobulin and all or substantially all of the FRregions are those of a human immunoglobulin consensus sequence. Thehumanized antibody optimally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin.

Methods for humanizing non-human antibodies are well known in the art.Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source which is non-human. These non-humanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. Humanization canbe essentially performed by substituting rodent CDRs or CDR sequencesfor the corresponding sequences of a human antibody. Accordingly, such“humanized” antibodies are chimeric antibodies (U.S. Pat. No.4,816,567), wherein substantially less than an intact human variabledomain has been substituted by the corresponding sequence from anon-human species. In practice, humanized antibodies are typically humanantibodies in which some CDR residues and possibly some FR residues aresubstituted by residues from analogous sites in rodent antibodies.

Transgenic animals (e.g., mice) that are capable, upon immunization, ofproducing a full repertoire of human antibodies in the absence ofendogenous immunoglobulin production can be employed. For example, ithas been described that the homozygous deletion of the antibody heavychain joining region gene in chimeric and germ-line mutant mice resultsin complete inhibition of endogenous antibody production. Transfer ofthe human germ-line immunoglobulin gene array in such germ-line mutantmice will result in the production of human antibodies upon antigenchallenge. Human antibodies can also be produced in phage displaylibraries.

Antibodies of the invention are preferably administered to a subject ina pharmaceutically acceptable carrier. Typically, an appropriate amountof a pharmaceutically-acceptable salt is used in the formulation torender the formulation isotonic. Examples of thepharmaceutically-acceptable carrier include saline, Ringer's solutionand dextrose solution. The pH of the solution is preferably from about 5to about 8, and more preferably from about 7 to about 7.5. Furthercarriers include sustained release preparations such as semipermeablematrices of solid hydrophobic polymers containing the antibody, whichmatrices are in the form of shaped articles, e.g., films, liposomes ormicroparticles. It will be apparent to those persons skilled in the artthat certain carriers may be more preferable depending upon, forinstance, the route of administration and concentration of antibodybeing administered.

The antibodies can be administered to the subject, patient, or cell byinjection (e.g., intravenous, intraperitoneal, subcutaneous,intramuscular), or by other methods such as infusion that ensure itsdelivery to the bloodstream in an effective form. The antibodies mayalso be administered by intratumoral or peritumoral routes, to exertlocal as well as systemic therapeutic effects. Local or intravenousinjection is preferred.

Effective dosages and schedules for administering the antibodies may bedetermined empirically, and making such determinations is within theskill in the art. Those skilled in the art will understand that thedosage of antibodies that must be administered will vary depending on,for example, the subject that will receive the antibody, the route ofadministration, the particular type of antibody used and other drugsbeing administered. A typical daily dosage of the antibody used alonemight range from about 1 (μg/kg to up to 100 mg/kg of body weight ormore per day, depending on the factors mentioned above. Followingadministration of an antibody, preferably for treating breast cancer,the efficacy of the therapeutic antibody can be assessed in various wayswell known to the skilled practitioner. For instance, the size, number,and/or distribution of cancer in a subject receiving treatment may bemonitored using standard tumor imaging techniques. Atherapeutically-administered antibody that arrests tumor growth, resultsin tumor shrinkage, and/or prevents the development of new tumors,compared to the disease course that would occurs in the absence ofantibody administration, is an efficacious antibody for treatment ofcancer.

It is a further aspect of the invention to provide a method forproducing a soluble T-cell receptor (sTCR) recognizing a specificpeptide-MHC complex. Such soluble T-cell receptors can be generated fromspecific T-cell clones, and their affinity can be increased bymutagenesis targeting the complementarity-determining regions. For thepurpose of T-cell receptor selection, phage display can be used (US2010/0113300, (Liddy et al., 2012)). For the purpose of stabilization ofT-cell receptors during phage display and in case of practical use asdrug, alpha and beta chain can be linked e.g. by non-native disulfidebonds, other covalent bonds (single-chain T-cell receptor), or bydimerization domains (Boulter et al., 2003; Card et al., 2004; Willcoxet al., 1999). The T-cell receptor can be linked to toxins, drugs,cytokines (see, for example, US 2013/0115191), domains recruitingeffector cells such as an anti-CD3 domain, etc., in order to executeparticular functions on target cells. Moreover, it could be expressed inT cells used for adoptive transfer. Further information can be found inWO 2004/033685A1 and WO 2004/074322A1. A combination of sTCRs isdescribed in WO 2012/056407A1. Further methods for the production aredisclosed in WO 2013/057586A1.

In addition, the peptides and/or the TCRs or antibodies or other bindingmolecules of the present invention can be used to verify a pathologist'sdiagnosis of a cancer based on a biopsied sample.

The antibodies or TCRs may also be used for in vivo diagnostic assays.Generally, the antibody is labeled with a radionucleotide (such as¹¹¹In, ⁹⁹Tc, ¹⁴C, ¹³¹I, ³H, ³²P or ³⁵S) so that the tumor can belocalized using immunoscintiography. In one embodiment, antibodies orfragments thereof bind to the extracellular domains of two or moretargets of a protein selected from the group consisting of theabove-mentioned proteins, and the affinity value (Kd) is less than 1×10μM.

Antibodies for diagnostic use may be labeled with probes suitable fordetection by various imaging methods. Methods for detection of probesinclude, but are not limited to, fluorescence, light, confocal andelectron microscopy; magnetic resonance imaging and spectroscopy;fluoroscopy, computed tomography and positron emission tomography.Suitable probes include, but are not limited to, fluorescein, rhodamine,eosin and other fluorophores, radioisotopes, gold, gadolinium and otherlanthanides, para-magnetic iron, fluorine-18 and other positron-emittingradionuclides. Additionally, probes may be bi- or multi-functional andbe detectable by more than one of the methods listed. These antibodiesmay be directly or indirectly labeled with said probes. Attachment ofprobes to the antibodies includes covalent attachment of the probe,incor-poration of the probe into the antibody, and the covalentattachment of a chelating compound for binding of probe, amongst otherswell recognized in the art. For immunohistochemistry, the disease tissuesample may be fresh or frozen or may be embedded in paraffin and fixedwith a preservative such as formalin. The fixed or embedded sec-tioncontains the sample are contacted with a labeled primary antibody andsecondary antibody, wherein the antibody is used to detect theexpression of the proteins in situ.

Another aspect of the present invention includes an in vitro method forproducing activated T cells, the method comprising contacting in vitro Tcells with antigen loaded human MHC molecules expressed on the surfaceof a suitable antigen-presenting cell for a period of time sufficient toactivate the T cell in an antigen specific manner, wherein the antigenis a peptide according to the invention. Preferably a sufficient amountof the antigen is used with an antigen-presenting cell.

Preferably the mammalian cell lacks or has a reduced level or functionof the TAP peptide transporter. Suitable cells that lack the TAP peptidetransporter include T2, RMA-S and Drosophila cells. TAP is thetransporter associated with antigen processing.

The human peptide loading deficient cell line T2 is available from theAmerican Type Culture Collection, 12301 Parklawn Drive, Rockville, Md.20852, USA under Catalogue No CRL 1992; the Drosophila cell lineSchneider line 2 is available from the ATCC under Catalogue No CRL19863; the mouse RMA-S cell line is described in Ljunggren et al.(Ljunggren and Karre, 1985).

Preferably, before transfection the host cell expresses substantially noMHC class I molecules. It is also preferred that the stimulator cellexpresses a molecule important for providing a co-stimulatory signal forT-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The nucleic acidsequences of numerous MHC class I molecules and of the co-stimulatormolecules are publicly available from the GenBank and EMBL databases.

In case of a MHC class I epitope being used as an antigen, the T cellsare CD8-positive T cells.

If an antigen-presenting cell is transfected to express such an epitope,preferably the cell comprises an expression vector capable of expressinga peptide containing SEQ ID NO: 1 to SEQ ID NO: 43, or a variant aminoacid sequence thereof.

A number of other methods may be used for generating T cells in vitro.For example, autologous tumor-infiltrating lymphocytes can be used inthe generation of CTL. Plebanski et al. (Plebanski et al., 1995) madeuse of autologous peripheral blood lymphocytes (PLBs) in the preparationof T cells. Furthermore, the production of autologous T cells by pulsingdendritic cells with peptide or polypeptide, or via infection withrecombinant virus is possible. Also, B cells can be used in theproduction of autologous T cells. In addition, macrophages pulsed withpeptide or polypeptide, or infected with recombinant virus, may be usedin the preparation of autologous T cells. S. Walter et al. (Walter etal., 2003) describe the in vitro priming of T cells by using artificialantigen presenting cells (aAPCs), which is also a suitable way forgenerating T cells against the peptide of choice. In the presentinvention, aAPCs were generated by the coupling of preformed MHC:peptidecomplexes to the surface of polystyrene particles (microbeads) bybiotin:streptavidin biochemistry. This system permits the exact controlof the MHC density on aAPCs, which allows to selectively elicit high- orlow-avidity antigen-specific T cell responses with high efficiency fromblood samples. Apart from MHC:peptide complexes, aAPCs should carryother proteins with co-stimulatory activity like anti-CD28 antibodiescoupled to their surface. Furthermore, such aAPC-based systems oftenrequire the addition of appropriate soluble factors, e.g. cytokines,like interleukin-12.

Allogeneic cells may also be used in the preparation of T cells and amethod is described in detail in WO 97/26328, incorporated herein byreference. For example, in addition to Drosophila cells and T2 cells,other cells may be used to present antigens such as CHO cells,baculovirus-infected insect cells, bacteria, yeast, vaccinia-infectedtarget cells. In addition plant viruses may be used (see, for example,Porta et al. (Porta et al., 1994) which describes the development ofcowpea mosaic virus as a high-yielding system for the presentation offoreign peptides.

The activated T cells that are directed against the peptides of theinvention are useful in therapy. Thus, a further aspect of the inventionprovides activated T cells obtainable by the foregoing methods of theinvention.

Activated T cells, which are produced by the above method, willselectively recognize a cell that aberrantly expresses a polypeptidethat comprises an amino acid sequence of SEQ ID NO: 1 to SEQ ID NO 43.

Preferably, the T cell recognizes the cell by interacting through itsTCR with the HLA/peptide-complex (for example, binding). The T cells areuseful in a method of killing target cells in a patient whose targetcells aberrantly express a polypeptide comprising an amino acid sequenceof the invention wherein the patient is administered an effective numberof the activated T cells. The T cells that are administered to thepatient may be derived from the patient and activated as described above(i.e. they are autologous T cells). Alternatively, the T cells are notfrom the patient but are from another individual. Of course, it ispreferred if the individual is a healthy individual. By “healthyindividual” the inventors mean that the individual is generally in goodhealth, preferably has a competent immune system and, more preferably,is not suffering from any disease that can be readily tested for, anddetected.

In vivo, the target cells for the CD8-positive T cells according to thepresent invention can be cells of the tumor (which sometimes express MHCclass II) and/or stromal cells surrounding the tumor (tumor cells)(which sometimes also express MHC class (Dengjel et al., 2006)).

The T cells of the present invention may be used as active ingredientsof a therapeutic composition. Thus, the invention also provides a methodof killing target cells in a patient whose target cells aberrantlyexpress a polypeptide comprising an amino acid sequence of theinvention, the method comprising administering to the patient aneffective number of T cells as defined above.

By “aberrantly expressed” the inventors also mean that the polypeptideis over-expressed compared to levels of expression in normal tissues orthat the gene is silent in the tissue from which the tumor is derivedbut in the tumor, it is expressed. By “over-expressed” the inventorsmean that the polypeptide is present at a level at least 1.2-fold ofthat present in normal tissue; preferably at least 2-fold, and morepreferably at least 5-fold or 10-fold the level present in normaltissue.

T cells may be obtained by methods known in the art, e.g. thosedescribed above. Protocols for this so-called adoptive transfer of Tcells are well known in the art. Reviews can be found in: Gattioni etal. and Morgan et al. (Gattinoni et al., 2006; Morgan et al., 2006).

Another aspect of the present invention includes the use of the peptidescomplexed with MHC to generate a T-cell receptor whose nucleic acid iscloned and is introduced into a host cell, preferably a T cell. Thisengineered T cell can then be transferred to a patient for therapy ofcancer.

Any molecule of the invention, i.e. the peptide, nucleic acid, antibody,expression vector, cell, activated T cell, T-cell receptor or thenucleic acid encoding it, is useful for the treatment of disorders,characterized by cells escaping an immune response. Therefore, anymolecule of the present invention may be used as medicament or in themanufacture of a medicament. The molecule may be used by itself orcombined with other molecule(s) of the invention or (a) knownmolecule(s).

The present invention is further directed at a kit comprising:

(a) a container containing a pharmaceutical composition as describedabove, in solution or in lyophilized form;(b) optionally a second container containing a diluent or reconstitutingsolution for the lyophilized formulation; and(c) optionally, instructions for (i) use of the solution or (ii)reconstitution and/or use of the lyophilized formulation.

The kit may further comprise one or more of (iii) a buffer, (iv) adiluent, (v) a filter, (vi) a needle, or (v) a syringe. The container ispreferably a bottle, a vial, a syringe or test tube; and it may be amulti-use container. The pharmaceutical composition is preferablylyophilized.

Kits of the present invention preferably comprise a lyophilizedformulation of the present invention in a suitable container andinstructions for its reconstitution and/or use. Suitable containersinclude, for example, bottles, vials (e.g. dual chamber vials), syringes(such as dual chamber syringes) and test tubes. The container may beformed from a variety of materials such as glass or plastic. Preferablythe kit and/or container contain/s instructions on or associated withthe container that indicates directions for reconstitution and/or use.For example, the label may indicate that the lyophilized formulation isto be reconstituted to peptide concentrations as described above. Thelabel may further indicate that the formulation is useful or intendedfor subcutaneous administration.

The container holding the formulation may be a multi-use vial, whichallows for repeat administrations (e.g., from 2-6 administrations) ofthe reconstituted formulation. The kit may further comprise a secondcontainer comprising a suitable diluent (e.g., sodium bicarbonatesolution).

Upon mixing of the diluent and the lyophilized formulation, the finalpeptide concentration in the reconstituted formulation is preferably atleast 0.15 mg/mL/peptide (=75 μg) and preferably not more than 3mg/mL/peptide (=1500 μg). The kit may further include other materialsdesirable from a commercial and user standpoint, including otherbuffers, diluents, filters, needles, syringes, and package inserts withinstructions for use.

Kits of the present invention may have a single container that containsthe formulation of the pharmaceutical compositions according to thepresent invention with or without other components (e.g., othercompounds or pharmaceutical compositions of these other compounds) ormay have distinct container for each component.

Preferably, kits of the invention include a formulation of the inventionpackaged for use in combination with the co-administration of a secondcompound (such as adjuvants (e.g. GM-CSF), a chemotherapeutic agent, anatural product, a hormone or antagonist, an anti-angiogenesis agent orinhibitor, an apoptosis-inducing agent or a chelator) or apharmaceutical composition thereof. The components of the kit may bepre-complexed or each component may be in a separate distinct containerprior to administration to a patient. The components of the kit may beprovided in one or more liquid solutions, preferably, an aqueoussolution, more preferably, a sterile aqueous solution. The components ofthe kit may also be provided as solids, which may be converted intoliquids by addition of suitable solvents, which are preferably providedin another distinct container.

The container of a therapeutic kit may be a vial, test tube, flask,bottle, syringe, or any other means of enclosing a solid or liquid.Usually, when there is more than one component, the kit will contain asecond vial or other container, which allows for separate dosing. Thekit may also contain another container for a pharmaceutically acceptableliquid. Preferably, a therapeutic kit will contain an apparatus (e.g.,one or more needles, syringes, eye droppers, pipette, etc.), whichenables administration of the agents of the invention that arecomponents of the present kit.

The present formulation is one that is suitable for administration ofthe peptides by any acceptable route such as oral (enteral), nasal,ophthal, subcutaneous, intradermal, intramuscular, intravenous ortransdermal. Preferably, the administration is s.c., and most preferablyi.d. administration may be by infusion pump.

Since the peptides of the invention were isolated from breast cancer,the medicament of the invention is preferably used to treat breastcancer.

The present invention further relates to a method for producing apersonalized pharmaceutical for an individual patient comprisingmanufacturing a pharmaceutical composition comprising at least onepeptide selected from a warehouse of pre-screened TUMAPs, wherein the atleast one peptide used in the pharmaceutical composition is selected forsuitability in the individual patient. In one embodiment, thepharmaceutical composition is a vaccine. The method could also beadapted to produce T cell clones for down-stream applications, such asTCR isolations, or soluble antibodies, and other treatment options.

A “personalized pharmaceutical” shall mean specifically tailoredtherapies for one individual patient that will only be used for therapyin such individual patient, including actively personalized cancervaccines and adoptive cellular therapies using autologous patienttissue.

As used herein, the term “warehouse” shall refer to a group or set ofpeptides that have been pre-screened for immunogenicity and/orover-presentation in a particular tumor type. The term “warehouse” isnot intended to imply that the particular peptides included in thevaccine have been pre-manufactured and stored in a physical facility,although that possibility is contemplated. It is expressly contemplatedthat the peptides may be manufactured de novo for each individualizedvaccine produced, or may be pre-manufactured and stored. The warehouse(e.g. in the form of a database) is composed of tumor-associatedpeptides which were highly overexpressed in the tumor tissue of breastcancer patients with various HLA-A HLA-B and HLA-C alleles. It maycontain MHC class I and MHC class II peptides or elongated MHC class Ipeptides. In addition to the tumor associated peptides collected fromseveral breast cancer tissues, the warehouse may contain HLA-A*02 andHLA-A*24 marker peptides. These peptides allow comparison of themagnitude of T-cell immunity induced by TUMAPS in a quantitative mannerand hence allow important conclusion to be drawn on the capacity of thevaccine to elicit anti-tumor responses. Secondly, they function asimportant positive control peptides derived from a “non-self” antigen inthe case that any vaccine-induced T-cell responses to TUMAPs derivedfrom “self” antigens in a patient are not observed. And thirdly, it mayallow conclusions to be drawn, regarding the status of immunocom-petenceof the patient.

TUMAPs for the warehouse are identified by using an integratedfunctional genomics approach combining gene expression analysis, massspectrometry, and T-cell immu-nology (XPresident®). The approach assuresthat only TUMAPs truly present on a high percentage of tumors but not oronly minimally expressed on normal tissue, are chosen for furtheranalysis. For initial peptide selection, breast cancer samples frompatients and blood from healthy donors were analyzed in a stepwiseapproach:

1. HLA ligands from the malignant material were identified by massspectrometry2. Genome-wide messenger ribonucleic acid (mRNA) expression analysis wasused to identify genes over-expressed in the malignant tissue (breastcancer) compared with a range of normal organs and tissues3. Identified HLA ligands were compared to gene expression data.Peptides over-presented or selectively presented on tumor tissue,preferably encoded by selectively expressed or over-expressed genes asdetected in step 2 were considered suitable TUMAP candidates for amulti-peptide vaccine.4. Literature research was performed in order to identify additionalevidence supporting the relevance of the identified peptides as TUMAPs5. The relevance of over-expression at the mRNA level was confirmed byredetection of selected TUMAPs from step 3 on tumor tissue and lack of(or infrequent) detection on healthy tissues.6. In order to assess, whether an induction of in vivo T-cell responsesby the selected peptides may be feasible, in vitro immunogenicity assayswere performed using human T cells from healthy donors as well as frombreast cancer patients.

In an aspect, the peptides are pre-screened for immunogenicity beforebeing included in the warehouse. By way of example, and not limitation,the immunogenicity of the peptides included in the warehouse isdetermined by a method comprising in vitro T-cell priming throughrepeated stimulations of CD8+ T cells from healthy donors withartificial antigen presenting cells loaded with peptide/MHC complexesand anti-CD28 antibody.

This method is preferred for rare cancers and patients with a rareexpression profile. In contrast to multi-peptide cocktails with a fixedcomposition as currently developed, the warehouse allows a significantlyhigher matching of the actual expression of antigens in the tumor withthe vaccine. Selected single or combinations of several “off-the-shelf”peptides will be used for each patient in a multitarget approach. Intheory, an approach based on selection of e.g. 5 different antigenicpeptides from a library of 50 would already lead to approximately 17million possible drug product (DP) compositions.

In an aspect, the peptides are selected for inclusion in the vaccinebased on their suitability for the individual patient based on themethod according to the present invention as described herein, or asbelow.

The HLA phenotype, transcriptomic and peptidomic data is gathered fromthe patient's tumor material, and blood samples to identify the mostsuitable peptides for each patient containing “warehouse” andpatient-unique (i.e. mutated) TUMAPs. Those peptides will be chosen,which are selectively or over-expressed in the patients' tumor and,where possible, show strong in vitro immunogenicity if tested with thepatients' individual PBMCs.

Preferably, the peptides included in the vaccine are identified by amethod comprising: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient; (b) comparingthe peptides identified in (a) with a warehouse (database) of peptidesas described above; and (c) selecting at least one peptide from thewarehouse (database) that correlates with a tumor-associated peptideidentified in the patient. For example, the TUMAPs presented by thetumor sample are identified by: (a1) comparing expression data from thetumor sample to expression data from a sample of normal tissuecorresponding to the tissue type of the tumor sample to identifyproteins that are over-expressed or aberrantly expressed in the tumorsample; and (a2) correlating the expression data with sequences of MHCligands bound to MHC class I and/or class II molecules in the tumorsample to identify MHC ligands derived from proteins over-expressed oraberrantly expressed by the tumor. Preferably, the sequences of MHCligands are identified by eluting bound peptides from MHC moleculesisolated from the tumor sample, and sequencing the eluted ligands.Preferably, the tumor sample and the normal tissue are obtained from thesame patient.

In addition to, or as an alternative to, selecting peptides using awarehousing (database) model, TUMAPs may be identified in the patient denovo, and then included in the vaccine. As one example, candidate TUMAPsmay be identified in the patient by (a1) comparing expression data fromthe tumor sample to expression data from a sample of normal tissuecorresponding to the tissue type of the tumor sample to identifyproteins that are over-expressed or aberrantly expressed in the tumorsample; and (a2) correlating the expression data with sequences of MHCligands bound to MHC class I and/or class II molecules in the tumorsample to identify MHC ligands derived from proteins over-expressed oraberrantly expressed by the tumor. As another example, proteins may beidentified containing mutations that are unique to the tumor samplerelative to normal corresponding tissue from the individual patient, andTUMAPs can be identified that specifically target the mutation. Forexample, the genome of the tumor and of corresponding normal tissue canbe sequenced by whole genome sequencing: For discovery of non-synonymousmutations in the protein-coding regions of genes, genomic DNA and RNAare extracted from tumor tissues and normal non-mutated genomic germlineDNA is extracted from peripheral blood mononuclear cells (PBMCs). Theapplied NGS approach is confined to the re-sequencing of protein codingregions (exome re-sequencing). For this purpose, exonic DNA from humansamples is captured using vendor-supplied target enrichment kits,followed by sequencing with e.g. a HiSeq2000 (Illumine). Additionally,tumor mRNA is sequenced for direct quantification of gene expression andvalidation that mutated genes are expressed in the patients' tumors. Theresultant millions of sequence reads are processed through softwarealgorithms. The output list contains mutations and gene expression.Tumor-specific somatic mutations are determined by comparison with thePBMC-derived germline variations and prioritized. The de novo identifiedpeptides can then be tested for immunogenicity as described above forthe warehouse, and candidate TUMAPs possessing suitable immunogenicityare selected for inclusion in the vaccine.

In one exemplary embodiment, the peptides included in the vaccine areidentified by: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient by the method asdescribed above; (b) comparing the peptides identified in a) with awarehouse of peptides that have been prescreened for immunogenicity andoverpresentation in tumors as compared to corresponding normal tissue;(c) selecting at least one peptide from the warehouse that correlateswith a tumor-associated peptide identified in the patient; and (d)optionally, selecting at least one peptide identified de novo in (a)confirming its immunogenicity.

In one exemplary embodiment, the peptides included in the vaccine areidentified by: (a) identifying tumor-associated peptides (TUMAPs)presented by a tumor sample from the individual patient; and (b)selecting at least one peptide identified de novo in (a) and confirmingits immunogenicity.

Once the peptides for a personalized peptide based vaccine are selected,the vaccine is produced. The vaccine preferably is a liquid formulationconsisting of the individual peptides dissolved in between 20-40% DMSO,preferably about 30-35% DMSO, such as about 33% DMSO.

Each peptide to be included into a product is dissolved in DMSO. Theconcentration of the single peptide solutions has to be chosen dependingon the number of peptides to be included into the product. The singlepeptide-DMSO solutions are mixed in equal parts to achieve a solutioncontaining all peptides to be included in the product with aconcentration of ˜2.5 mg/ml per peptide. The mixed solution is thendiluted 1:3 with water for injection to achieve a concentration of 0.826mg/ml per peptide in 33% DMSO. The diluted solution is filtered througha 0.22 μm sterile filter. The final bulk solution is obtained.

Final bulk solution is filled into vials and stored at −20° C. untiluse. One vial contains 700 μL solution, containing 0.578 mg of eachpeptide. Of this, 500 μL (approx. 400 μg per peptide) will be appliedfor intradermal injection.

In addition to being useful for treating cancer, the peptides of thepresent invention are also useful as diagnostics. Since the peptideswere generated from breast cancer cells and since it was determined thatthese peptides are not or at lower levels present in normal tissues,these peptides can be used to diagnose the presence of a cancer.

The presence of claimed peptides on tissue biopsies in blood samples canassist a pathologist in diagnosis of cancer. Detection of certainpeptides by means of antibodies, mass spectrometry or other methodsknown in the art can tell the pathologist that the tissue sample ismalignant or inflamed or generally diseased, or can be used as abiomarker for breast cancer. Presence of groups of peptides can enableclassification or sub-classification of diseased tissues.

The detection of peptides on diseased tissue specimen can enable thedecision about the benefit of therapies involving the immune system,especially if T-lymphocytes are known or expected to be involved in themechanism of action. Loss of MHC expression is a well describedmechanism by which infected of malignant cells escapeimmuno-surveillance. Thus, presence of peptides shows that thismechanism is not exploited by the analyzed cells.

The peptides of the present invention might be used to analyzelymphocyte responses against those peptides such as T cell responses orantibody responses against the peptide or the peptide complexed to MHCmolecules. These lymphocyte responses can be used as prognostic markersfor decision on further therapy steps. These responses can also be usedas surrogate response markers in immunotherapy ap-proaches aiming toinduce lymphocyte responses by different means, e.g. vaccination ofprotein, nucleic acids, autologous materials, adoptive transfer oflymphocytes. In gene therapy settings, lymphocyte responses againstpeptides can be considered in the assessment of side effects. Monitoringof lymphocyte responses might also be a valuable tool for follow-upexaminations of transplantation therapies, e.g. for the detection ofgraft versus host and host versus graft diseases.

The present invention will now be described in the following exampleswhich describe preferred embodiments thereof, and with reference to theaccompanying figures, nevertheless, without being limited thereto. Forthe purposes of the present invention, all references as cited hereinare incorporated by reference in their entireties.

FIGURES

FIGS. 1A to 1N show the over-presentation of various peptides in normaltissues (white bars) and breast cancer (black bars). FIG. 1A—CILP,Peptide: KMPEHISTV (SEQ ID NO.: 1), Tissues from left to right: 2adipose tissues, 3 adrenal glands, 4 blood cells, 10 blood vessels, 9bone marrows, 7 brains, 6 breasts, 2 cartilages, 2 eyes, 3gallblad-ders, 6 hearts, 14 kidneys, 19 large intestines, 20 livers, 45lungs, 8 lymph nodes, 7 nerves, 3 ovaries, 10 pancreases, 3 parathyroidglands, 1 peritoneum, 5 pituitary glands, 6 placentas, 3 pleuras, 3prostates, 7 salivary glands, 5 skeletal muscles, 6 skins, 4 smallintestines, 11 spleens, 5 stomachs, 6 testes, 2 thymi, 3 thyroid glands,9 tracheas, 3 ureters, 6 urinary bladders, 4 uteri, 6 esophagi, 22breast cancer sam-pies. The peptide has additionally been detected on1/19 pancreatic cancers and 2/89 non-small cell lung cancers. FIG.1B—TFAP2B, TFAP2C, TFAP2E, TFAP2A, Peptide: SLVEGEAVHLA (SEQ ID NO.:4),Tissues from left to right: 2 adipose tissues, 3 adrenal glands, 4 bloodcells, 10 blood vessels, 9 bone marrows, 7 brains, 6 breasts, 2cartilages, 2 eyes, 3 gallbladders, 6 hearts, 14 kidneys, 19 largeintestines, 20 livers, 45 lungs, 8 lymph nodes, 7 nerves, 3 ovaries, 10pancreases, 3 parathyroid glands, 1 peritoneum, 5 pituitary glands, 6placentas, 3 pleuras, 3 prostates, 7 salivary glands, 5 skeletalmuscles, 6 skins, 4 small intestines, 11 spleens, 5 stomachs, 6 testes,2 thymi, 3 thyroid glands, 9 tracheas, 3 ureters, 6 urinary bladders, 4uteri, 6 esophagi, 22 breast cancer samples. The peptide hasadditionally been detected on 1/6 gallbladder and bile duct cancers,1/20 ovarian cancers, 1/18 esophageal cancers and 1/89 non-small celllung cancers. FIG. 1C—DUSP4, Peptide: FSFPVSVGV (SEQ ID NO.: 20),Tissues from left to right: 2 adipose tissues, 3 adrenal glands, 4 bloodcells, 10 blood vessels, 9 bone marrows, 7 brains, 6 breasts, 2cartilages, 2 eyes, 3 gallbladders, 6 hearts, 14 kidneys, 19 largeintestines, 20 livers, 45 lungs, 8 lymph nodes, 7 nerves, 3 ovaries, 10pancreases, 3 parathyroid glands, 1 peritoneum, 5 pituitary glands, 6pla-centas, 3 pleuras, 3 prostates, 7 salivary glands, 5 skeletalmuscles, 6 skins, 4 small intestines, 11 spleens, 5 stomachs, 6 testes,2 thymi, 3 thyroid glands, 9 tracheas, 3 ureters, 6 urinary bladders, 4uteri, 6 esophagi, 22 breast cancer samples. The peptide hasadditionally been detected on 2/6 gallbladder and bile duct cancers,8/12 melano-mas, 10/20 non-Hodgkin lymphoma samples, 2/20 ovariancancers, 2/19 pancreatic cancers, 7/47 gastric cancers, 23/89 non-smallcell lung cancers, 2/18 renal cell can-cers, 2/17 small cell lungcancers, 6/15 urinary bladder cancers and 2/15 uterine can-cers. FIG.1D)—MAGED1, Peptide: GLLGFQAEA (SEQID NO.: 24), Tissues from left toright: 2 adipose tissues, 3 adrenal glands, 4 blood cells, 10 bloodvessels, 9 bone marrows, 7 brains, 6 breasts, 2 cartilages, 2 eyes, 3gallbladders, 6 hearts, 14 kidneys, 19 large intestines, 20 livers, 45lungs, 8 lymph nodes, 7 nerves, 3 ovaries, 10 pancreases, 3 parathyroidglands, 1 peritoneum, 5 pituitary glands, 6 placentas, 3 pleuras, 3prostates, 7 salivary glands, 5 skeletal muscles, 6 skins, 4 smallintestines, 11 spleens, 5 stomachs, 6 testes, 2 thymi, 3 thyroid glands,9 tracheas, 3 ureters, 6 urinary bladders, 4 uteri, 6 esophagi, 22breast cancer samples. The peptide has additionally been detected on4/21 acute myeloid leukemias, 2/48 prostate cancers, 1/17 chroniclymphocytic leukemias, 2/27 colorectal cancers, 1/6 gallbladder and bileduct cancers, 3/18 hepatocellular cancers, 3/12 melanomas, 6/20non-Hodgkin lymphomas, 7/20 ovarian cancers, 3/18 esophageal cancers,1/19 pancreatic cancers, 6/31 brain cancers, 3/47 gastric cancers, 12/89non-small cell lung cancers, 2/18 renal cell cancers and 3/15 uterinecancers. Discrepancies regarding the list of tumor types between FIG. 1Dand table 4 may be due to the more stringent selection criteria appliedin table 4 (for details please refer to table 4). FIG. 1E) Gene: CNTD2,Peptide: ALAGSSPQV (SEQ ID No.: 2). Samples from left to right: 5 cancertissues (3 breast cancers, 1 colon cancer, 1 liver cancer). FIG. 1F)Gene: LRRC8E, Peptide: GLHSLPPEV (SEQ ID No.: 10). Samples from left toright: 2 cancer tissues (1 breast cancer, 1 head and neck cancer). FIG.1G) Gene: NAIP, Peptide: KAFPFYNTV (SEQ ID No.: 12). Samples from leftto right: 2 cancer tissues (1 breast cancer, 1 stomach cancer). FIG. 1H)Gene: MUC6, Peptide: KQLELELEV (SEQ ID No.: 14). Samples from left toright: 2 cancer tissues (1 breast cancer, 1 pancreas cancer). FIG. 1I)Gene: PLEC, Peptide: SLFPSLVVV (SEQ ID No.: 15). Samples from left toright: 8 cancer tissues (1 bile duct cancer, 1 breast cancer, 1 coloncancer, 1 gallbladder cancer, 1 head and neck cancer, 1 leukocyticleukemia cancer, 1 lymph node cancer, 1 skin cancer). FIG. 1J) Gene:CREB3L4, Peptide: YIDGLESRV (SEQ ID No.: 22). Samples from left toright: 1 pri-mary culture, 2 benign neoplasms, 5 normal tissues (2colons, 1 spleen, 1 stomach, 1 trachea), 47 cancer tissues (2 bonemarrow cancers, 4 breast cancers, 1 esophageal cancer, 1 gallbladdercancer, 8 leukocytic leukemia cancers, 4 lung cancers, 3 lymph nodecancers, 1 myeloid cell cancer, 2 ovarian cancers, 1 pancreas cancer, 13prostate cancers, 2 rectum cancers, 1 stomach cancer, 1 urinary bladdercancer, 3 uterus cancers). FIG. 1K) Gene: THADA, Peptide: SAFPEVRSL (SEQID No.: 34). Samples from left to right: 6 cell lines, 4 normal tissues(1 leukocyte sample, 1 lymph node, 1 lymphocyte sample, 1 placenta), 9cancer tissues (3 breast cancers, 1 gallbladder cancer, 2 leukocyticleukemia cancers, 1 liver cancer, 1 ovarian cancer, 1 skin cancer). FIG.1L) Gene: KDM5B, Peptide: VLAHITADI (SEQ ID No.: 37). Samples from leftto right: 1 cell line, 1 primary culture, 31 cancer tissues (3 bonemarrow cancers, 1 breast cancer, 2 colon cancers, 2 esophageal cancers,1 head and neck cancer, 5 leukocytic leukemia cancers, 5 lung cancers, 2lymph node cancers, 2 myeloid cell cancers, 1 ovarian cancer, 3 urinarybladder cancers, 4 uterus cancers). FIG. 1M) Gene: PCNXL3, Peptide:LLMUVAGLKL (SEQ ID No.: 38). Samples from left to right: 2 cell lines, 1normal tissue (1 lymph node), 16 cancer tissues (1 bile duct cancer, 2colon cancers, 1 head and neck cancer, 5 lung cancers, 2 lymph nodecancers, 1 myeloid cell cancer, 1 ovarian cancer, 1 rectum cancer, 1skin cancer, 1 urinary bladder cancer). FIG. 1N) Gene: MCM8, Peptide:SLNDQGYLL (SEQ ID No.: 41). Samples from left to right: 1 cell line, 1normal tissue (1 small intestine), 9 cancer tissues (1 breast cancer, 1lung cancer, 4 lymph node cancers, 1 myeloid cell cancer, 1 ovariancancer, 1 skin cancer).

FIGS. 2A to 2C show exemplary expression profiles of source genes of thepresent invention that are highly over-expressed or exclusivelyexpressed in breast cancer in a panel of normal tissues (white bars) and10 breast cancer samples (black bars). Tissues from left to right: 6arteries, 2 blood cells, 2 brains, 2 hearts, 2 livers, 3 lungs, 2 veins,1 adipose tissue, 1 adrenal gland, 6 bone marrows, 1 cartilage, 1 colon,1 esophagus, 2 eyes, 2 gallbladders, 1 kidney, 6 lymph nodes, 5pancreases, 2 periph-eral nerves, 2 pituitary glands, 1 rectum, 2salivary glands, 2 skeletal muscles, 1 skin, 1 small intestine, 1spleen, 1 stomach, 1 thyroid gland, 7 tracheas, 1 urinary bladder, 1breast, 5 ovaries, 5 placentas, 1 prostate, 1 testis, 1 thymus, 1uterus, 10 breast cancer samples. FIG. 2A) Gene symbol: ESR1; FIG. 2B)Gene symbol: ABCC11, FIG. 2C) Gene symbol: SLC39A6.

FIGS. 3A to 3D show exemplary immunogenicity data: flow cytometryresults after peptide-specific multimer staining. Exemplary results ofpeptide-specific in vitro CD8+ T cell responses of a healthy HLA-A*02+donor are shown. CD8+ T cells were primed using artificial APCs coatedwith anti-CD28 mAb and HLA-A*02 in complex with SeqID No 1 peptide (FIG.3B, left panel), SeqID No 22 peptide (FIG. 3C, left panel) and SeqID No24 peptide (FIG. 3D, left panel), respectively. After three cycles ofstimulation, the detection of peptide-reactive cells was performed by 2Dmultimer staining with A*02/SeqID No 1 (FIG. 3B), A*02/SeqID No 22 (FIG.3C) or A*02/SeqID No 24 (FIG. 3D). Right panels (FIGS. 3B, 3C, and 3D)show control staining of cells stimulated with irrelevant A*02/peptidecomplexes. Viable sin-glet cells were gated for CD8+ lymphocytes.Boolean gates helped excluding false-positive events detected withmultimers specific for different peptides. Frequencies of specificmultimer+ cells among CD8+ lymphocytes are indicated.

EXAMPLES Example 1 Identification and Quantitation of Tumor AssociatedPeptides Presented on the Cell Surface Tissue Samples

Patients' tumor tissues were obtained from: Asterand (Detroit, Mich.,USA & Royston, Herts, UK); BioServe (Beltsville, Md., USA); GeneticistInc. (Glendale, Calif., USA); Tis-sue Solutions Ltd (Glasgow, UK); andUniversity Hospital Heidelberg (Heidelberg, Germany)

Normal tissues were obtained from Asterand (Detroit, Mich., USA &Royston, Herts, UK); Bio-Options Inc. (Brea, Calif., USA); BioServe(Beltsville, Md., USA); Capital BioScience Inc. (Rockville, Md., USA);Geneticist Inc. (Glendale, Calif., USA); Kyoto Prefectural Uni-versityof Medicine (KPUM) (Kyoto, Japan); ProteoGenex Inc. (Culver City,Calif., USA); Tissue Solutions Ltd (Glasgow, UK); University HospitalGeneva (Geneva, Switzer-land); University Hospital Heidelberg(Heidelberg, Germany); University Hospital Mu-nich (Munich, Germany);and University Hospital Tübingen (Tübingen, Germany)

Written informed consents of all patients had been given before surgeryor autopsy. Tissues were shock-frozen immediately after excision andstored until isolation of TUMAPs at −70° C. or below.

Isolation of HLA Peptides from Tissue Samples

HLA peptide pools from shock-frozen tissue samples were obtained byimmune pre-cipitation from solid tissues according to a slightlymodified protocol (Falk et al., 1991; Seeger et al., 1999) using theHLA-A*02-specific antibody BB7.2, the HLA-A, -B, C-specific antibodyW6/32, CNBr-activated sepharose, acid treatment, and ultrafiltra-tion.

Mass Spectrometry Analyses

The HLA peptide pools as obtained were separated according to theirhydrophobicity by reversed-phase chromatography (nanoAcquity UPLCsystem, Waters) and the eluting peptides were analyzed in LTQ-velos andfusion hybrid mass spectrometers (Ther-moElectron) equipped with an ESIsource. Peptide pools were loaded directly onto the analyticalfused-silica micro-capillary column (75 μm i.d.×250 mm) packed with 1.7μm C18 reversed-phase material (Waters) applying a flow rate of 400 nLper minute. Subsequently, the peptides were separated using a two-step180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nLper minute. The gradient was composed of Solvent A (0.1% formic acid inwater) and solvent B (0.1% formic acid in acetonitrile). A gold coatedglass capillary (PicoTip, New Objective) was used for introduction intothe nanoESI source. The LTQ-Orbitrap mass spectrometers were operated inthe data-dependent mode using a TOPS strategy. In brief, a scan cyclewas initiated with a full scan of high mass accuracy in the orbitrap(R=30 000), which was followed by MS/MS scans also in the orbitrap(R=7500) on the 5 most abundant precursor ions with dy-namic exclusionof previously selected ions. Tandem mass spectra were interpreted bySEQUEST and additional manual control. The identified peptide sequencewas assured by comparison of the generated natural peptide fragmentationpattern with the fragmentation pattern of a synthetic sequence-identicalreference peptide.

Label-free relative LC-MS quantitation was performed by ion countingi.e. by extraction and analysis of LC-MS features (Mueller et al.,2007). The method assumes that the peptide's LC-MS signal areacorrelates with its abundance in the sample. Extracted features werefurther processed by charge state deconvolution and retention timealignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MSfeatures were cross-referenced with the sequence identification resultsto combine quantitative data of different samples and tissues to peptidepresentation profiles. The quantitative data were normalized in atwo-tier fashion according to central tendency to account for variationwithin technical and biological replicates. Thus, each identifiedpeptide can be associated with quantitative data allowing relativequantification between samples and tissues. In addition, allquantitative data acquired for peptide candidates was inspected manuallyto assure data consistency and to verify the accuracy of the automatedanalysis. For each peptide, a presentation profile was calculatedshowing the mean sample presentation as well as replicate variations.The profiles juxtapose breast cancer samples to a baseline of normaltissue samples. Presentation profiles of exemplary over-presentedpeptides are shown in FIGS. 1A-1N. Presentation scores for exemplarypeptides are shown in Table 8.

TABLE 8 Presentation scores.The table lists peptides that are very highlyover-presented on tumors compared to a panelof normal tissues (+++), highly over-presentedon tumors compared to a panel of normal tissues(++) or over-presented on tumors compared to apanel of normal tissues (+). The panel of normaltissues considered relevant for comparison withtumors consisted of: adipose tissue, adrenalgland, blood cells, blood vessel, bone marrow,brain, cartilage, esophagus, eye, gallbladder,heart, kidney, large intestine, liver, lung,lymph node, nerve, pancreas, parathyroid gland,peritoneum, pituitary gland, pleura, salivarygland, skeletal muscle, skin, small intestine,spleen, stomach, thymus, thyroid gland, trachea,ureter, and urinary bladder. SEQ Peptide ID NO Sequence Presentation  1KMPEHISTV +++  2 ALAGSSPQV +++  3 ILLPPAHNJQ +++  4 SLVEGEAVHLA +++  5ALNPVIYTV +++  6 ALTALQNYL +++  7 FIIPTVATA +++  8 GLVQSLTSI +++  9FMSKLVPAI +++ 10 GLHSLPPEV +++ 11 GLLPTSVSPRV +++ 12 KAFPFYNTV +++ 13KLYEGIPVL +++ 14 KQLELELEV +++ 15 SLFPSLVVV +++ 16 SMMGLLTNL +++ 17TIASSIEKA +++ 18 YILLQSPQL +++ 19 ALEEQLHQV +++ 21 SLLTEPALV ++ 22YIDGLESRV ++ 23 SLADAVEKV ++ 26 SLAWDVPAA ++ 27 SLAEPRVSV + 30 FLSSEAANV+++ 31 GLSYIYNTV ++ 32 GLVATLQSL ++ 33 ILTELPPGV +++ 34 SAFPEVRSL + 35SLLSEIQAL ++ 36 TLLGLAVNV ++ 37 VLAHITADI +++ 38 LLMUVAGLKL +++ 39KLLDMELEM ++ 40 SAAFPGASL ++ 43 FLDEEVKLI +

Example 2 Expression Profiling of Genes Encoding the Peptides of theInvention

Over-presentation or specific presentation of a peptide on tumor cellscompared to normal cells is sufficient for its usefulness inimmunotherapy, and some peptides are tumor-specific despite their sourceprotein occurring also in normal tissues. Still, mRNA expressionprofiling adds an additional level of safety in selection of peptidetargets for immunotherapies. Especially for therapeutic options withhigh safety risks, such as af-finity-matured TCRs, the ideal targetpeptide will be derived from a protein that is unique to the tumor andnot found on normal tissues.

RNA Sources and Preparation

Surgically removed tissue specimens were provided as indicated above(see Example 1) after written informed consent had been obtained fromeach patient. Tumor tissue specimens were snap-frozen immediately aftersurgery and later homogenized with mortar and pestle under liquidnitrogen. Total RNA was prepared from these samples using TRI Reagent(Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy (QIAGEN,Hilden, Germany); both methods were performed according to themanufacturer's protocol.

Total RNA from healthy human tissues for RNASeq experiments was obtainedfrom: Asterand (Detroit, Mich., USA & Royston, Herts, UK); BioCat GmbH(Heidelberg, Germany); BioServe (Beltsville, Md., USA); CapitalBioScience Inc. (Rockville, Md., USA); Geneticist Inc. (Glendale,Calif., USA); Istituto Nazionale Tumori “Pascale” (Naples, Italy);ProteoGenex Inc. (Culver City, Calif., USA); and University HospitalHeidelberg (Heidelberg, Germany)

Total RNA from tumor tissues for RNASeq experiments was obtained from:Asterand (Detroit, Mich., USA & Royston, Herts, UK); BioServe(Beltsville, Md., USA); and Tissue Solutions Ltd (Glasgow, UK)

Quality and quantity of all RNA samples were assessed on an Agilent 2100Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 PicoLabChip Kit (Agilent).

RNAseq Experiments

Gene expression analysis of—tumor and normal tissue RNA samples wasperformed by next generation sequencing (RNAseq) by CeGaT (Tübingen,Germany). Briefly, sequencing libraries are prepared using the IlluminaHiSeq v4 reagent kit according to the provider's protocol (Illumina Inc,San Diego, Calif., USA), which includes RNA fragmentation, cDNAconversion and addition of sequencing adaptors. Libraries derived frommultiple samples are mixed equimolarly and sequenced on the IlluminaHiSeq 2500 sequencer according to the manufacturer's instructions,generating 50 bp single end reads. Processed reads are mapped to thehuman genome (GRCh38) using the STAR software. Expression data areprovided on transcript level as RPKM (Reads Per Kilobase per Millionmapped reads, generated by the software Cufflinks) and on exon level(total reads, generated by the software Bedtools), based on annotationsof the ensembl sequence database (Ensembl77). Exon reads are normalizedfor exon length and alignment size to obtain RPKM values.

Exemplary expression profiles of source genes of the present inventionthat are highly over-expressed or exclusively expressed in breast cancerare shown in FIGS. 2A-2C. Ex-pression scores for further exemplary genesare shown in Table 9.

TABLE 9 Expression scores. The table lists peptides fromgenes that are very highly over-expressed intumors compared to a panel of normal tissues(+++), highly over-expressed in tumors comparedto a panel of normal tissues (++) or over-expressed in tumors compared to a panel ofnormal tissues (+). The baseline for this scorewas calculated from measurements of thefollowing relevant normal tissues: adiposetissue, adrenal gland, artery, blood cells, bonemarrow, brain, cartilage, colon, esophagus, eyegallbladder, heart, kidney, liver, lung, lymphnode, pancreas, peripheral nerve, pi-tuitary,rectum, salivary land, skeletal muscle, skin,small intestine, spleen, stomach, thyroid gland,thyroid gland, trachea, urinary bladder, vein.In case expression data for several samples ofthe same tissue type were available, thearithmetic mean of all respective samples was used for the calculation.SEQ ID NO Sequence Gene Expression  2 ALAGSSPQV ++  4 SLVEGEAVHLA +++  6ALTALQNYL +++  7 FIIPTVATA +++  8 GLVQSLTSI +++  9 FMSKLVPAI ++ 10GLHSLPPEV + 11 GLLPTSVSPRV +++ 16 SMMGLLTNL +++ 20 FSFPVSVGV ++ 21SLLTEPALV + 22 YIDGLESRV ++ 32 GLVATLQSL ++ 42 FLVEHVLTL +++

Example 3 In Vitro Immunogenicity for MHC Class I Presented Peptides

In order to obtain information regarding the immunogenicity of theTUMAPs of the present invention, the inventors performed investigationsusing an in vitro T-cell priming assay based on repeated stimulations ofCD8+ T cells with artificial antigen presenting cells (aAPCs) loadedwith peptide/MHC complexes and anti-CD28 antibody. This way theinventors could show immunogenicity for HLA-A*0201 restricted TUMAPs ofthe invention, demonstrating that these peptides are T-cell epitopesagainst which CD8+ precursor T cells exist in humans (Table 10).

In Vitro Priming of CD8+ T Cells

In order to perform in vitro stimulations by artificial antigenpresenting cells loaded with peptide-MHC complex (pMHC) and anti-CD28antibody, the inventors first isolated CD8+ T cells from fresh HLA-A*02leukapheresis products via positive selection using CD8 microbeads(Miltenyi Biotec, Bergisch-Gladbach, Germany) of healthy donors obtainedfrom the University clinics Mannheim, Germany, after informed consent.

PBMCs and isolated CD8+ lymphocytes were incubated in T-cell medium(TCM) until use consisting of RPMI-Glutamax (Invitrogen, Karlsruhe,Germany) supplemented with 10% heat inactivated human AB serum(PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin/100 μg/mlStreptomycin (Cambrex, Cologne, Germany), 1 mM sodium py-ruvate (CC Pro,Oberdorla, Germany), 20 μg/ml Gentamycin (Cambrex). 2.5 ng/ml IL-7(PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Novartis Pharma,Nurnberg, Germany) were also added to the TCM at this step.

Generation of pMHC/anti-CD28 coated beads, T-cell stimulations andreadout was performed in a highly defined in vitro system using fourdifferent pMHC molecules per stimulation condition and 8 different pMHCmolecules per readout condition.

The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung etal., 1987) was chemically biotinylated usingSulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer(Perbio, Bonn, Germany). Beads used were 5.6 μm diameter streptavidincoated polystyrene particles (Bangs Laboratories, Illinois, USA).

pMHC used for positive and negative control stimulations wereA*0201/MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 72) from modifiedMelan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO.73), respectively.

800.000 beads/200 μl were coated in 96-well plates in the presence of4×12.5 ng different biotin-pMHC, washed and 600 ng biotin anti-CD28 wereadded subsequently in a volume of 200 μl. Stimulations were initiated in96-well plates by co-incubating 1×10⁶ CD8+ T cells with 2×10⁵ washedcoated beads in 200 μl TCM supplemented with 5 ng/ml IL-12 (PromoCell)for 3 days at 37° C. Half of the medium was then exchanged by fresh TCMsupplemented with 80 U/ml IL-2 and incubating was continued for 4 daysat 37° C. This stimulation cycle was performed for a total of threetimes. For the pMHC multimer readout using 8 different pMHC moleculesper condition, a two-dimensional combinatorial coding approach was usedas previously described (Andersen et al., 2012) with minor modificationsencompassing coupling to 5 different fluorochromes. Finally, multimericanalyses were performed by staining the cells with Live/dead near IR dye(Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD,Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BDLSRII SORP cytometer equipped with appropriate lasers and filters wasused. Peptide specific cells were calculated as percentage of total CD8+cells. Evaluation of multimeric analysis was done using the FlowJosoftware (Tree Star, Oregon, USA). In vitro priming of specificmultimer+CD8+ lymphocytes was detected by comparing to negative controlstimulations. Immunogenicity for a given antigen was detected if atleast one evaluable in vitro stimulated well of one healthy donor wasfound to contain a specific CD8+ T-cell line after in vitro stimulation(i.e. this well contained at least 1% of specific multimer+ among CD8+T-cells and the percentage of specific multimer+ cells was at least 10×the median of the negative control stimulations).

In Vitro Immunogenicity for Breast Cancer Peptides

For tested HLA class I peptides, in vitro immunogenicity could bedemonstrated by generation of peptide specific T-cell lines. Exemplaryflow cytometry results after TUMAP-specific multimer staining for onepeptide of the invention are shown in FIGS. 3A-3D,

together with corresponding negative controls. Results for threepeptides from the invention are summarized in Table 10A, and foradditional peptides in Table 10B.

TABLE 10A in vitro immunogenicity of HLA class I peptidesof the invention Exemplary results of in vitro immunogenicityexperiments conducted by theapplicant for the peptides of the invention. <20% = +, 20%-49% =++, 50%-69% = +++, >= 70% = ++++ Seq ID Sequence wells 66 ILFPDIIARA ++51 SLYKGLLSV ++ 50 TLSSIKVEV +

In vitro immunogenicity of HLA class I peptides of the inventionExemplary results of in vitro immunogenicityexperiments for HLA-A*02 restricted peptides ofthe invention. Results of in vitro immunogenicityexperiments are indicated. Percentage of positivewells and donors (among evaluable) are summarized as indicated <20% =+, 20%-49% = ++, 50%-69% = +++, >= 70%= ++++ Wells positive SEQ ID NO:Sequence [%]  1 KMPEHISTV “+”  2 ALAGSSPQV “++” 21 SLLTEPALV “++” 22YIDGLESRV “+” 23 SLADAVEKV “+++” 24 GLLGFQAEA “++”

Example 4 Synthesis of Peptides

All peptides were synthesized using standard and well-established solidphase peptide synthesis using the Fmoc-strategy. Identity and purity ofeach individual peptide have been determined by mass spectrometry andanalytical RP-HPLC. The peptides were obtained as white to off-whitelyophilizates (trifluoro acetate salt) in purities of >50%. All TUMAPsare preferably administered as trifluoro-acetate salts or acetate salts,other salt-forms are also possible.

Example 5 MHC Binding Assays

Candidate peptides for T cell based therapies according to the presentinvention were further tested for their MHC binding capacity (affinity).The individual peptide-MHC complexes were produced by UV-ligandexchange, where a UV-sensitive peptide is cleaved upon UV-irradiation,and exchanged with the peptide of interest as analyzed. Only peptidecandidates that can effectively bind and stabilize the peptide-receptiveMHC molecules prevent dissociation of the MHC complexes. To determinethe yield of the exchange reaction, an ELISA was performed based on thedetection of the light chain (β2m) of stabilized MHC complexes. Theassay was performed as generally described in Rodenko et al. (Rodenko etal., 2006).

96 well MAXISorp plates (NUNC) were coated over night with 2 ug/mlstreptavidin in PBS at room temperature, washed 4× and blocked for 1 hat 37° C. in 2% BSA containing blocking buffer. RefoldedHLA-A*02:01/MLA-001 monomers served as standards, cov-ering the range of15-500 ng/ml. Peptide-MHC monomers of the UV-exchange reaction werediluted 100-fold in blocking buffer. Samples were incubated for 1 h at37° C., washed four times, incubated with 2 ug/ml HRP conjugatedanti-β2m for 1 h at 37° C., washed again and detected with TMB solutionthat is stopped with NH2SO4. Absorp-tion was measured at 450 nm.Candidate peptides that show a high exchange yield (preferably higherthan 50%, most preferred higher than 75%) are generally preferred for ageneration and production of antibodies or fragments thereof, and/or Tcell receptors or fragments thereof, as they show sufficient avidity tothe MHC molecules and prevent dissociation of the MHC complexes.

TABLE 11 MHC class I binding scores. Binding of HLA-classI restricted peptides to HLA-A*02:01 was rangedby peptide exchange yield: ≥10% = +; ≥20% = ++; ≥50 = +++; ≥75% = ++++SEQ ID Sequence Peptide Exchange  1 KMPEHISTV “+++”  2 ALAGSSPQV “+++” 4 SLVEGEAVHLA “++”  5 ALNPVIYTV “++”  6 ALTALQNYL “+++”  7 FIIPTVATA“++++”  8 GLVQSLTSI “++++”  9 FMSKLVPAI “+++” 10 GLHSLPPEV “+++” 11GLLPTSVSPRV “++” 12 KAFPFYNTV “++” 13 KLYEGIPVL “++” 14 KQLELELEV “+++”15 SLFPSLVVV “+++” 16 SMMGLLTNL “++++” 17 TIASSIEKA “++” 18 YILLQSPQL“+++” 19 ALEEQLHQV “++” 20 FSFPVSVGV “+++” 21 SLLTEPALV “+++” 22YIDGLESRV “+++” 23 SLADAVEKV “+++” 24 GLLGFQAEA “++++” 25 ILFDVVVFL “++”26 SLAWDVPAA “+++” 27 SLAEPRVSV “+++” 28 SLFSVPFFL “++++” 29 ALEAUQLYL“+++” 30 FLSSEAANV “++” 31 GLSYIYNTV “++” 32 GLVATLQSL “+++” 33ILTELPPGV “++” 35 SLLSEIQAL “++++” 36 TLLGLAVNV “++++” 38 LLMUVAGLKL“++++” 39 KLLDMELEM “++++” 41 SLNDQGYLL “+++” 42 FLVEHVLTL “++++” 43FLDEEVKLI “+++”

REFERENCE LIST

-   Akbari, M. E. et al., Breast Cancer (2015)-   Albulescu, R., Biomark. Med. 7 (2013): 203-   Allison, J. P. et al., Science 270 (1995): 932-933-   Andersen, R. S. et al., Nat. Protoc. 7 (2012): 891-902-   Andres, S. A. et al., BMC. Cancer 13 (2013): 326-   Andres, S. A. et al., Breast 23 (2014): 226-233-   Appay, V. et al., Eur. J Immunol. 36 (2006): 1805-1814-   Arafat, H. et al., Surgery 150 (2011): 306-315-   Ariga, N. et al., Int J Cancer 95 (2001): 67-72-   Aylon, Y. et al., Mol. Oncol 5 (2011): 315-323-   Balko, J. M. et al., Nat Med 18 (2012): 1052-1059-   Banchereau, J. et al., Cell 106 (2001): 271-274-   Band, A. M. et al., J Mammary. Gland. Biol Neoplasia. 16 (2011):    109-115-   Bausch, D. et al., Clin Cancer Res 17 (2011): 302-309-   Beatty, G. et al., J Immunol 166 (2001): 2276-2282-   Beggs, J. D., Nature 275 (1978): 104-109-   Benjamini, Y. et al., Journal of the Royal Statistical Society.    Series B (Methodological), Vol. 57 (1995): 289-300-   Berger, C. et al., Curr. Mol. Med. 13 (2013): 1229-1240-   Bogush, T. A. et al., Antibiot. Khimioter. 54 (2009): 41-49-   Borel, F. et al., Hepatology 55 (2012): 821-832-   Bornstein, S. et al., BMC. Genomics 17 (2016): 38-   Bouameur, J. E. et al., J Invest Dermatol. 134 (2014): 885-894-   Boulter, J. M. et al., Protein Eng 16 (2003): 707-711-   Braumuller, H. et al., Nature (2013)-   Brossart, P. et al., Blood 90 (1997): 1594-1599-   Bruckdorfer, T. et al., Curr. Pharm. Biotechnol. 5 (2004): 29-43-   Buranrat, B. et al., Oncol Rep. 34 (2015): 2790-2796-   Card, K. F. et al., Cancer Immunol Immunother. 53 (2004): 345-357-   Chang, H. Y. et al., PLoS. One. 8 (2013): e54117-   Chanock, S. J. et al., Hum. Immunol. 65 (2004): 1211-1223-   Chekhun, V. F. et al., Int. J Oncol 43 (2013): 1481-1486-   Chen, L. C. et al., Mod. Pathol. 24 (2011): 175-184-   Cheng, I. et al., Gut 60 (2011): 1703-1711-   Cheng, Z. et al., J Exp. Clin Cancer Res 34 (2015): 27-   Cheriyath, V. et al., Oncogene 31 (2012): 2222-2236-   Choi, J. et al., Cell Stress. Chaperones. 19 (2014): 439-446-   Chung, F. Y. et al., J Surg. Oncol 102 (2010): 148-153-   Ciruelos Gil, E. M., Cancer Treat. Rev 40 (2014): 862-871-   Cohen, C. J. et al., J Mol Recognit. 16 (2003a): 324-332-   Cohen, C. J. et al., J Immunol 170 (2003b): 4349-4361-   Cohen, S. J. et al., Pancreas 37 (2008): 154-158-   Cohen, S. N. et al., Proc. Natl. Acad. Sci. U.S.A 69 (1972):    2110-2114-   Coligan, J. E. et al., Current Protocols in Protein Science (1995)-   Colombetti, S. et al., J Immunol. 176 (2006): 2730-2738-   Cui, X. B. et al., J Transl. Med 13 (2015): 321-   Delaval, B. et al., J Cell Biol. 188 (2010): 181-190-   Dengjel, J. et al., Clin Cancer Res 12 (2006): 4163-4170-   Denkberg, G. et al., J Immunol 171 (2003): 2197-2207-   Ding, K. et al., Med. Hypotheses 83 (2014): 359-364-   Drazkowska, K. et al., Nucleic Acids Res 41 (2013): 3845-3858-   Du, L. et al., Tumori 101 (2015): 384-389-   Egloff, A. M. et al., Cancer Res 66 (2006): 6-9-   Emens, L. A., Expert. Rev. Anticancer Ther. 12 (2012): 1597-1611-   Fagin, J. A., Mol. Endocrinol. 16 (2002): 903-911-   Falk, K. et al., Nature 351 (1991): 290-296-   Fang, Y. et al., Cancer Biol Ther. 15 (2014): 1268-1279-   Feng, Y. et al., J Biol. Chem. 289 (2014): 2072-2083-   Fong, L. et al., Proc. Natl. Acad. Sci. U.S.A 98 (2001): 8809-8814-   Frasor, J. et al., Mol. Cell Endocrinol. 418 Pt 3 (2015): 235-239-   Fry, A. M. et al., J Cell Sci. 125 (2012): 4423-4433-   Fu, L. et al., Mol. Cancer 13 (2014): 89-   Fuqua, S. A. et al., Breast Cancer Res Treat. 144 (2014): 11-19-   Gabrilovich, D. I. et al., Nat Med. 2 (1996): 1096-1103-   Ganly, I. et al., J Clin Endocrinol. Metab 98 (2013): E962-E972-   Gardina, P. J. et al., BMC. Genomics 7 (2006): 325-   Garg, M. et al., J Clin Endocrinol. Metab 99 (2014): E62-E72-   Gattinoni, L. et al., Nat Rev. Immunol 6 (2006): 383-393-   Gershenwald, J. E. et al., Oncogene 20 (2001): 3363-3375-   Gilkes, D. M. et al., Mol Cancer Res 11 (2013): 456-466-   Gnjatic, S. et al., Proc Natl. Acad. Sci. U.S.A 100 (2003):    8862-8867-   Godkin, A. et al., Int. Immunol 9 (1997): 905-911-   Grady, W. M., Cancer Metastasis Rev 23 (2004): 11-27-   Green, M. R. et al., Molecular Cloning, A Laboratory Manual 4th    (2012)-   Greenfield, E. A., Antibodies: A Laboratory Manual 2nd (2014)-   Gumireddy, K. et al., Mol. Cancer Res 12 (2014): 1334-1343-   Guo, Y. et al., Clin Cancer Res 15 (2009): 1762-1769-   Harvey, H. et al., Int. J Cancer 136 (2015): 1579-1588-   Hayashi, S. I. et al., Endocr. Relat Cancer 10 (2003): 193-202-   Hiramoto, T. et al., Oncogene 18 (1999): 3422-3426-   Hlavata, I. et al., Mutagenesis 27 (2012): 187-196-   Hoei-Hansen, C. E. et al., Clin Cancer Res 10 (2004): 8521-8530-   Hogstrand, C. et al., Biochem. J 455 (2013): 229-237-   Honorat, M. et al., BMC. Struct. Biol 13 (2013): 7-   Hu, P. et al., Biosci. Rep. 35 (2015a)-   Hu, P. et al., Int. J Clin Exp. Pathol. 8 (2015b): 2638-2648-   Hu, Z. Y. et al., Biochim. Biophys. Acta 1862 (2016): 1172-1181-   Huang, C. C. et al., PLoS. One. 8 (2013): e76421-   Hwang, M. L. et al., J Immunol. 179 (2007): 5829-5838-   Jacob, M. et al., Curr. Mol Med. 12 (2012): 1220-1243-   Januchowski, R. et al., Biomed. Res Int 2014 (2014): 365867-   Jezequel, P. et al., Int. J Cancer 131 (2012): 426-437-   Jia, M. et al., Cancer Res (2016)-   Jung, G. et al., Proc Natl Acad Sci USA 84 (1987): 4611-4615-   Jung, H. J. et al., J Mol Med. (Berl) 91(2013): 1117-1128-   Kang, C. Y. et al., J Gastrointest. Surg. 18 (2014): 7-15-   Karagiannis, G. S. et al., Oncotarget. 3 (2012): 267-285-   Karess, R. E. et al., Int. Rev Cell Mol. Biol 306 (2013): 223-273-   Karvonen, U. et al., J Mol Biol. 382 (2008): 585-600-   Kashyap, M. K. et al., Cancer Biol. Ther 8 (2009): 36-46-   Katada, K. et al., J Proteomics. 75 (2012): 1803-1815-   Kevans, D. et al., Int J Surg. Pathol. 19 (2011): 751-760-   Kibbe, A. H., Handbook of Pharmaceutical Excipients rd (2000)-   Kim, H. C. et al., Cell Mol. Life Sci. 67 (2010): 3499-3510-   Kim, S. Z. et al., J Inherit. Metab Dis. 23 (2000): 791-804-   Klinke, 0. K. et al., PLoS. One. 10 (2015): e0130149-   Koppen, A. et al., Eur. J Cancer 43 (2007): 2413-2422-   Krieg, A. M., Nat Rev. Drug Discov. 5 (2006): 471-484-   Kristensen, V. N. et al., Proc. Natl. Acad. Sci. U.S.A 109 (2012):    2802-2807-   Lai, Y. H. et al., Carcinogenesis 34 (2013): 1069-1080-   Langnaese, K. et al., Cytogenet. Cell Genet. 94 (2001): 233-240-   Lascorz, J. et al., BMC. Med. Genet. 13 (2012): 31-   Lee, K. Y. et al., J Med. 35 (2004): 141-149-   Leiszter, K. et al., PLoS. One. 8 (2013): e74140-   Leivo, I. et al., Cancer Genet. Cytogenet. 156 (2005): 104-113-   Li, G. et al., Asian Pac. J Cancer Prev. 14 (2013a): 4943-4952-   Li, H. et al., Neoplasia. 8 (2006): 568-577-   Li, K. C. et al., Mol. Cancer 13 (2014): 172-   Li, M. et al., Int. J Oncol. 24 (2004): 305-312-   Li, X. et al., Genes Chromosomes. Cancer 49 (2010): 819-830-   Li, X. H. et al., J BUON. 20 (2015): 1223-1228-   Li, Y. et al., PLoS. One. 8 (2013b): e84489-   Li, Y. et al., Asian Pac. J Cancer Prev. 12 (2011): 2405-2409-   Lian, J. et al., Oncotarget. 7 (2016): 2672-2683-   Liddy, N. et al., Nat Med. 18 (2012): 980-987-   Lin, C. S. et al., Cancer Lett. 368 (2015): 36-45-   Lin, Y. C. et al., J Cell Sci. 127 (2014): 85-100-   Liu, Q. et al., Asian Pac. J Cancer Prev. 15 (2014): 8623-8629-   Liu, Z. et al., Carcinogenesis 32 (2011): 1668-1674-   Ljunggren, H. G. et al., J Exp. Med. 162 (1985): 1745-1759-   Longenecker, B. M. et al., Ann N.Y. Acad. Sci. 690 (1993): 276-291-   Lonsdale, J., Nat. Genet. 45 (2013): 580-585-   Lu, X. et al., Mol. Cancer Ther. 3 (2004): 861-872-   Lukas, T. J. et al., Proc. Natl. Acad. Sci. U.S.A 78 (1981):    2791-2795-   Lundblad, R. L., Chemical Reagents for Protein Modification 3rd    (2004)-   Mahomed, F., Oral Oncol 47 (2011): 797-803-   Malumbres, M. et al., Curr. Opin. Genet. Dev. 17 (2007): 60-65-   Mason, J. M. et al., Nucleic Acids Res. 43 (2015): 3180-3196-   Mehta, A. et al., Breast 23 (2014): 2-9-   Mentlein, R. et al., Biol. Chem. 392 (2011): 199-207-   Meziere, C. et al., J Immunol 159 (1997): 3230-3237-   Milne, R. L. et al., Hum. Mol. Genet. 23 (2014): 6096-6111-   Mitchell, D. C. et al., J Biol Chem 281 (2006): 51-58-   Miyoshi, Y. et al., Med. Mol. Morphol. 43 (2010): 193-196-   Mo, Q. Q. et al., Acta Pharmacol. Sin. 34 (2013): 541-548-   Moniz, L. S. et al., Mol. Cell Biol 31 (2011): 30-42-   Morgan, R. A. et al., Science 314 (2006): 126-129-   Mori, M. et al., Transplantation 64 (1997): 1017-1027-   Mortara, L. et al., Clin Cancer Res. 12 (2006): 3435-3443-   Mueller, L. N. et al., J Proteome. Res 7 (2008): 51-61-   Mueller, L. N. et al., Proteomics. 7 (2007): 3470-3480-   Mukhopadhyay, P. et al., Biochim. Biophys. Acta 1815 (2011): 224-240-   Mulligan, A. M. et al., Breast Cancer Res 13 (2011): R110-   Mumberg, D. et al., Proc. Natl. Acad. Sci. U.S.A 96 (1999):    8633-8638-   Na, C. H. et al., Mol. Cells 38 (2015): 624-629-   Oji, Y. et al., Int. J Oncol 44 (2014): 1461-1469-   Onken, M. D. et al., Clin Cancer Res 20 (2014): 2873-2884-   Ono, A. et al., Hum. Pathol. 40 (2009): 41-49-   Orentas, R. J. et al., Front Oncol 2 (2012): 194-   Papageorgio, C. et al., Int. J Oncol. 31 (2007): 1205-1211-   Park, S. H. et al., Clin Cancer Res. 13 (2007): 858-867-   Park, S. J. et al., Oncology 88 (2015): 122-132-   Parris, T. Z. et al., BMC. Cancer 14 (2014): 324-   Pei, L. et al., Mol. Med Rep. 4 (2011): 817-823-   Perez, E. A. et al., Cancer 118 (2012): 3014-3025-   Pinheiro, J. et al., nlme: Linear and Nonlinear Mixed Effects Models    (CRAN.R-project.org/packe=nlme) (2015)-   Plebanski, M. et al., Eur. J Immunol 25 (1995): 1783-1787-   Pornour, M. et al., Asian Pac. J Cancer Prev. 15 (2014): 10339-10343-   Porta, C. et al., Virology 202 (1994): 949-955-   Qi, H. et al., Cancer Res 62 (2002): 721-733-   Qu, Y. et al., J Gastroenterol. 49 (2014): 408-418-   Quyun, C. et al., Recent Pat DNA Gene Seq. 4 (2010): 86-93-   Rammensee, H. et al., Immunogenetics 50 (1999): 213-219-   Rao, C. V. et al., Carcinogenesis 30 (2009): 1469-1474-   RefSeq, The NCBI handbook [Internet], Chapter 18, (2002),    www.ncbi.nlm.nih.gov/books/NBK21091-   Resende, C. et al., Helicobacter. 15 Suppl 1 (2010): 34-39-   Resende, C. et al., Helicobacter. 16 Suppl 1 (2011): 38-44-   Rini, B. I. et al., Cancer 107 (2006): 67-74-   Rippe, V. et al., Oncogene 22 (2003): 6111-6114-   Rock, K. L. et al., Science 249 (1990): 918-921-   Roth, U. et al., Proteomics. 10 (2010): 194-202-   S3-Leitlinie Mammakarzinom, 032-045OL, (2012)-   Saiki, R. K. et al., Science 239 (1988): 487-491-   Sakurai, Y. et al., Mol. Pharm. 11 (2014): 2713-2719-   Saleem, M. et al., Chem Biol Drug Des 82 (2013): 243-251-   Schmid, C. A. et al., J Exp. Med 212 (2015): 775-792-   Seeger, F. H. et al., Immunogenetics 49 (1999): 571-576-   Shen, R. et al., PLoS. One. 8 (2013): e56542-   Shen, X. et al., Tumour. Biol 36 (2015): 7133-7142-   Sherman, F. et al., Laboratory Course Manual for Methods in Yeast    Genetics (1986)-   Sherman-Baust, C. A. et al., Cancer Cell 3 (2003): 377-386-   Shi, D. et al., Oncotarget. 6 (2015): 5005-5021-   Shi, D. et al., Cancer Prev. Res (Phila) 7 (2014): 266-277-   Shi, Y. et al., Genomics Proteomics. Bioinformatics. 2 (2004): 47-54-   Shi, Y. W. et al., Chin Med J (Engl.) 120 (2007): 1659-1665-   Shimizu, D. et al., Oncol Lett. 11 (2016): 1847-1854-   Singh-Jasuja, H. et al., Cancer Immunol. Immunother. 53 (2004):    187-195-   Skandalis, S. S. et al., Matrix Biol 35 (2014): 182-193-   Skrzypczak, M. et al., Gynecol. Endocrinol. 29 (2013): 1031-1035-   Small, E. J. et al., J Clin Oncol. 24 (2006): 3089-3094-   Smith, M. J. et al., Br. J Cancer 100 (2009): 1452-1464-   Song, Q. et al., Oncol Rep. 33 (2015): 1956-1964-   Stefanska, B. et al., Clin Cancer Res 20 (2014): 3118-3132-   Stephens, P. J. et al., Nature 486 (2012): 400-404-   Stone, B. et al., Gene 267 (2001): 173-182-   Strekalova, E. et al., Clin. Cancer Res. (2015)-   Sturm, M. et al., BMC. Bioinformatics. 9 (2008): 163-   Sun, H. et al., J BUON. 20 (2015): 296-308-   Sun, J. et al., Technol. Cancer Res Treat. 15 (2016): 285-295-   Sussman, D. et al., Mol. Cancer Ther. 13 (2014): 2991-3000-   Tahara E Jr et al., Cancer Immunol. Immunother. 54 (2005): 729-740-   Takashima, S. et al., Tumour. Biol. 35 (2014): 4257-4265-   Tan, M. K. et al., Mol Cell Biol. 31 (2011): 3687-3699-   Tang, B. et al., Oncotarget. 6 (2015): 12723-12739-   Tanguay, R. M. et al., Acta Biochim. Pol. 43 (1996): 209-216-   Tasker, P. N. et al., Osteoporos. Int. 17 (2006): 1078-1085-   Terabayashi, T. et al., PLoS. One. 7 (2012): e39714-   Teufel, R. et al., Cell Mol Life Sci. 62 (2005): 1755-1762-   Thorsen, K. et al., Mol Cell Proteomics. 7 (2008): 1214-1224-   Tran, E. et al., Science 344 (2014): 641-645-   Trojani, A. et al., Cancer Biomark. 11 (2011): 15-28-   Tsuchiya, T. et al., Chemotherapy 61 (2016): 77-86-   Turner, B. C. et al., Cancer Res 58 (1998): 5466-5472-   Uemura, T. et al., Cancer Sci. 101 (2010): 2404-2410-   Unland, R. et al., J Neurooncol. 116 (2014): 237-249-   Unno, J. et al., Scand. J Gastroenterol. 49 (2014): 215-221-   van de Vijver, M. J. et al., N. Engl. J Med. 347 (2002): 1999-2009-   Walter, S. et al., J Immunol 171 (2003): 4974-4978-   Walter, S. et al., Nat Med. 18 (2012): 1254-1261-   Wang, G. H. et al., Oncol Lett. 5 (2013a): 544-548-   Wang, J. et al., J Exp. Clin Cancer Res 34 (2015): 13-   Wang, Q. et al., PLoS. One. 8 (2013b): e61640-   Wang, X. et al., Cancer Genet. Cytogenet. 196 (2010): 64-67-   Wikberg, M. L. et al., Tumour. Biol. 34 (2013): 1013-1020-   Willcox, B. E. et al., Protein Sci. 8 (1999): 2418-2423-   Winzer, B. M. et al., Cancer Causes Control 22 (2011): 811-826-   World Cancer Report, (2014)-   Wu, F. L. et al., Cancer Lett. 363 (2015): 7-16-   Wu, T. et al., PLoS. One. 11 (2016): e0149361-   Wu, X. et al., Am. J Clin Exp. Urol. 2 (2014): 111-120-   Xie, X. et al., Oncol Lett. 7 (2014): 1537-1543-   Xiong, D. et al., Carcinogenesis 33 (2012): 1797-1805-   Xu, L. et al., Zhongguo Fei. Ai. Za Zhi. 14 (2011): 727-732-   Xu, X. et al., Int. J Mol. Med 36 (2015): 1630-1638-   Xu, Y. et al., PLoS. One. 8 (2013): e64973-   Xue, H. et al., Autophagy. 12 (2016a): 1129-1152-   Xue, H. et al., Int. J Oncol 49 (2016b): 519-528-   Yakimchuk, K. et al., Mol. Cell Endocrinol. 375 (2013): 121-129-   Yamada, A. et al., Breast Cancer Res Treat. 137 (2013): 773-782-   Yang, Q. et al., Carcinogenesis 35 (2014): 1643-1651-   Yang, S. et al., Biochim. Biophys. Acta 1772 (2007): 1033-1040-   Ye, H. et al., BMC. Genomics 9 (2008): 69-   Yu, J. et al., Gut 64 (2015): 636-645-   Yuan, D. et al., J Surg. Oncol 108 (2013): 157-162-   Zanaruddin, S. N. et al., Hum. Pathol. 44 (2013): 417-426-   Zaravinos, A. et al., PLoS. One. 6 (2011): e18135-   Zaremba, S. et al., Cancer Res. 57 (1997): 4570-4577-   Zhang, G. et al., Tumour. Biol (2016)-   Zhang, J. et al., PLoS. One. 9 (2014a): e109318-   Zhang, Y. et al., Cancer Lett. 303 (2011): 47-55-   Zhang, Z. M. et al., J Cancer Res Clin Oncol 140 (2014b): 2119-2127-   Zhao, F. et al., Oncol Res Treat. 37 (2014): 106-110-   Zhao, L. H. et al., Genet. Mol. Res 14 (2015): 5417-5426-   Zhao, Y. et al., Cell Death. Dis. 4 (2013): e532-   Zhen, X. et al., Mol. Pharmacol. 60 (2001): 857-864-   Zhou, H. et al., Tumour. Biol 37 (2016): 8741-8752-   Zhu, H. et al., Cell Stress. Chaperones. (2014)-   Zou, T. T. et al., Oncogene 21 (2002): 4855-4862

1. A method of treating cancer in a HLA-A*02+ patient having the canceroverexpressing a polypeptide comprising the amino acid sequence selectedfrom the group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ IDNO: 9, SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ IDNO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43 and presenting at its surfacea peptide consisting of the amino acid sequence selected from the groupconsisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ IDNO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQID NO: 41, and SEQ ID NO: 43 in complex with an MHC class I molecule,said method comprising administering to said patient an effective amountof activated antigen-specific CD8+ cytotoxic T cells to selectivelyeliminate the cancer cells, wherein said activated antigen-specific CD8+cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells withan antigen presenting cell presenting at its surface a peptideconsisting of the amino acid sequence selected from the group consistingof from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, fromSEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQ ID NO: 41, andSEQ ID NO: 43 in complex with an MHC class I molecule in vitro, whereinthe cancer is selected from the group consisting of breast cancer, acutemyelogenous leukemia, bile duct cancer, brain cancer, chroniclymphocytic leukemia, colorectal carcinoma, esophageal cancer,gallbladder cancer, gastric cancer, hepatocellular cancer, Merkel cellcarcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer,ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer,small cell lung cancer, urinary bladder cancer, and uterine cancer. 2.The method of claim 1, wherein the cytotoxic T cells produced bycontacting CD8+ cytotoxic T cells with an antigen presenting cellpresenting at its surface a peptide consisting of the amino acidsequence selected from the group consisting of from SEQ ID NO: 1 to SEQID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO:15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43 in complexwith an MHC class I molecule are cytotoxic T cells autologous to thepatient.
 3. The method of claim 1, wherein the cytotoxic T cellsproduced by contacting CD8+ cytotoxic T cells with an antigen presentingcell presenting at its surface a peptide consisting of the amino acidsequence selected from the group consisting of from SEQ ID NO: 1 to SEQID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO:15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43 in complexwith an MHC class I molecule are cytotoxic T cells obtained from ahealthy donor.
 4. The method of claim 1, wherein the cytotoxic T cellsproduced by contacting CD8+ cytotoxic T cells with an antigen presentingcell presenting at its surface a peptide consisting of the amino acidsequence selected from the group consisting of from SEQ ID NO: 1 to SEQID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO:15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43 in complexwith an MHC class I molecule are cytotoxic T cells isolated from tumorinfiltrating lymphocytes or peripheral blood mononuclear cells.
 5. Themethod of claim 1, wherein the cytotoxic T cells produced by contactingCD8+ cytotoxic T cells with an antigen presenting cell presenting at itssurface a peptide consisting of the amino acid sequence selected fromthe group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9,SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17to SEQ ID NO: 41, and SEQ ID NO: 43 in complex with an MHC class Imolecule are expanded in vitro before being administered to the patient.6. The method of claim 5, wherein the cytotoxic T cells are expanded invitro in the presence of an anti-CD28 antibody and IL-12.
 7. The methodof claim 1, wherein the effective amount of activated antigen-specificCD8+ cytotoxic T cells to selectively eliminate the cancer cells areadministered in the form of a composition.
 8. The method of claim 7,wherein said composition further comprises at least one adjuvant.
 9. Themethod of claim 8, wherein said at least one adjuvant is selected fromanti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide,sunitinib, interferon-alpha, interferon-beta, CpG oligonucleotides,poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactideco-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7,IL-12, IL-13, IL-15, IL-21, and IL-23.
 10. The method of claim 1,wherein the antigen presenting cell is a dendritic cell or a macrophage.11. The method of claim 1, wherein the antigen presenting cell isinfected with a recombinant virus expressing the peptide consisting ofthe amino acid sequence selected from the group consisting of from SEQID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO:12 to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO:43.
 12. The method of claim 1, wherein the antigen presenting cell is anartificial antigen presenting cell (aAPC) comprising an anti-CD28antibody coupled to its surface.
 13. The method of claim 1, wherein thecancer is breast cancer.
 14. A method of eliciting an immune response ina HLA-A*02+ patient who has cancer overexpressing a polypeptidecomprising the amino acid sequence selected from the group consisting offrom SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQID NO: 43 and presenting at its surface a peptide consisting of theamino acid sequence selected from the group consisting of from SEQ IDNO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43in complex with an MHC class I molecule, said method comprisingadministering to said patient an effective amount of activatedantigen-specific CD8+ cytotoxic T cells to selectively eliminate thecancer cells, wherein said activated antigen-specific CD8+ cytotoxic Tcells are produced by contacting CD8+ cytotoxic T cells with an antigenpresenting cell presenting at its surface a peptide consisting of theamino acid sequence selected from the group consisting of from SEQ IDNO: 1 to SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12to SEQ ID NO: 15, from SEQ ID NO: 17 to SEQ ID NO: 41, and SEQ ID NO: 43in complex with an MHC class I molecule in vitro, wherein the cancer isselected from the group consisting of breast cancer, acute myelogenousleukemia, bile duct cancer, brain cancer, chronic lymphocytic leukemia,colorectal carcinoma, esophageal cancer, gallbladder cancer, gastriccancer, hepatocellular cancer, Merkel cell carcinoma, melanoma,non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer,pancreatic cancer, prostate cancer, renal cell cancer, small cell lungcancer, urinary bladder cancer, and uterine cancer.
 15. The method ofclaim 14, wherein the cytotoxic T cells produced by contacting CD8+cytotoxic T cells with an antigen presenting cell presenting at itssurface a peptide consisting of the amino acid sequence selected fromthe group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9,SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17to SEQ ID NO: 41, and SEQ ID NO: 43 in complex with an MHC class Imolecule are cytotoxic T cells autologous to the patient.
 16. The methodof claim 14, wherein the cytotoxic T cells produced by contacting CD8+cytotoxic T cells with an antigen presenting cell presenting at itssurface a peptide consisting of the amino acid sequence selected fromthe group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9,SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17to SEQ ID NO: 41, and SEQ ID NO: 43 in complex with an MHC class Imolecule are cytotoxic T cells obtained from a healthy donor.
 17. Themethod of claim 14, wherein the cytotoxic T cells produced by contactingCD8+ cytotoxic T cells with an antigen presenting cell presenting at itssurface a peptide consisting of the amino acid sequence selected fromthe group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9,SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17to SEQ ID NO: 41, and SEQ ID NO: 43 in complex with an MHC class Imolecule are cytotoxic T cells isolated from tumor infiltratinglymphocytes or peripheral blood mononuclear cells.
 18. The method ofclaim 14, wherein the cytotoxic T cells produced by contacting CD8+cytotoxic T cells with an antigen presenting cell presenting at itssurface a peptide consisting of the amino acid sequence selected fromthe group consisting of from SEQ ID NO: 1 to SEQ ID NO: 6, SEQ ID NO: 9,SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 15, from SEQ ID NO: 17to SEQ ID NO: 41, and SEQ ID NO: 43 in complex with an MHC class Imolecule are expanded in vitro before being administered to the patient.19. The method of claim 18, wherein the cytotoxic T cells are expandedin vitro in the presence of an anti-CD28 antibody and IL-12.
 20. Themethod of claim 14, wherein the cancer is breast cancer.